ATE297465T1 - Verfahren zur herstellung von multivalenten antigenbindenden proteinen - Google Patents

Verfahren zur herstellung von multivalenten antigenbindenden proteinen

Info

Publication number: ATE297465T1
Authority: AT; Austria
Prior art keywords: heterodimer; binding proteins; sfv; multivalent antigen; active
Prior art date: 1991-11-25

Application number

AT01109203T

Other languages

English (en)

Inventor

Marc D Whitlow

James F Wood

Karl Hardman

Robert E Bird

David Filpula

Michele Rollence

Original Assignee

Enzon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-11-25

Filing date

1992-11-20

Publication date

2005-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25169441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE297465(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-11-20 Application filed by Enzon Inc filed Critical Enzon Inc

2005-06-15 Application granted granted Critical

2005-06-15 Publication of ATE297465T1 publication Critical patent/ATE297465T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

AT01109203T 1991-11-25 1992-11-20 Verfahren zur herstellung von multivalenten antigenbindenden proteinen ATE297465T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US79693691A	1991-11-25	1991-11-25

Publications (1)

Publication Number	Publication Date
ATE297465T1 true ATE297465T1 (de)	2005-06-15

Family

ID=25169441

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT01109203T ATE297465T1 (de)	1991-11-25	1992-11-20	Verfahren zur herstellung von multivalenten antigenbindenden proteinen
AT93900545T ATE207080T1 (de)	1991-11-25	1992-11-20	Multivalente antigen-bindende proteine

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT93900545T ATE207080T1 (de)	1991-11-25	1992-11-20	Multivalente antigen-bindende proteine

Country Status (10)

Country	Link
US (1)	US20060063715A1 (de)
EP (2)	EP1136556B1 (de)
JP (1)	JPH07501451A (de)
AT (2)	ATE297465T1 (de)
AU (1)	AU3178993A (de)
CA (1)	CA2122732C (de)
DE (2)	DE69232137T2 (de)
DK (2)	DK0617706T3 (de)
ES (2)	ES2165851T3 (de)
WO (1)	WO1993011161A1 (de)

Families Citing this family (1593)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1997894B1 (de) *	1992-02-06	2011-03-30	Novartis Vaccines and Diagnostics, Inc.	Biosynthetisches Bindeprotein für Tumormarker
US6329507B1 (en) *	1992-08-21	2001-12-11	The Dow Chemical Company	Dimer and multimer forms of single chain polypeptides
JPH08504320A (ja) *	1992-09-25	1996-05-14	コモンウエルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼーション	標的結合性ポリペプチド
PT676965E (pt) *	1992-11-16	2007-10-29	Centocor Inc	Método para reduzir a imunogenicidade da região variável de anticorpos
WO1994012520A1 (en) *	1992-11-20	1994-06-09	Enzon, Inc.	Linker for linked fusion polypeptides
WO1994013804A1 (en) *	1992-12-04	1994-06-23	Medical Research Council	Multivalent and multispecific binding proteins, their manufacture and use
GB9225453D0 (en)	1992-12-04	1993-01-27	Medical Res Council	Binding proteins
ATE187494T1 (de) *	1992-12-11	1999-12-15	Dow Chemical Co	Multivalente einkettige antikörper
GB9412166D0 (en) *	1993-09-22	1994-08-10	Medical Res Council	Retargetting antibodies
CA2169620A1 (en)	1993-09-22	1995-03-30	Gregory Paul Winter	Retargeting antibodies
WO1995009917A1 (en) *	1993-10-07	1995-04-13	The Regents Of The University Of California	Genetically engineered bispecific tetravalent antibodies
US5837544A (en) *	1995-02-02	1998-11-17	Cell Genesys, Inc.	Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
US6103521A (en) *	1995-02-06	2000-08-15	Cell Genesys, Inc.	Multispecific chimeric receptors
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US7368111B2 (en)	1995-10-06	2008-05-06	Cambridge Antibody Technology Limited	Human antibodies specific for TGFβ2
EP0799244A1 (de) *	1995-10-16	1997-10-08	Unilever N.V.	Ein bifunktionneles oder bivalentes antikörper-fragment-analog
AU2507397A (en)	1996-04-04	1997-10-29	Unilever Plc	Multivalent and multispecific antigen-binding protein
GB9610967D0 (en)	1996-05-24	1996-07-31	Cambridge Antibody Tech	Specific binding members,materials and methods
IT1286663B1 (it) *	1996-06-27	1998-07-15	Ministero Uni Ricerca Scient E	Proteina capace di inibire l'attivita' ribosomiale,sua preparazione ed uso come immunoconiugato chimico o ricombinante e sequenza di cdna
GB9712818D0 (en)	1996-07-08	1997-08-20	Cambridge Antibody Tech	Labelling and selection of specific binding molecules
US5922845A (en)	1996-07-11	1999-07-13	Medarex, Inc.	Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
WO1999027098A2 (en)	1997-11-21	1999-06-03	Genentech, Inc.	A-33 related antigens and their pharmacological uses
WO1998045332A2 (en)	1997-04-07	1998-10-15	Genentech, Inc.	Humanized antibodies and methods for forming humanized antibodies
CN100480269C (zh)	1997-04-07	2009-04-22	基因技术股份有限公司	抗-血管内皮生长因子的抗体
EP0981548A4 (de)	1997-04-30	2005-11-23	Enzon Inc	Glykosylierungsfähige einzelkettige antigen-bindende proteine, herstellung und verwendung derselben
GB9710154D0 (en) *	1997-05-16	1997-07-09	Medical Res Council	Detection of retroviruses
JP2001510483A (ja)	1997-06-13	2001-07-31	ジェネンテク，インコーポレイテッド	タンパク質の回収
US5994511A (en) *	1997-07-02	1999-11-30	Genentech, Inc.	Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en)	1997-07-02	2001-01-09	Genentech, Inc.	Anti-IgE antibodies and method of improving polypeptides
US6342220B1 (en)	1997-08-25	2002-01-29	Genentech, Inc.	Agonist antibodies
CN1203178C (zh)	1997-10-27	2005-05-25	尤尼利弗公司	多价抗原结合蛋白
US7192589B2 (en)	1998-09-16	2007-03-20	Genentech, Inc.	Treatment of inflammatory disorders with STIgMA immunoadhesins
US8088386B2 (en)	1998-03-20	2012-01-03	Genentech, Inc.	Treatment of complement-associated disorders
EP1947119A3 (de)	1997-12-12	2012-12-19	Genentech, Inc.	Krebsbehandlung mit Antikörpern gegen ERBB2 und einem chemotherapeutischen Mittel
EP1965213A3 (de)	1998-02-04	2009-07-15	Invitrogen Corporation	Microarrays und ihre Verwendungen
NZ525914A (en)	1998-03-10	2004-03-26	Genentech Inc	Novel polypeptides and nucleic acids encoding the same
EP1941905A1 (de)	1998-03-27	2008-07-09	Genentech, Inc.	APO-2 Liganden-Anti-HER-2-Antikörper-Synergismus
CZ121599A3 (cs) *	1998-04-09	1999-10-13	Aventis Pharma Deutschland Gmbh	Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
EP1076703B2 (de)	1998-05-15	2010-12-15	Genentech, Inc.	Therapeutische verwendungen von il-17 homologe polypeptide
EP3112468A1 (de)	1998-05-15	2017-01-04	Genentech, Inc.	Il-17-homologe polypeptide und therapeutische verwendung davon
US20020172678A1 (en)	2000-06-23	2002-11-21	Napoleone Ferrara	EG-VEGF nucleic acids and polypeptides and methods of use
WO2001051635A2 (en)	2000-01-13	2001-07-19	Genentech, Inc.	Novel stra6 polypeptides
US6333396B1 (en)	1998-10-20	2001-12-25	Enzon, Inc.	Method for targeted delivery of nucleic acids
EP1950300A3 (de)	1998-11-18	2011-03-23	Genentech, Inc.	Antikörpervarianten mit höherer Bindungsaffinität im Vergleich zu verwandten Antikörpern
US20030035798A1 (en)	2000-08-16	2003-02-20	Fang Fang	Humanized antibodies
US6492497B1 (en)	1999-04-30	2002-12-10	Cambridge Antibody Technology Limited	Specific binding members for TGFbeta1
DE60043322D1 (de)	1999-06-15	2009-12-24	Genentech Inc	Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
BR122014028365B8 (pt)	1999-06-25	2021-07-06	Genentech Inc	artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida
CA2381495A1 (en) *	1999-08-11	2001-02-22	Unilever Plc	Internally referenced immunoassay and test device
JP2003508447A (ja)	1999-08-27	2003-03-04	ジェネンテック・インコーポレーテッド	抗ＥｒｂＢ２抗体を用いた治療のためのドーセージ
US20040214783A1 (en)	2002-05-08	2004-10-28	Terman David S.	Compositions and methods for treatment of neoplastic disease
US7947496B2 (en)	1999-10-08	2011-05-24	Hoffmann-La Roche Inc.	Cytotoxicity mediation of cells evidencing surface expression of CD44
IL148936A0 (en)	1999-10-20	2002-09-12	Genentech Inc	Modulation of t cell differentiation for the treatment of t helper cell mediated diseases
EP1669371A3 (de)	1999-12-01	2006-06-21	Genentech, Inc.	Zusammensetzung und Verfahren zur Diagnose eines Tumors
EP1897945B1 (de)	1999-12-23	2012-01-18	Genentech, Inc.	IL-17-homologe Polypeptide und ihre therapeutische Verwendung
WO2001062800A1 (en)	2000-02-24	2001-08-30	Eidgenössische Technische Hochschule Zürich	Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US20040002068A1 (en)	2000-03-01	2004-01-01	Corixa Corporation	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6740520B2 (en)	2000-03-21	2004-05-25	Genentech, Inc.	Cytokine receptor and nucleic acids encoding the same
WO2004043361A2 (en)	2002-11-08	2004-05-27	Genentech, Inc.	Compositions and methods for the treatment of natural killer cell related diseases
EP2857516B1 (de)	2000-04-11	2017-06-14	Genentech, Inc.	Multivalente Antikörper und deren Verwendung
DE10021678A1 (de) *	2000-05-05	2002-04-18	Stefan Duebel	Antikörperkonstrukte mit variablen Regionen
JP2004512262A (ja)	2000-06-20	2004-04-22	アイデック　ファーマスーティカルズ　コーポレイション	非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
CA2709771A1 (en)	2000-06-23	2002-01-03	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2792747A1 (de)	2000-06-23	2014-10-22	Genentech, Inc.	Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
EP2014298A3 (de)	2000-08-24	2009-10-07	Genentech, Inc.	Interleukin-22-Polypeptide, Nukleinsäuren zu deren Codierung und Verfahren zur Behandlung von Bauchspeicheldrüsenerkrankungen
EP1944317A3 (de)	2000-09-01	2008-09-17	Genentech, Inc.	Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
ES2332402T5 (es)	2000-10-12	2018-05-14	Genentech, Inc.	Formulaciones de proteína concentradas de viscosidad reducida
US7534429B2 (en)	2000-11-29	2009-05-19	Hoffmann-La Roche Inc.	Cytotoxicity mediation of cells evidencing surface expression of CD63
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) *	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
US20020159996A1 (en)	2001-01-31	2002-10-31	Kandasamy Hariharan	Use of CD23 antagonists for the treatment of neoplastic disorders
US7087726B2 (en)	2001-02-22	2006-08-08	Genentech, Inc.	Anti-interferon-α antibodies
PT1381384E (pt)	2001-04-24	2011-09-01	Merck Patent Gmbh	Terapia de combinação usando agentes anti-angiogénicos e tnfa
US20100056762A1 (en)	2001-05-11	2010-03-04	Old Lloyd J	Specific binding proteins and uses thereof
GB0111628D0 (en)	2001-05-11	2001-07-04	Scancell Ltd	Binding member
EP1392359B2 (de)	2001-05-11	2013-03-13	Ludwig Institute for Cancer Research Ltd.	Spezifische bindungsproteine und ihre verwendung
MXPA03010911A (es)	2001-05-30	2004-02-17	Genentech Inc	Anticuerpos contra ngf para el tratamiento de varios desordenes.
US20070160576A1 (en)	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
AU2002318371B2 (en)	2001-06-20	2006-06-15	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
MXPA04001566A (es)	2001-08-27	2004-05-17	Genentech Inc	Un sistema para expresion y ensamblado de anticuerpos.
JP4361791B2 (ja)	2001-08-29	2009-11-11	ジェネンテック・インコーポレーテッド	マイトジェン活性を有するＢｖ８核酸及びポリペプチド
WO2003024392A2 (en)	2001-09-18	2003-03-27	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
EP2072059A1 (de)	2001-10-12	2009-06-24	Schering Corporation	Verwendung von bispezifischen Antikörpern zur Regulierung der Immunreaktion
US20050123925A1 (en)	2002-11-15	2005-06-09	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
AU2002364956C1 (en) *	2001-11-16	2009-05-28	Biogen Idec Inc.	Polycistronic expression of antibodies
GB0130543D0 (en)	2001-12-20	2002-02-06	Univ Cambridge Tech	Human antibodies and their use
WO2003057881A1 (fr)	2001-12-28	2003-07-17	Chugai Seiyaku Kabushiki Kaisha	Procede de stabilisation d'une proteine
WO2003057160A2 (en)	2002-01-02	2003-07-17	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
ES2496493T3 (es)	2002-01-11	2014-09-19	Bioasis Technologies Inc.	Uso de p97 como sistema de administración de enzimas para la administración de enzimas lisosómicas terapéuticas
EP2388265A1 (de)	2002-02-22	2011-11-23	Genentech, Inc.	Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
EP2277522B1 (de)	2002-03-01	2012-11-21	UCB Manufacturing, Inc.	Verfahren zur Erhöhung oder Verminderung der Knochendichte und zur Identifizierung von Molekulen
EP1540018B1 (de)	2002-04-12	2010-05-26	Colorado School Of Mines	Verfahren zum nachweis geringer konzentrationen eines zielbakteriums unter verwendung von phagen zur infizierung von zielbakterienzellen
KR20040101502A (ko)	2002-04-16	2004-12-02	제넨테크, 인크.	종양의 진단 및 치료 방법 및 이를 위한 조성물
NZ556507A (en)	2002-06-03	2010-03-26	Genentech Inc	Synthetic antibody phage libraries
EP2305710A3 (de)	2002-06-03	2013-05-29	Genentech, Inc.	Synthetische Antikörperphagenbibliotheken
US7585501B2 (en)	2002-06-14	2009-09-08	Stowers Institute For Medical Research	Compositions and methods for treating kidney disease
EP2383278A1 (de)	2002-07-08	2011-11-02	Genentech, Inc.	Methodenbestimmung zu B-Zell-vermittelten Krankheiten
SI2269656T1 (sl)	2002-07-15	2014-11-28	Board Of Regents, The University Of Texas System	Izbrana protitelesa, ki se veĹľejo na aminofosfolipide, in njihova uporaba v zdravljanju raka
CA2490758C (en)	2002-07-15	2014-09-23	Genentech, Inc.	Dosage form of recombinant humanized monoclonal antibody 2c4
AU2003251238A1 (en)	2002-08-07	2004-02-25	Umc Utrecht Holding B.V.	Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
US20040067532A1 (en)	2002-08-12	2004-04-08	Genetastix Corporation	High throughput generation and affinity maturation of humanized antibody
DK1543038T4 (da)	2002-09-11	2020-11-09	Genentech Inc	Proteinoprensning
EP1539228B1 (de)	2002-09-11	2010-12-29	Genentech, Inc.	Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
JP2006521082A (ja)	2002-09-11	2006-09-21	ジェネンテック・インコーポレーテッド	免疫関連疾患の治療のための新規組成物と方法
EP2444409A2 (de)	2002-09-16	2012-04-25	Genentech, Inc.	Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
EP2500438A3 (de)	2002-09-25	2012-11-28	Genentech, Inc.	Neue Zusammensetzungen und Verfahren zur Behandlung von Psoriasis
US9453251B2 (en)	2002-10-08	2016-09-27	Pfenex Inc.	Expression of mammalian proteins in Pseudomonas fluorescens
US7622270B2 (en)	2002-10-22	2009-11-24	Eisai R&D Management Co., Ltd.	Methods of isolating dopaminergic neuron precursor cells
EP2322203A3 (de)	2002-10-29	2011-07-27	Genentech, Inc.	Gestaltungen und methoden für die behandlung von Immune verwandte Krankheiten
ITMI20022411A1 (it) *	2002-11-14	2004-05-15	Bracco Imaging Spa	Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
CN1787837A (zh)	2002-11-15	2006-06-14	希龙公司	防止和治疗癌转移以及与癌转移相关的骨质损失的方法
AU2003300817A1 (en)	2002-11-21	2004-06-18	Celltech R And D, Inc.	Modulating immune responses
CA2504144A1 (en)	2002-11-26	2004-06-10	Genentech, Inc.	Compositions and methods for the diagnosis of immune related diseases using pro7
US9028816B2 (en)	2003-01-10	2015-05-12	Ablynx N.V.	Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
US7488475B2 (en)	2003-01-21	2009-02-10	Arius Research, Inc.	Antibody therapy of tumors
PE20040942A1 (es)	2003-01-24	2004-12-28	Elan Pharm Inc	Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes
EP2192172B1 (de)	2003-02-03	2014-12-03	iBio, Inc.	System zur Expression von Genen in Pflanzen
AU2004219592C1 (en)	2003-03-12	2011-02-24	Genentech, Inc.	Use of Bv8 and/or EG-VEGF to promote hematopoiesis
DK2335725T3 (en)	2003-04-04	2017-01-23	Genentech Inc	Highly concentrated antibody and protein formulations
DK1613350T3 (da)	2003-04-09	2009-06-22	Genentech Inc	Behandling af autoimmun sygdom hos en patient med et utilstrækkeligt respons på en TNF-alfa-inhibitor
CA2897608C (en)	2003-05-09	2018-07-31	Duke University	Cd20-specific antibodies and methods employing same
WO2005026375A2 (en)	2003-05-22	2005-03-24	Fraunhofer Usa, Inc.	Recombinant carrier molecule for expression, delivery and purification of target polypeptides
CA2536357A1 (en)	2003-05-29	2004-12-23	The Scripps Research Institute	Targeted delivery to legumain-expressing cells
NZ621449A (en)	2003-05-30	2015-07-31	Genentech Inc	Treatment with anti-vegf antibodies
DE602004028249D1 (de)	2003-06-18	2010-09-02	Chugai Pharmaceutical Co Ltd	Fucosetransporter
PL1641822T3 (pl)	2003-07-08	2013-10-31	Genentech Inc	Heterologiczne polipeptydy IL-17 A/F i ich zastosowania terapeutyczne
DE10331054A1 (de) *	2003-07-09	2005-02-03	Schering Ag	Emitter-bindende Peptide die eine Veränderung der spektralen Emissionseigenschaften des Emitters bewirken
WO2005005482A1 (de) *	2003-07-09	2005-01-20	Schering Ag	Emitter-bindende peptide die eine veränderung der spektralen emissionseigenschaften des emitters bewirken
GB0407315D0 (en)	2003-07-15	2004-05-05	Cambridge Antibody Tech	Human antibody molecules
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
US7758859B2 (en)	2003-08-01	2010-07-20	Genentech, Inc.	Anti-VEGF antibodies
WO2005019258A2 (en)	2003-08-11	2005-03-03	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
US8883147B2 (en)	2004-10-21	2014-11-11	Xencor, Inc.	Immunoglobulins insertions, deletions, and substitutions
US8399618B2 (en)	2004-10-21	2013-03-19	Xencor, Inc.	Immunoglobulin insertions, deletions, and substitutions
AU2003271174A1 (en)	2003-10-10	2005-04-27	Chugai Seiyaku Kabushiki Kaisha	Double specific antibodies substituting for functional protein
EP1693448A4 (de)	2003-10-14	2008-03-05	Chugai Pharmaceutical Co Ltd	Doppelt spezifische antikörper als ersatz für funktionelles protein
US7304139B2 (en)	2003-10-28	2007-12-04	University Of Florida Research Foundation, Inc.	Polynucleotides and polypeptides of Anaplasma phagocytophilum and methods of using the same
BRPI0416243A (pt)	2003-11-05	2007-01-09	Palingen Inc	método de tratamento de um paciente humano que sofre de uma condição que inclui uma hiper-proliferação de células b; formulação farmacêutica para injeção parenteral; kit para o tratamento de um paciente que sofre de uma condição que inclui uma hiper-proliferação de células b; e método para purgar a medula óssea de um paciente que sofre de cáncer linfóide de células b malignas antes do reimplante da medula óssea no paciente após a terapia mieloablativa
BR122018071968B8 (pt)	2003-11-06	2021-07-27	Seattle Genetics Inc	conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
AR046833A1 (es)	2003-11-10	2005-12-28	Schering Corp	Anticuerpos anti-interleuquina-10
WO2005048938A2 (en)	2003-11-13	2005-06-02	California Pacific Medical Center	Anti-pecam therapy for metastasis suppression
DE602004024921D1 (de)	2003-11-17	2010-02-11	Genentech Inc	Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
EP1710255A4 (de)	2003-12-12	2008-09-24	Chugai Pharmaceutical Co Ltd	Modifizierte antikörper, die rezeptortrimere oder höhere multimere erkennen
PL2311873T3 (pl)	2004-01-07	2019-01-31	Novartis Vaccines And Diagnostics, Inc.	Przeciwciało monoklonalne specyficzne wobec M-CSF i jego zastosowania
EP3653641A1 (de)	2004-02-19	2020-05-20	Genentech, Inc.	Antikörper mit korrigiertem cdr
KR101245983B1 (ko)	2004-03-31	2013-06-28	제넨테크, 인크.	인간화 항-ｔｇｆ-베타 항체
CN101921340A (zh)	2004-03-31	2010-12-22	佳能株式会社	一种蛋白质
MY162179A (en)	2004-04-01	2017-05-31	Elan Pharm Inc	Steroid sparing agents and methods of using same
US7794713B2 (en)	2004-04-07	2010-09-14	Lpath, Inc.	Compositions and methods for the treatment and prevention of hyperproliferative diseases
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
US20150017671A1 (en)	2004-04-16	2015-01-15	Yaping Shou	Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US7514223B2 (en)	2004-05-15	2009-04-07	Genentech, Inc.	Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
RU2381234C2 (ru)	2004-05-28	2010-02-10	Эдженсис, Инк.	Антитела и родственные молекулы, связывающиеся с белками psca
CA2567520A1 (en)	2004-06-01	2005-12-15	Genentech, Inc.	Maytansinoid-antibody conjugates
AR049200A1 (es)	2004-06-04	2006-07-05	Genentech Inc	Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20
US7604947B2 (en)	2004-06-09	2009-10-20	Cornell Research Foundation, Inc.	Detection and modulation of cancer stem cells
SV2006002143A (es)	2004-06-16	2006-01-26	Genentech Inc	Uso de un anticuerpo para el tratamiento del cancer resistente al platino
WO2006012361A2 (en)	2004-07-01	2006-02-02	University Of Southern California	Genetic markers for predicting disease and treatment outcome
US7973134B2 (en)	2004-07-07	2011-07-05	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
SI1771474T1 (sl)	2004-07-20	2010-06-30	Genentech Inc	Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
US8604185B2 (en)	2004-07-20	2013-12-10	Genentech, Inc.	Inhibitors of angiopoietin-like 4 protein, combinations, and their use
JP3996627B2 (ja)	2004-07-22	2007-10-24	エーザイ・アール・アンド・ディー・マネジメント株式会社	Ｌｒｐ４／Ｃｏｒｉｎドーパミン産生ニューロン前駆細胞マーカー
KR20170054551A (ko)	2004-07-22	2017-05-17	제넨테크, 인크.	Ｈｅｒ２ 항체 조성물
BRPI0513826A2 (pt)	2004-07-26	2010-06-22	Dow Global Technologies Inc	processo para expressão de proteìna melhorada através de engenharia de cepa
EP1789070B1 (de)	2004-08-03	2012-10-24	Biogen Idec MA Inc.	Taj in der neuronalen funktion
ES2365037T3 (es)	2004-08-06	2011-09-21	Genentech, Inc.	Ensayos y métodos usando biomarcadores.
JP5237638B2 (ja)	2004-08-06	2013-07-17	ジェネンテック，インコーポレイテッド	バイオマーカーを用いたアッセイおよび方法
US20100111856A1 (en)	2004-09-23	2010-05-06	Herman Gill	Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR101270829B1 (ko)	2004-09-23	2013-06-07	제넨테크, 인크.	시스테인 유전자조작 항체 및 접합체
US7935790B2 (en)	2004-10-04	2011-05-03	Cell Singaling Technology, Inc.	Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
KR20070100228A (ko)	2004-10-05	2007-10-10	제넨테크, 인크.	혈관염의 치료 방법
WO2006042177A2 (en)	2004-10-07	2006-04-20	Argos Therapeutics, Inc.	Mature dendritic cell compositions and methods for culturing same
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
PT1802334E (pt)	2004-10-21	2012-11-28	Genentech Inc	Método para tratamento de doenças neovasculares intraoculares
MX2007005320A (es)	2004-11-05	2007-11-12	Palingen Inc	Herida de la membrana celular inducida por anticuerpo.
US7807789B2 (en)	2004-12-21	2010-10-05	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
WO2006067847A1 (ja)	2004-12-22	2006-06-29	Chugai Seiyaku Kabushiki Kaisha	フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
WO2006067210A1 (en)	2004-12-23	2006-06-29	Laboratoires Serono S.A.	Bcma polypeptides and uses thereof
EP2230517A1 (de)	2005-01-07	2010-09-22	Diadexus, Inc.	OVR110-Antikörperzusammensetzungen und Verwendungsverfahren dafür
PT1836500E (pt)	2005-01-14	2010-09-28	Ablynx Nv	Métodos e ensaios para distinguir diferentes formas de doenças e perturbações caracterizadas por trombocitopenia e/ou por interacção espontânea entre o factor de von willebrand (vwf) e plaquetas
KR20150083139A (ko)	2005-01-21	2015-07-16	제넨테크, 인크.	Ｈｅｒ 항체의 고정 용량 투여법
KR101289537B1 (ko)	2005-02-15	2013-07-31	듀크 유니버시티	항-ｃｄ19 항체 및 종양학에서 이의 용도
DK1850874T3 (da)	2005-02-23	2013-11-11	Genentech Inc	Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
WO2006105488A2 (en)	2005-03-31	2006-10-05	Agensys, Inc.	Antibodies and related molecules that bind to 161p2f10b proteins
WO2006105414A2 (en)	2005-03-31	2006-10-05	Colorado School Of Mines	Apparatus and method for detecting microscopic organisms using microphage
DK3050963T3 (da)	2005-03-31	2019-12-09	Chugai Pharmaceutical Co Ltd	Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
EP1876236B9 (de)	2005-04-08	2015-02-25	Chugai Seiyaku Kabushiki Kaisha	Antikörper als funktioneller ersatz für blutgerinnungsfaktor viii
AU2006235695B2 (en)	2005-04-09	2011-10-13	Fusion Antibodies Limited	Cathepsin S antibody
AU2006236225C1 (en)	2005-04-19	2013-05-02	Seagen Inc.	Humanized anti-CD70 binding agents and uses thereof
AU2006244445B2 (en)	2005-05-05	2013-04-18	Duke University	Anti-CD19 antibody therapy for autoimmune disease
ME02461B (me)	2005-05-10	2017-02-20	Incyte Holdings Corp	Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
EP1888629B1 (de)	2005-05-10	2013-04-24	Neoloch Aps	Neuritogene peptide
EP3415535B1 (de)	2005-05-20	2020-12-09	Ablynx N.V.	Verbesserte nanokörper (tm) zur behandlung von aggregationsvermittelten erkrankungen
AU2006255686A1 (en)	2005-06-06	2006-12-14	Genentech, Inc.	Transgenic models for different genes and their use for gene characterization
EP2322552B1 (de)	2005-06-21	2016-02-10	Xoma (Us) Llc	IL-1 beta bindende Antikörper und deren Fragmente
CA2614436C (en)	2005-07-07	2016-05-17	Seattle Genetics, Inc.	Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
EP2004695A2 (de)	2005-07-08	2008-12-24	Xencor, Inc.	Optimierte anti-ep-cam-antikörper
EP3248613B1 (de)	2005-07-18	2021-12-15	Seagen Inc.	Beta-glukuronid-linker-wirkstoffkonjugate
CA2616395C (en)	2005-07-25	2016-10-04	Trubion Pharmaceuticals	B-cell reduction using cd37-specific and cd20-specific binding molecules
EP2311876A3 (de)	2005-07-28	2011-04-27	Novartis AG	M-CSF-spezifischer monoklonaler Antikörper und Verwendungen davon
PL3006457T3 (pl)	2005-07-29	2018-05-30	The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services	Zmutowane egzotoksyny Pseudomonas o zmniejszonej antygenowości
US7452978B2 (en)	2005-08-02	2008-11-18	Arius Research, Inc.	Cancerous disease modifying antibodies
US7411046B2 (en)	2005-08-02	2008-08-12	Arius Research Inc	Cancerous disease modifying antibodies
US7452979B2 (en)	2005-08-02	2008-11-18	Arius Research, Inc.	Cancerous disease modifying antibodies
US7456258B2 (en)	2005-08-02	2008-11-25	Arius Research, Inc.	Cancerous disease modifying antibodies
US7456259B2 (en)	2005-08-02	2008-11-25	Arius Research, Inc.	Cancerous disease modifying antibodies
US7494648B2 (en)	2005-08-02	2009-02-24	Hoffmann-La Roche Inc.	Cancerous disease modifying antibodies
US8962278B2 (en)	2005-08-03	2015-02-24	Ibio Inc.	Compositions and methods for production of immunoglobulins
EP1913391B1 (de)	2005-08-11	2010-12-29	Siemens Healthcare Diagnostics Inc.	QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN
JP2009504183A (ja)	2005-08-15	2009-02-05	ジェネンテック・インコーポレーテッド	遺伝子破壊、それに関連する組成物および方法
ATE533058T1 (de)	2005-08-16	2011-11-15	Genentech Inc	Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe
WO2007027906A2 (en)	2005-08-31	2007-03-08	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in leukemia signaling pathways
EP2354160A1 (de)	2005-08-31	2011-08-10	Schering Corporation	Gentechnisch hergestellte Anti-IL-23-Antikörper
ES2333260T3 (es)	2005-09-01	2010-02-18	Schering Corporation	Uso de antagonistas de il-23 e il-17 para tratar la enfermedad inflamatoria ocular autoinmunologica.
JP2009508494A (ja)	2005-09-16	2009-03-05	ラプトールファーマシューティカルインコーポレイテッド	Ｃｒを含むタンパク質に対して特異的な受容体−結合タンパク質（ｒａｐ）変異体を含む組成物およびその使用
CA2903896A1 (en)	2005-11-04	2007-05-18	Genentech, Inc.	Use of complement pathway inhibitors to treat ocular diseases
EP2465870A1 (de)	2005-11-07	2012-06-20	Genentech, Inc.	Bindepolypeptide mit verschiedenartigen und übereinstimmenden hypervariablen VH/VL-Sequenzen
UA96139C2 (uk)	2005-11-08	2011-10-10	Дженентек, Інк.	Антитіло до нейропіліну-1 (nrp1)
NZ568324A (en)	2005-11-11	2012-01-12	Vertex Pharma	Hepatitis C virus variants
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
EP1948798B1 (de)	2005-11-18	2015-04-01	Glenmark Pharmaceuticals S.A.	Anti-alpha2-integrin-antikörper und deren verwendungen
EP2002714A1 (de)	2005-11-21	2008-12-17	Genentech, Inc.	Neuartige Genunterbrechung, dazugehörige Zusammensetzungen und Verfahren
EP1963369B1 (de)	2005-11-28	2013-05-15	Zymogenetics, Inc.	Il-21-antagonisten
AU2006338198B2 (en)	2005-12-02	2012-04-26	Genentech, Inc.	Binding polypeptides and uses thereof
DOP2006000277A (es)	2005-12-12	2007-08-31	Bayer Pharmaceuticals Corp	Anticuerpos anti mn y métodos para su utilización
US20090246208A1 (en)	2006-01-05	2009-10-01	Novartis Ag	Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
EP2402373B1 (de)	2006-01-05	2016-10-19	Genentech, Inc.	ANTI-EPHB4-Antikörper sowie Verfahren zu deren Verwendung
BRPI0706487A2 (pt)	2006-01-10	2011-03-29	Zymogenetics Inc	métodos de tratamento de inflamação em tecido neuronal de um mamìfero, de tratamento de dor em um mamìfero, de antagonizar transdução de sinal induzida por il-31 em células de gánglio da raiz dorsal, de tratamento de sintomas associados com queimadura, de tratamento de sintomas associados com infecção viral em um mamìfero, e, de tratamento de dor associada com doença intestinal inflamatória
EP1984405A4 (de)	2006-02-13	2010-06-30	Fraunhofer Usa Inc	Influenza-antigene, impfstoffzusammensetzungen und zugehörige verfahren
EP2412726B1 (de)	2006-02-14	2016-06-15	University Of Tasmania Through The Menzies Research Institute	Von Metallothionein abgeleitete Peptidfragmente
US20080311107A1 (en)	2006-02-17	2008-12-18	Genetech, Inc.	Novel Gene Disruptions, Compositions and Methods Relating Thereto
US8021839B2 (en)	2006-02-24	2011-09-20	Investigen, Inc.	Methods and compositions for detecting polynucleotides
WO2007103469A2 (en)	2006-03-06	2007-09-13	Aeres Biomedical Ltd.	Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US20070218065A1 (en)	2006-03-10	2007-09-20	Jaspers Stephen R	Antibodies that bind both il-17a and il-17f and methods of using the same
EP4316465A3 (de)	2006-03-15	2024-04-24	Alexion Pharmaceuticals, Inc.	Behandlung paroxysmaler nächtlicher hämoglobinurie-patienten mit einem komplementhemmer
AR059851A1 (es)	2006-03-16	2008-04-30	Genentech Inc	Anticuerpos de la egfl7 y metodos de uso
EA015992B1 (ru)	2006-03-17	2012-01-30	Байоджен Айдек Эмэй Инк.	Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
US8278421B2 (en)	2006-03-20	2012-10-02	Xoma Techolology Ltd.	Human antibodies specific for gastrin materials and methods
NZ615012A (en)	2006-03-21	2015-11-27	Genentech Inc	Combinatorial therapy involving alpha5beta1 antagonists
EP2389950A1 (de)	2006-03-23	2011-11-30	Novartis AG	Antitumorzellenantigen-Antikörper-Therapeutika
CA2647846C (en)	2006-03-31	2016-06-21	Chugai Seiyaku Kabushiki Kaisha	Methods for controlling blood pharmacokinetics of antibodies
CN105177091A (zh)	2006-03-31	2015-12-23	中外制药株式会社	用于纯化双特异性抗体的抗体修饰方法
MY157366A (en)	2006-04-10	2016-05-31	Fusion Antibodies Ltd	Therapies and compositions comprising cathepsin s antibodies
JP2009536022A (ja)	2006-04-19	2009-10-08	ジェネンテック・インコーポレーテッド	新規の遺伝子破壊、それに関連する組成物および方法
TWI395754B (zh)	2006-04-24	2013-05-11	Amgen Inc	人類化之ｃ-ｋｉｔ抗體
RU2008147398A (ru)	2006-05-02	2010-06-10	Актогеникс Н.В. (Be)	Доставка пептидов, связанных с ожирением, через кишечник посредством микроорганизмов
US20080014205A1 (en)	2006-05-15	2008-01-17	Lawrence Horowitz	Neutralizing Antibodies to Influenza Viruses
US9274129B2 (en)	2006-05-31	2016-03-01	Lpath, Inc.	Methods and reagents for detecting bioactive lipids
US8796429B2 (en)	2006-05-31	2014-08-05	Lpath, Inc.	Bioactive lipid derivatives, and methods of making and using same
US7862812B2 (en)	2006-05-31	2011-01-04	Lpath, Inc.	Methods for decreasing immune response and treating immune conditions
US20080138334A1 (en)	2006-05-31	2008-06-12	Sabbadini Roger A	Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
US9274130B2 (en)	2006-05-31	2016-03-01	Lpath, Inc.	Prevention and treatment of pain using antibodies to lysophosphatidic acid
EP2032604A2 (de)	2006-06-06	2009-03-11	Genentech, Inc.	Anti-dll4-antikörper sowie verfahren zu deren verwendung
MX2008015524A (es) *	2006-06-12	2009-01-13	Trubion Pharmaceuticals Inc	Proteinas de union multivalentes monocatenarias con funcion efectora.
JPWO2007145227A1 (ja)	2006-06-14	2009-11-05	中外製薬株式会社	造血幹細胞増加促進剤
US8874380B2 (en)	2010-12-09	2014-10-28	Rutgers, The State University Of New Jersey	Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
US20130004480A1 (en)	2006-07-04	2013-01-03	Paul Parren	CD20 Binding Molecules for the Treatment of Copd
EP2048230A4 (de)	2006-07-13	2010-01-20	Chugai Pharmaceutical Co Ltd	Zelltodinduzierer
US9683026B2 (en)	2006-07-19	2017-06-20	The Trustees Of The University Of Pennslyvania	WSX-1/P28 as a target for anti-inflammatory responses
BRPI0715141A2 (pt)	2006-08-03	2013-06-04	Astrazeneca Ab	agente de ligaÇço alvejante, anticorpo isolado, fragmento de anticorpo isolado, molÉcula de Ácido nucleico, vetor, cÉlula hospedeira, mÉtodos para produzir um agente de ligaÇço alvejado, para produzir um anticorpo, para produzir um fragmento de anticorpo, para tratar um tumor maligno em um animal, para tratar inflamaÇço, e para inibir a interaÇço de alfabeta6 com seu ligando, e, conjugado
US7939636B2 (en)	2006-08-11	2011-05-10	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in c-Src signaling pathways
AU2007285217B2 (en)	2006-08-14	2013-02-07	Forerunner Pharma Research Co., Ltd	Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
ME00588A (en)	2006-08-18	2011-12-20		Prlr-specific antibody and uses thereof
JP4780405B2 (ja) *	2006-08-29	2011-09-28	アイシン精機株式会社	結合親和性を利用する被検物質の測定方法、及び被検物質の測定のための結合親和性解析の制御方法
WO2008027236A2 (en)	2006-08-30	2008-03-06	Genentech, Inc.	Multispecific antibodies
SI2061810T1 (sl)	2006-09-05	2015-04-30	Alexion Pharmaceuticals, Inc.	Postopki in sestavki za zdravljenje s protitelesi povezanih nevropatij
US7767206B2 (en)	2006-10-02	2010-08-03	Amgen Inc.	Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US9017684B2 (en)	2006-10-12	2015-04-28	Chugai Seiyaku Kabushiki Kaisha	Diagnosis and treatment of cancer using anti-EREG antibody
WO2008047925A1 (fr)	2006-10-20	2008-04-24	Forerunner Pharma Research Co., Ltd.	Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif
CN101589059A (zh)	2006-10-20	2009-11-25	株式会社未来创药研究所	包含抗hb-egf抗体作为活性成分的药物组合物
US7846434B2 (en)	2006-10-24	2010-12-07	Trubion Pharmaceuticals, Inc.	Materials and methods for improved immunoglycoproteins
WO2008055072A2 (en)	2006-10-27	2008-05-08	Lpath, Inc.	Compositions and methods for treating ocular diseases and conditions
WO2008070344A2 (en)	2006-10-27	2008-06-12	Lpath, Inc.	Compositions and methods for binding sphingosine-1-phosphate
CA2668484A1 (en)	2006-11-13	2008-05-22	F. Hoffmann-La Roche Ag	Cancerous disease modifying antibodies 180706-02
EP3156415A1 (de)	2006-11-22	2017-04-19	Bristol-Myers Squibb Company	Gezielte therapeutik auf grundlage manipulierter proteine für tyrosinkinaserezeptoren, einschliesslich igf-ir
AU2007325283B2 (en)	2006-11-27	2012-08-30	Diadexus, Inc.	Ovr110 antibody compositions and methods of use
US8455622B2 (en)	2006-12-01	2013-06-04	Seattle Genetics, Inc.	Variant target binding agents and uses thereof
CA2672120A1 (en)	2006-12-07	2008-06-12	Novartis Ag	Antagonistic antibodies against ephb3
AR064333A1 (es)	2006-12-14	2009-04-01	Schering Corp	Anticuerpo anti-tslp de diseno
CA2672581A1 (en)	2006-12-14	2008-06-19	Forerunner Pharma Research Co., Ltd.	Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
DK2101807T3 (en)	2006-12-19	2016-08-29	Genentech Inc	VEGF-SPECIFIC ANTAGONISTS FOR ADMINISTRATIVE AND NEOADVERTIVE TREATMENT AND TREATMENT OF TEMPERATURES IN EARLY STAGE
CA2673592C (en)	2006-12-20	2014-03-25	Xoma Technology Ltd.	Methods for the treatment of il-1.beta. related diseases
US7888069B2 (en)	2006-12-22	2011-02-15	Dow Agrosciences Llc	Plant-made west nile virus (WNV) vaccines, vectors and plant codon optimized sequences
WO2008081942A1 (ja)	2007-01-05	2008-07-10	The University Of Tokyo	抗prg-3抗体を用いる癌の診断および治療
PL2104682T3 (pl)	2007-01-11	2017-03-31	Michael Bacher	Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
US8664364B2 (en)	2007-01-24	2014-03-04	Carnegie Mellon University	Optical biosensors
WO2008091701A2 (en)	2007-01-25	2008-07-31	Dana-Farber Cancer Institute	Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
EP2119777A4 (de)	2007-02-09	2011-05-25	Eisai R&D Man Co Ltd	Gaba-neuronen-vorläuferzellen-marker 65b13
CA2678451A1 (en)	2007-02-20	2008-08-28	Robert A. Horlick	Somatic hypermutation systems
WO2008103473A1 (en)	2007-02-23	2008-08-28	Schering Corporation	Engineered anti-il-23p19 antibodies
US7771947B2 (en)	2007-02-23	2010-08-10	Investigen, Inc.	Methods and compositions for rapid light-activated isolation and detection of analytes
NZ579158A (en)	2007-02-23	2012-01-12	Schering Corp	Engineered anti-il-23p19 antibodies
US8192740B2 (en)	2007-02-27	2012-06-05	Forerunner Pharma Research Co., Ltd.	Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient
CN101675076B (zh)	2007-02-28	2013-09-18	默沙东公司	工程化的抗il-23r抗体
US20100135998A1 (en)	2007-02-28	2010-06-03	Schering Corporation	Combination therapy for treatment of immune disorders
PL2132573T3 (pl)	2007-03-02	2014-09-30	Genentech Inc	Prognozowanie odpowiedzi na inhibitor dimeryzacji HER oparte na niskiej ekspresji HER3
US20090081659A1 (en)	2007-03-07	2009-03-26	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
CL2008000719A1 (es)	2007-03-12	2008-09-05	Univ Tokushima Chugai Seiyaku	Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
EP2134854B1 (de)	2007-03-15	2015-04-15	Ludwig Institute for Cancer Research Ltd.	Behandlungsverfahren unter verwendung von egfr-antikörpern und src-inhibitoren und damit verbundene formulierungen
EP1975184A3 (de)	2007-03-26	2008-11-26	Cell Signaling Technology, Inc.	Serin- oder Threonin-Phosphorylationsorte
US7928202B2 (en)	2007-04-12	2011-04-19	The Brigham And Women's Hospital, Inc.	Targeting ABCB5 for cancer therapy
US7977462B2 (en)	2007-04-19	2011-07-12	Cell Signaling Technology, Inc.	Tyrosine phosphorylation sites
EP1983002A3 (de)	2007-04-19	2009-03-11	Peter Hornbeck	Tyrosinphosphorylations-Stellen und spezifische Antikörper
EP1983003A3 (de)	2007-04-19	2009-03-11	Peter Hornbeck	Tyrosinphosphorylationsstellen und spezifische Antikörper
BRPI0810120A2 (pt)	2007-04-27	2014-11-11	Dow Global Technologies Inc	Processo para selecionar rapidamente hospedeiros microbianos para a identificação de certas cepas com maior rendimento e/ou qualidade na expressão de proteínas heterólogas
US9580719B2 (en)	2007-04-27	2017-02-28	Pfenex, Inc.	Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
EP2392597B1 (de)	2007-04-27	2014-04-02	ZymoGenetics, Inc.	IL-17A-, IL-17F- und IL-23P19-Antagonisten und Verwendungsverfahren
US8778348B2 (en)	2007-04-28	2014-07-15	Ibio Inc.	Trypanosoma antigens, vaccine compositions, and related methods
US20090053831A1 (en)	2007-05-01	2009-02-26	Cell Signaling Technology, Inc.	Tyrosine phosphorylation sites
RU2549701C2 (ru)	2007-05-07	2015-04-27	Медиммун, Ллк	Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний
DK2164992T3 (en)	2007-05-30	2016-08-15	Lpath Inc	COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID
US9163091B2 (en)	2007-05-30	2015-10-20	Lpath, Inc.	Compositions and methods for binding lysophosphatidic acid
WO2008154251A2 (en)	2007-06-07	2008-12-18	Genentech, Inc.	C3b antibodies and methods for the prevention and treatment of complement- associated disorders
EP2592156B1 (de)	2007-06-08	2016-04-20	Genentech, Inc.	Genexpressionsmarker für Tumorresistenz gegen Behandlung mit HER2-Inhibitor
CA2958672A1 (en)	2007-06-15	2008-12-18	Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts	Treatment of tumors using specific anti-l1 antibody
ME02093B (me)	2007-06-18	2014-04-30	N V Organon	Antitijela za humani receptor programirane smrti pd-1
WO2009023386A2 (en) *	2007-07-06	2009-02-19	Trubion Pharmaceuticals, Inc.	Binding peptides having a c-terminally disposed specific binding domain
UA107557C2 (xx)	2007-07-06	2015-01-26		Композиція антитіла офатумумабу
US8404252B2 (en)	2007-07-11	2013-03-26	Fraunhofer Usa, Inc.	Yersinia pestis antigens, vaccine compositions, and related methods
EP2641618A3 (de)	2007-07-16	2013-10-23	Genentech, Inc.	Humanisierte Anti-CD79b Antikörper und Immunkonjugate sowie Verwendungsverfahren
CN111499748A (zh)	2007-07-16	2020-08-07	健泰科生物技术公司	抗cd79b抗体和免疫偶联物及使用方法
CN105330743B (zh)	2007-08-02	2019-05-28	吉利德生物制剂公司	Lox和loxl2抑制剂及其应用
JP5749009B2 (ja)	2007-08-13	2015-07-15	バスジーンセラピューティクス, インコーポレイテッドVasgenetherapeutics, Inc.	ＥｐｈＢ４に結合するヒト化抗体を利用する癌治療剤
CA2696360C (en)	2007-08-14	2018-11-20	Ludwig Institute For Cancer Research	Monoclonal antibody targeting the egfr receptor and uses thereof
US8916135B2 (en)	2007-08-22	2014-12-23	Colorado School Of Mines	Lanthanide nanoparticle conjugates and uses thereof
EP2570425B1 (de)	2007-09-04	2017-08-23	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES	Deletionen in der Domäne II von Pseudomonas Exotoxin A zur Reduzierung von nichtspezifischer Toxizität
US7704508B2 (en)	2007-09-14	2010-04-27	New York Blood Center	Babesia subtilisin
US8877688B2 (en)	2007-09-14	2014-11-04	Adimab, Llc	Rationally designed, synthetic antibody libraries and uses therefor
BRPI0816785A2 (pt)	2007-09-14	2017-05-02	Adimab Inc	bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas
EP2348052A3 (de)	2007-09-17	2011-10-26	The Regents of The University of California	Auf Prostatazellen in situ abzielende internalisierende humane monoklonale Antikörper
GB0718843D0 (en)	2007-09-26	2007-11-07	Cancer Rec Tech Ltd	Materials and methods relating to modifying the binding of antibodies
CN101874042B9 (zh)	2007-09-26	2019-01-01	中外制药株式会社	利用cdr的氨基酸取代来改变抗体等电点的方法
CA2700714C (en)	2007-09-26	2018-09-11	Ucb Pharma S.A.	Dual specificity antibody fusions
CA2701032C (en)	2007-09-27	2021-01-26	Amgen Inc.	Pharmaceutical formulations
BR122022001846B1 (pt)	2007-09-28	2022-12-27	Portola Pharmaceuticals, Inc.	Uso de polipeptídeo de duas cadeias para preparo de medicamento para reduzir sangramento
US8470560B2 (en)	2007-10-03	2013-06-25	The United States Of America As Represented By The Secretary Of The Army	CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
US20110014196A1 (en) *	2007-10-03	2011-01-20	Covalys Biosciences Ag	Drug Transfer into Living Cells
EP2050764A1 (de)	2007-10-15	2009-04-22	sanofi-aventis	Neues polyvalentes bispezifisches Antikörperformat und Verwendung
WO2009055343A2 (en)	2007-10-22	2009-04-30	Schering Corporation	Fully human anti-vegf antibodies and methods of using
EP2215117B2 (de)	2007-10-30	2018-01-10	Genentech, Inc.	Antikörperaufreinigung durch kationen-austausch-chromatographie
WO2009061910A1 (en)	2007-11-08	2009-05-14	Genetech, Inc.	Anti-factor b antibodies and their uses
CN101918030B (zh)	2007-11-09	2015-10-14	派瑞格恩医药公司	抗vegf抗体的组合物和方法
KR20100097691A (ko)	2007-11-12	2010-09-03	테라클론 사이언시스, 아이엔씨.	인플루엔자의 치료 및 진단을 위한 조성물 및 방법
CA2705509A1 (en)	2007-11-14	2009-05-22	Forerunner Pharma Research Co., Ltd.	Diagnosis and treatment of cancer using anti-gpr49 antibody
BRPI0820543A2 (pt)	2007-11-15	2015-06-16	Chugai Pharmaceutical Co Ltd	Anticorpo monoclonal capaz de ligar a anexelekto, e uso do mesmo
ES2962777T3 (es)	2007-11-15	2024-03-21	Amgen Inc	Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral
EP3115469B1 (de)	2007-11-19	2020-04-29	Celera Corporation	Lungenkrebsmarker und verwendungen davon
EP2062920A3 (de)	2007-11-21	2009-06-17	Peter Hornbeck	Proteinphosphorylation durch basophilische Serin-/Threonin-Kinasen in Insulinsignalisierungspfaden
CA2706729A1 (en)	2007-11-29	2009-06-11	Genentech, Inc.	Gene expression markers for inflammatory bowel disease
TWI468417B (zh)	2007-11-30	2015-01-11	Genentech Inc	抗－ｖｅｇｆ抗體
WO2009072604A1 (ja)	2007-12-05	2009-06-11	Chugai Seiyaku Kabushiki Kaisha	抗nr10抗体、およびその利用
GB0723797D0 (en)	2007-12-05	2008-01-16	Immunosolv Ltd	Method
EP2067787A1 (de)	2007-12-06	2009-06-10	Boehringer Ingelheim International GmbH	Verfahren zur Kontrolle von Insektenpopulationen
EP2227483B1 (de)	2007-12-19	2017-04-19	The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.	Lösliche formen von hendra- und nipah-virus-f-glycoprotein und anwendungen davon
MX2010006823A (es)	2007-12-20	2010-09-30	Xoma Technology Ltd	Metodos para el tratamiento de la gota.
AU2008343855B2 (en)	2007-12-21	2013-08-15	Amgen Inc.	Anti-amyloid antibodies and uses thereof
EP2077281A1 (de)	2008-01-02	2009-07-08	Bergen Teknologioverforing AS	Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
US7914785B2 (en)	2008-01-02	2011-03-29	Bergen Teknologieverforing As	B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US8697434B2 (en)	2008-01-11	2014-04-15	Colorado School Of Mines	Detection of phage amplification by SERS nanoparticles
CA2711557A1 (en)	2008-01-11	2009-07-16	The University Of Tokyo	Anti-cldn6 antibody
ATE548052T1 (de)	2008-01-17	2012-03-15	Philogen Spa	Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
CA2711826C (en)	2008-01-25	2018-02-27	Amgen Inc.	Ferroportin antibodies and methods of use
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
HUE029869T2 (en)	2008-01-31	2017-04-28	Genentech Inc	Anti-cd79b antibodies and immunoconjugates and methods of use
AU2009223688B2 (en)	2008-03-10	2014-12-11	Theraclone Sciences, Inc.	Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
DK2842575T3 (da)	2008-03-18	2017-11-27	Seattle Genetics Inc	Auristatin-lægemiddel-linker-konjugater
US9441034B2 (en)	2008-03-27	2016-09-13	Zymogenetics, Inc.	Compositions and methods for inhibiting PDGFRβ and VEGF-A
EP2698380A1 (de)	2008-03-28	2014-02-19	Sea Lane Biotechnologies, LLC	Neutralisierung von Molekülen in Virusantigene
US9441204B2 (en)	2008-04-03	2016-09-13	Colorado School Of Mines	Compositions and methods for detecting Yersinia pestis bacteria
WO2009124294A2 (en)	2008-04-05	2009-10-08	Lpath, Inc.	Pharmaceutical compositions for binding sphingosine-1-phosphate
EP3605088A1 (de)	2008-04-09	2020-02-05	Genentech, Inc.	Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen
US10000568B2 (en)	2008-04-10	2018-06-19	Cell Signaling Technology, Inc.	Compositions and methods for detecting EGFR in cancer
WO2009126944A1 (en) *	2008-04-11	2009-10-15	Trubion Pharmaceuticals, Inc.	Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
SG190572A1 (en)	2008-04-29	2013-06-28	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
AU2009246946B2 (en)	2008-05-01	2013-09-26	Amgen Inc.	Anti-hepcidin antibodies and methods of use
WO2009135181A2 (en)	2008-05-02	2009-11-05	Seattle Genetics, Inc.	Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
EP2116555A1 (de)	2008-05-08	2009-11-11	Bayer Schering Pharma Aktiengesellschaft	Verwendung eines spezifisch an ED-B Fibronectin bindenden radioaktiv markierten Moleküls bei einem Verfahren zur Behandlung von Hodgkin-Lymphom
CN102046806B (zh)	2008-05-09	2014-10-08	阿科尼生物系统公司	微阵列系统
US8680025B2 (en)	2008-05-09	2014-03-25	Akonni Biosystems, Inc.	Microarray system
US8093018B2 (en)	2008-05-20	2012-01-10	Otsuka Pharmaceutical Co., Ltd.	Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
PE20091931A1 (es)	2008-05-22	2009-12-31	Bristol Myers Squibb Co	Proteinas de dominio de armazon basadas en fibronectina multivalentes
JP2011523853A (ja)	2008-06-03	2011-08-25	アボット・ラボラトリーズ	二重可変ドメイン免疫グロブリン及びその使用
BRPI0913366A8 (pt)	2008-06-03	2017-07-11	Abbott Lab	Imunoglobulinas de domínio variável duplo e seus usos
US8575314B2 (en)	2008-06-20	2013-11-05	National University Corporation Okayama University	Antibody against oxidized LDL/β2GPI complex and use of the same
WO2009155932A2 (en)	2008-06-25	2009-12-30	H. Lundbeck A/S	Modulation of the trpv : vps10p-domain receptor system for the treatment of pain
PL2315756T3 (pl)	2008-07-08	2015-02-27	Incyte Holdings Corp	1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
SG192489A1 (en)	2008-07-08	2013-08-30	Abbott Lab	Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
ES2613841T3 (es)	2008-07-16	2017-05-26	Medical And Biological Laboratories Co., Ltd.	Anticuerpo anti-CLCP1 humano y uso del mismo
US8148088B2 (en)	2008-07-18	2012-04-03	Abgent	Regulation of autophagy pathway phosphorylation and uses thereof
EP2633864A1 (de)	2008-07-25	2013-09-04	The Regents of the University of Colorado	Clip-Hemmer und Verfahren zur Modulation der Immunfunktion
PT2848625T (pt)	2008-08-14	2019-10-25	Genentech Inc	Métodos para remover um contaminante com a utilização de cromatografia de membrana de permuta iónica de deslocação de proteína indígena.
US8968705B2 (en)	2008-08-22	2015-03-03	Colorado School Of Mines	Gold/lanthanide nanoparticle conjugates and uses thereof
US8790642B2 (en)	2008-08-29	2014-07-29	Genentech, Inc.	Cross-reactive and bispecific anti-IL-17A/F antibodies
ES2628108T3 (es)	2008-09-03	2017-08-01	F. Hoffmann-La Roche Ag	Anticuerpos multiespecíficos
TW201014605A (en)	2008-09-16	2010-04-16	Genentech Inc	Methods for treating progressive multiple sclerosis
JP5778577B2 (ja)	2008-09-19	2015-09-16	メディミューン，エルエルシー	Ｄｌｌ４に対する抗体およびその使用
BRPI0918947A2 (pt)	2008-09-26	2015-12-01	Ucb Pharma Sa	proteína de fusão de anticorpo
US8734803B2 (en)	2008-09-28	2014-05-27	Ibio Inc.	Humanized neuraminidase antibody and methods of use thereof
CN102271724B (zh)	2008-10-09	2015-10-14	塔夫茨大学信托人	含有甘油的改性丝膜
US8871202B2 (en)	2008-10-24	2014-10-28	Lpath, Inc.	Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
JP5775458B2 (ja)	2008-11-06	2015-09-09	グレンマークファーマシューティカルズ，エセ．アー．	抗α２インテグリン抗体を使用する処置
WO2010054264A1 (en)	2008-11-07	2010-05-14	Triact Therapeutics, Inc.	Use of catecholic butane derivatives in cancer therapy
US8298533B2 (en)	2008-11-07	2012-10-30	Medimmune Limited	Antibodies to IL-1R1
CN102438652B (zh)	2008-11-12	2014-08-13	米迪缪尼有限公司	抗体制剂
AU2009314091B2 (en)	2008-11-12	2015-05-14	Theraclone Sciences, Inc.	Human M2e peptide immunogens
CN104922669A (zh)	2008-11-13	2015-09-23	通用医疗公司	用于通过调整bmp-6来调节铁稳态的方法和组合物
WO2010059315A1 (en)	2008-11-18	2010-05-27	Merrimack Pharmaceuticals, Inc.	Human serum albumin linkers and conjugates thereof
EP2189539B2 (de)	2008-11-21	2018-06-13	Chimera Biotec GmbH	Konjugatkomplexe zum Analytnachweis
PL2361085T5 (pl)	2008-11-22	2018-12-31	F.Hoffmann-La Roche Ag	Zastosowanie przeciwciała anty-vegf w połączeniu z chemioterapią w leczeniu raka sutka
JP5761653B2 (ja)	2008-12-04	2015-08-12	ランケナーインスティテュートフォーメディカルリサーチ	水晶体線維症疾患の治療および予防用の組成物と方法
KR20190069615A (ko)	2008-12-09	2019-06-19	제넨테크, 인크.	항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
CA2747248A1 (en)	2008-12-17	2010-07-15	Sharookh Kapadia	Hepatitis c virus combination therapy
WO2010071800A1 (en)	2008-12-19	2010-06-24	Schering Corporation	Feed supplement for mammalian cell culture and methods of use
WO2010073972A1 (ja)	2008-12-22	2010-07-01	エーザイ・アール・アンド・ディー・マネジメント株式会社	Ｎｅｐｈ３を用いた膵臓前駆細胞の取得方法
EP2388320B1 (de)	2008-12-22	2017-02-15	Chugai Seiyaku Kabushiki Kaisha	Anti-hs6st2-antikörper und verwendung davon
CA2748158A1 (en)	2008-12-23	2010-07-01	Astrazeneca Ab	Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
WO2010073694A1 (ja)	2008-12-25	2010-07-01	国立大学法人東京大学	抗tm4sf20抗体を用いた癌の診断と治療
SG172427A1 (en)	2008-12-26	2011-07-28	Univ Tokyo	Diagnosis and treatment of cancer using anti-lgr7 antibody
GB0902916D0 (en)	2009-02-20	2009-04-08	Fusion Antibodies Ltd	Antibody therapy
GB0903168D0 (en)	2009-02-25	2009-04-08	Fusion Antibodies Ltd	Diagnostic method and kit
ES2573404T3 (es)	2009-03-02	2016-06-07	Aduro Biotech Holdings, Europe B.V.	Anticuerpos contra un ligando inductor de proliferación (APRIL)
JP2010210772A (ja)	2009-03-13	2010-09-24	Dainippon Screen Mfg Co Ltd	液晶表示装置の製造方法
EP2230515B1 (de)	2009-03-16	2014-12-17	Agilent Technologies, Inc.	Passivierung von Oberflächen nach Ligandenkupplung
SI3260136T1 (sl)	2009-03-17	2021-05-31	Theraclone Sciences, Inc.	Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
EP2408814B1 (de)	2009-03-20	2018-11-21	Amgen Inc.	Träger-immunglobuline und verwendungen davon
TW201438739A (zh)	2009-03-20	2014-10-16	Genentech Inc	抗-ｈｅｒ抗體
CN102365297B (zh)	2009-03-25	2014-10-29	霍夫曼-拉罗奇有限公司	新型抗-α5β1抗体及其应用
EP2411414B1 (de)	2009-03-25	2015-07-15	Genentech, Inc.	Anti-fgfr3-antikörper und verfahren zu deren anwendung
EP2233496A1 (de)	2009-03-26	2010-09-29	Ruhr-Universität Bochum	Fluoreszenzproteine
WO2010117729A1 (en)	2009-03-30	2010-10-14	Portola Pharmaceuticals, Inc.	Antidotes for factor xa inhibitors and methods of using the same
TW201038286A (en)	2009-04-01	2010-11-01	Genentech Inc	Anti-FcRH5 antibodies and immunoconjugates and methods of use
TWI474833B (zh)	2009-04-01	2015-03-01	Genentech Inc	胰島素阻抗性疾病之治療
WO2010112034A2 (en)	2009-04-02	2010-10-07	Aarhus Universitet	Compositions and methods for treatment and diagnosis of synucleinopathies
CN102369215B (zh)	2009-04-02	2015-01-21	罗切格利卡特公司	包含全长抗体和单链Fab片段的多特异性抗体
WO2010118243A2 (en)	2009-04-08	2010-10-14	Genentech, Inc.	Use of il-27 antagonists to treat lupus
US9079957B2 (en)	2009-04-16	2015-07-14	The University Of Tokyo	Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
SG175305A1 (en)	2009-04-23	2011-11-28	Theraclone Sciences Inc	Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
UY32560A (es)	2009-04-29	2010-11-30	Bayer Schering Pharma Ag	Inmunoconjugados de antimesotelina y usos de los mismos
AU2010248365A1 (en)	2009-05-15	2011-12-22	Chugai Seiyaku Kabushiki Kaisha	Anti-AXL antibody
JP2012527473A (ja)	2009-05-20	2012-11-08	セラクローンサイエンシーズ，インコーポレイテッド	インフルエンザの治療および診断のための組成物および方法
US8921281B2 (en)	2009-05-20	2014-12-30	Novimmune S.A.	Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
US20120128673A1 (en)	2009-05-20	2012-05-24	Schering Corporation	Modulation of pilr receptors to treat microbial infections
EP2436397B1 (de)	2009-05-29	2017-05-10	Chugai Seiyaku Kabushiki Kaisha	Pharmazeutische zusammensetzung mit einem antagonisten eines liganden der egf-familie als bestandteil
GB0909904D0 (en)	2009-06-09	2009-07-22	Affitech As	Product
GB0909906D0 (en)	2009-06-09	2009-07-22	Affitech As	Antibodies
CA2766152A1 (en)	2009-06-24	2011-01-13	Lpath, Inc.	Methods of increasing neuronal differentiation using antibodies to lysophosphatidic acid
WO2011004899A1 (en)	2009-07-06	2011-01-13	Takeda Pharmaceutical Company Limited	Cancerous disease modifying antibodies
MX2012000417A (es)	2009-07-07	2012-02-08	Genentech Inc	Diagnostico y tratamiento de enfermedades desmielinizantes autoinmunitarias.
PT2453910T (pt)	2009-07-15	2016-12-07	Portola Pharm Inc	Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
US20110033486A1 (en)	2009-07-20	2011-02-10	Abbas Alexander R	Gene expression markers for crohn's disease
CA2768617C (en)	2009-07-24	2018-03-27	Akonni Biosystems	Flow cell device
US8563694B2 (en)	2009-07-31	2013-10-22	Medarex, Inc.	Fully human antibodies to BTLA
NZ597531A (en)	2009-07-31	2014-05-30	Genentech Inc	Inhibition of tumor metastasis using bv8- or g-csf-antagonists
CA2770235C (en)	2009-08-06	2021-06-29	Genentech, Inc.	Method to improve virus removal in protein purification
PT2464725T (pt)	2009-08-11	2020-05-21	Hoffmann La Roche	Produção de proteínas em meios de cultura celular isentos de glutamina
TW201431558A (zh)	2009-08-15	2014-08-16	建南德克公司	用於治療先前治療過之乳癌之抗-血管新生療法
EP2468771A4 (de)	2009-08-17	2013-06-05	Forerunner Pharma Res Co Ltd	Pharmazeutische zusammensetzung mit einem antikörper gegen hb-egf als wirkstoff
AU2010284433B2 (en)	2009-08-17	2013-12-05	Health Research, Inc.	Combination therapy of cancer with anti-endoglin antibodies and anti-VEGF agents
US8221753B2 (en)	2009-09-30	2012-07-17	Tracon Pharmaceuticals, Inc.	Endoglin antibodies
CA2770174A1 (en)	2009-08-31	2011-03-03	Roche Glycart Ag	Affinity-matured humanized anti cea monoclonal antibodies
RU2012112550A (ru)	2009-09-01	2013-10-10	Эбботт Лэборетриз	Иммуноглобулины с двумя вариабельными доменами и их применение
IN2015DN02826A (de)	2009-09-03	2015-09-11	Merck Sharp & Dohme
WO2011032022A1 (en)	2009-09-11	2011-03-17	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Improved pseudomonas exotoxin a with reduced immunogenicity
CN102712696A (zh)	2009-09-16	2012-10-03	弗·哈夫曼-拉罗切有限公司	包含卷曲螺旋和/或系链的蛋白质复合体及其用途
ES2530732T3 (es)	2009-09-17	2015-03-05	Hoffmann La Roche	Procedimientos de diagnóstico para el cáncer de pulmón
TW201118166A (en)	2009-09-24	2011-06-01	Chugai Pharmaceutical Co Ltd	HLA class I-recognizing antibodies
US8926976B2 (en)	2009-09-25	2015-01-06	Xoma Technology Ltd.	Modulators
EP3187877A1 (de)	2009-09-25	2017-07-05	XOMA Technology Ltd.	Screening-verfahren
EP2483307A1 (de)	2009-09-29	2012-08-08	Fraunhofer USA, Inc.	Influenza-hämagglutinin-antikörper, zusammensetzungen daraus und zugehörige verfahren
UY32948A (es)	2009-10-15	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011047267A1 (en)	2009-10-15	2011-04-21	Genentech, Inc.	Chimeric fibroblast growth factors with altered receptor specificity
GB0918383D0 (en)	2009-10-20	2009-12-02	Cancer Rec Tech Ltd	Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
TW201121566A (en)	2009-10-22	2011-07-01	Genentech Inc	Anti-hepsin antibodies and methods using same
WO2011056494A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor type iib compositions and methods of use
WO2011056502A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Bone morphogenetic protein receptor type ii compositions and methods of use
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2322149A1 (de)	2009-11-03	2011-05-18	Universidad del Pais Vasco	Verfahren und Zusammensetzung zur Behandlung von Ischämie
US20110165648A1 (en)	2009-11-04	2011-07-07	Menno Van Lookeren Campagne	Co-crystal structure of factor D and anti-factor D antibody
PE20121646A1 (es)	2009-11-04	2012-12-02	Merck Sharp & Dohme	Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica
US8361744B2 (en)	2009-11-05	2013-01-29	Genentech, Inc.	Methods and composition for secretion of heterologous polypeptides
JP5888728B2 (ja)	2009-11-05	2016-03-22	国立大学法人大阪大学	自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
AR078986A1 (es)	2009-11-12	2011-12-14	Genentech Inc	Un metodo para promover la densidad de espinas dendriticas
JP2013511279A (ja)	2009-11-20	2013-04-04	アムジエン・インコーポレーテツド	抗Ｏｒａｉ１抗原結合蛋白及びその使用
RU2706200C2 (ru)	2009-11-24	2019-11-14	Медиммьюн Лимитед	Специфические связывающие агенты против в7-н1
JP5856065B2 (ja)	2009-11-30	2016-02-09	ジェネンテック，インコーポレイテッド	腫瘍の診断と治療のための組成物と方法
MX2012006406A (es)	2009-12-04	2012-07-25	Genentech Inc	Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
WO2011084357A1 (en)	2009-12-17	2011-07-14	Schering Corporation	Modulation of pilr to treat immune disorders
AU2010334809C1 (en)	2009-12-23	2015-02-26	Agenus Inc.	Binding members for human cytomegalovirus
GB0922553D0 (en)	2009-12-23	2010-02-10	Fusion Antibodies Ltd	Prognostic marker
RU2559542C2 (ru)	2009-12-23	2015-08-10	Дженентек, Инк.	Антитела против bv8 и их применение
EP2338492A1 (de)	2009-12-24	2011-06-29	Universidad del Pais Vasco	Verfahren und Zusammensetzung zur Behandlung von Alzheimer
US20110159588A1 (en)	2009-12-30	2011-06-30	Kui Lin	Methods for Modulating a PDGF-AA Mediated Biological Response
SG10201604093XA (en)	2010-01-15	2016-07-28	Kirin Amgen Inc	Antibody formulation and therapeutic regimens
EP2530109A4 (de)	2010-01-29	2013-08-28	Toray Industries	Harzfolie auf polymilchsäurebasis
PT2530091T (pt)	2010-01-29	2018-05-17	Chugai Pharmaceutical Co Ltd	Anticorpo anti-dll3
TW201129384A (en)	2010-02-10	2011-09-01	Immunogen Inc	CD20 antibodies and uses thereof
GB201002238D0 (en)	2010-02-10	2010-03-31	Affitech As	Antibodies
CN110227154A (zh)	2010-02-23	2019-09-13	霍夫曼-拉罗奇有限公司	用于治疗卵巢癌的抗血管发生疗法
BR112012020373A8 (pt)	2010-02-23	2018-01-02	Genentech Inc	anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico
WO2011105573A1 (ja)	2010-02-26	2011-09-01	株式会社未来創薬研究所	抗icam3抗体およびその用途
JP5845171B2 (ja)	2010-03-04	2016-01-20	大日本住友製薬株式会社	炎症性腸疾患用薬剤
WO2011119487A2 (en)	2010-03-22	2011-09-29	Genentech, Inc.	Compositions and methods useful for stabilizing protein-containing formulations
AR080793A1 (es)	2010-03-26	2012-05-09	Roche Glycart Ag	Anticuerpos biespecificos
WO2011133931A1 (en)	2010-04-22	2011-10-27	Genentech, Inc.	Use of il-27 antagonists for treating inflammatory bowel disease
MX346731B (es)	2010-04-23	2017-03-30	Genentech Inc *	Producción de proteínas heteromultiméricas.
RU2012151500A (ru)	2010-05-03	2014-06-10	Дженентек, Инк.	Композиции и способы, пригодные для снижения вязкости белковосодержащих составов
SG185027A1 (en)	2010-05-03	2012-11-29	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor
SMT202000095T1 (it)	2010-05-14	2020-03-13	Amgen Inc	Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
US9995679B2 (en)	2010-05-25	2018-06-12	Carnegie Mellon University	Targeted probes of cellular physiology
KR101976853B1 (ko)	2010-05-25	2019-05-09	제넨테크, 인크.	폴리펩티드의 정제 방법
DK2575881T3 (en)	2010-05-28	2017-01-09	Inst Nat Sante Rech Med	Specific anti-CD160-antibodies for the treatment of eye diseases on the basis of neoangiogenesis
WO2011153243A2 (en)	2010-06-02	2011-12-08	Genentech, Inc.	Anti-angiogenesis therapy for treating gastric cancer
AU2011259924A1 (en)	2010-06-02	2013-01-24	Sumitomo Dainippon Pharma Co., Ltd.	Treatment drug for autoimmune diseases and allergic diseases
EP2580240B1 (de)	2010-06-14	2018-11-28	Lykera Biomed S.A.	S100a4-antikörper und deren therapeutische anwendungen
BR112012033002B1 (pt)	2010-06-24	2021-10-13	Genentech, Inc	Composição aquosa de matéria, método de inibição de agregação induzida por agitação e método de prevenção de oxidação
WO2012001087A1 (en)	2010-06-30	2012-01-05	Novo Nordisk A/S	Antibodies that are capable of specifically binding tissue factor pathway inhibitor
JP6023706B2 (ja)	2010-07-09	2016-11-09	アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏＢｉｏｔｅｃｈＨｏｌｄｉｎｇｓ，ＥｕｒｏｐｅＢ．Ｖ．	Ｃｄ２７に対するアゴニスト抗体
AU2011274528B2 (en)	2010-07-09	2015-04-23	Genentech, Inc.	Anti-neuropilin antibodies and methods of use
JP2013538191A (ja)	2010-07-23	2013-10-10	トラスティーズオブボストンユニバーシティ	病的血管新生および腫瘍細胞侵襲性の阻害のための治療法としてならびに分子イメージングおよび標的化送達のための抗ＤＥｓｕｐＲ阻害剤
PE20131412A1 (es)	2010-08-03	2014-01-19	Abbvie Inc	Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012021648A1 (en)	2010-08-10	2012-02-16	Amgen Inc.	Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
AU2011289275A1 (en)	2010-08-12	2013-02-21	Theraclone Sciences, Inc.	Anti-hemagglutinin antibody compositions and methods of use thereof
ES2555864T3 (es)	2010-08-19	2016-01-11	F. Hoffmann-La Roche Ag	Ensayo para la medición de anticuerpos de unión a un anticuerpo monoclonal terapéutico
EP2609111B1 (de)	2010-08-24	2017-11-01	F. Hoffmann-La Roche AG	Bispezifische antikörper die ein disulfid-stabilisiertes fv enthalten
WO2012027440A1 (en)	2010-08-24	2012-03-01	Abbott Laboratories	Hiv core protein specific antibodies and uses thereof
CN103260639A (zh)	2010-08-26	2013-08-21	Abbvie公司	双重可变结构域免疫球蛋白及其用途
UA109908C2 (xx)	2010-08-27	2015-10-26		Виділений ммр9-зв'язувальний білок
ES2920140T3 (es)	2010-08-31	2022-08-01	Theraclone Sciences Inc	Anticuerpos neutralizantes del virus de la inmunodeficiencia humana (VIH)
WO2012028683A1 (en)	2010-09-02	2012-03-08	Novartis Ag	Antibody gel system for sustained drug delivery
WO2012032043A1 (en)	2010-09-07	2012-03-15	Areva Med Llc	212 pb imaging
JP5866130B2 (ja)	2010-09-10	2016-02-17	アペクシジェン，インコーポレイテッド	抗ＩＬ−１β抗体およびその使用方法
WO2012038382A2 (en)	2010-09-20	2012-03-29	Progenika Biopharma, S.A.	Markers for joint displasia, osteoarthritis and conditions secondary thereto
JP6159660B2 (ja)	2010-09-22	2017-07-05	アムジエン・インコーポレーテツド	担体としての免疫グロブリンおよびその使用
WO2012043533A1 (ja)	2010-09-28	2012-04-05	積水化学工業株式会社	抗ヒトｃｃｒ７抗体、ハイブリドーマ、核酸、ベクター、細胞、医薬組成物、並びに、抗体固定化担体
TWI720377B (zh)	2010-09-29	2021-03-01	美商艾澤西公司	與191p4d12蛋白結合之抗體藥物共軛物(adc)
AU2011317107B2 (en)	2010-10-19	2016-02-25	Trustees Of Tufts College	Silk fibroin-based microneedles and methods of making the same
MX2013004679A (es)	2010-10-25	2014-02-20	Univ Minnesota	Composicion terapeutica para el tratamiento de glioblastoma.
EP2633317A1 (de)	2010-10-25	2013-09-04	Genentech, Inc.	Behandlung von magen-darm-entzündung und psoriasis a
ES2784385T3 (es)	2010-10-27	2020-09-24	Univ New York State Res Found	Composiciones direccionadas al dominio extracelular soluble de la cadherina-E y procedimientos relacionados para la terapia del cáncer
TW201250003A (en)	2010-11-01	2012-12-16	Genentech Inc	Predicting progression to advanced age-related macular degeneration using a polygenic score
EP3205662A3 (de)	2010-11-10	2017-11-01	Laboratorios del Dr. Esteve S.A.	Hoch immunogene hiv-p24-sequenzen
PH12013500974A1 (en)	2010-11-17	2013-07-08	Chugai Pharmaceutical Co Ltd	Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
US20140199682A1 (en)	2010-11-17	2014-07-17	Sea Lane Biotechnologies, Llc	Influenza neutralizing agents
EP2643353A1 (de)	2010-11-24	2013-10-02	Novartis AG	Multispezifische moleküle
WO2012071436A1 (en)	2010-11-24	2012-05-31	Genentech, Inc.	Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
GB201020738D0 (en)	2010-12-07	2011-01-19	Affitech Res As	Antibodies
EP2655413B1 (de)	2010-12-23	2019-01-16	F.Hoffmann-La Roche Ag	Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
WO2012092539A2 (en)	2010-12-31	2012-07-05	Takeda Pharmaceutical Company Limited	Antibodies to dll4 and uses thereof
KR101614997B1 (ko)	2011-01-10	2016-04-22	씨티 아틀란틱 엘티디.	종양 관련 항원 결합 항체를 포함하는 조합 요법
US9772329B2 (en)	2011-01-11	2017-09-26	The Governing Council Of The University Of Toronto	Protein detection method
DK2665746T3 (en)	2011-01-17	2021-02-01	Lykera Biomed S A	Antibodies against the s100p protein for the treatment and diagnosis of cancer
WO2012100835A1 (en)	2011-01-28	2012-08-02	Laboratorios Del Dr. Esteve, S.A.	Methods and compositions for the treatment of aids
AR085138A1 (es)	2011-02-04	2013-09-11	Genentech Inc	VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
WO2012107728A2 (en)	2011-02-09	2012-08-16	Cancer Research Technology Limited	Frmd4a antagonists and their uses
US20120213781A1 (en)	2011-02-11	2012-08-23	Zyngenia, Inc.	Monovalent and Multivalent Multispecific Complexes and Uses Thereof
MX2013009357A (es)	2011-02-14	2014-02-17	Theraclone Sciences Inc	Composiciones y metodos para la terapia y diagnostico de la influenza.
EP2680875B1 (de)	2011-03-02	2019-10-23	Novo Nordisk Health Care AG	Gerinnungsfaktor-targeting auf tlt-1 auf aktivierten plättchen
US20140099264A1 (en)	2011-03-07	2014-04-10	F. Hoffman-La Roche Ag	Means and methods for in vivo testing of therapeutic antibodies
EP2683413A1 (de)	2011-03-07	2014-01-15	F.Hoffmann-La Roche Ag	In-vivo-auswahl therapeutisch aktiver antikörper
US8609818B2 (en)	2011-03-10	2013-12-17	Omeros Corporation	Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
JP2014509591A (ja)	2011-03-15	2014-04-21	セラクローンサイエンシーズ，インコーポレイテッド	インフルエンザの治療および診断のための組成物および方法
SG193434A1 (en)	2011-03-16	2013-10-30	Amgen Inc	Potent and selective inhibitors of nav1.3 and nav1.7
TWI700093B (zh)	2011-03-16	2020-08-01	法商賽諾菲公司	雙重ｖ區類抗體蛋白質之用途
EP2500073A1 (de)	2011-03-17	2012-09-19	ChromaCon AG	Verfahren zur Identifizierung und Reinigung von mehrfach spezifischen Polypeptiden
AU2012237026A1 (en)	2011-03-25	2013-10-24	Genentech, Inc.	Novel protein purification methods
TWI743461B (zh)	2011-03-28	2021-10-21	法商賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
CN103429264A (zh)	2011-03-31	2013-12-04	默沙东公司	针对人程序性死亡受体pd-1的抗体的稳定制剂和有关的治疗
AU2012236304C1 (en)	2011-03-31	2017-01-05	Genentech, Inc.	Methods of administering beta7 integrin antagonists
US10059746B2 (en)	2011-04-04	2018-08-28	University Of Iowa Research Foundation	Methods of improving vaccine immunogenicity
EP2694554A1 (de)	2011-04-08	2014-02-12	Gilead Biologics, Inc.	Verfahren und zusammensetzungen zur normalisierung einer tumorvaskulatur mittels loxl2-hemmung
JP6104794B2 (ja)	2011-04-18	2017-03-29	国立大学法人東京大学	抗ｉｔｍ２ａ抗体を用いる癌の診断および治療
WO2012145652A1 (en)	2011-04-20	2012-10-26	Trustees Of Tufts College	Dynamic silk coatings for implantable devices
CA2833879C (en)	2011-04-21	2023-03-14	David L. Kaplan	Compositions and methods for stabilization of active agents
PH12018502221B1 (en)	2011-05-02	2023-05-10	Millennium Pharm Inc	FORMULATION FOR ANTI-a4Ã7 ANTIBODY
UA116189C2 (uk)	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP2704735A1 (de)	2011-05-03	2014-03-12	Genentech, Inc.	Vaskuläre disruptoren und ihre verwendung
CN103648525B (zh)	2011-05-06	2016-08-24	由卫生与公共服务部部长代表的美国政府	靶向间皮素的重组免疫毒素
CA2835522C (en)	2011-05-09	2019-06-11	Duke University	Focused evolution of hiv-1 neutralizing antibodies revealed by crystal structures and deep sequencing
LT2710033T (lt)	2011-05-17	2021-06-10	The Rockefeller University	Žmogaus imunodeficito virusą neutralizuojantys antikūnai ir jų panaudojimo būdai
PT2714735T (pt)	2011-06-03	2021-10-26	Xoma Technology Ltd	Anticorpos específicos para tgf-beta
JP2014518889A (ja)	2011-06-03	2014-08-07	シーティーアトランティックリミテッド	Ｍａｇｅａ３結合抗体
WO2012163769A1 (en)	2011-06-03	2012-12-06	Ct Atlantic Ltd.	Magea3 binding antibodies
ES2635416T3 (es)	2011-06-09	2017-10-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Exotoxina A de pseudomonas con epítopos de linfocitos T y/o linfocitos B menos inmunogénicos
GB201109966D0 (en)	2011-06-10	2011-07-27	Cancer Res Inst Royal	Materials and methods for treating pten mutated or deficient cancer
GB201109965D0 (en)	2011-06-10	2011-07-27	Cancer Res Inst Royal	Materials and methods for treating estrogen receptor alpher(ER) positive cancer
MX342131B (es)	2011-06-17	2016-09-14	Novo Nordisk As	Eliminacion selectiva de celulas erosivas.
BR112013030472A2 (pt)	2011-06-30	2019-09-24	Genentech Inc	formulação farmacêutica, artigo de fabricação e método
KR20140058532A (ko)	2011-06-30	2014-05-14	겐자임 코포레이션	Ｔ-세포 활성화 억제제
JP2013040160A (ja)	2011-07-01	2013-02-28	Genentech Inc	自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
HUE029855T2 (en)	2011-07-05	2017-04-28	Bioasis Technologies Inc	p97 antibody conjugates
WO2013011059A1 (en)	2011-07-18	2013-01-24	Novo Nordisk A/S	Antagonist antibodies against oscar
WO2013011061A1 (en)	2011-07-18	2013-01-24	Novo Nordisk A/S	Antagonistic antibodies against oscar
WO2013011063A1 (en)	2011-07-18	2013-01-24	Novo Nordisk A/S	Antagonistic antibodies against oscar
WO2013011062A2 (en)	2011-07-18	2013-01-24	Novo Nordisk A/S	Oscar antagonists
EP2734232B1 (de)	2011-07-19	2017-11-01	Philogen S.p.A.	Sequentielle anti-ctla4 und zielgerichtete il-2 therapie
WO2013015821A1 (en)	2011-07-22	2013-01-31	The Research Foundation Of State University Of New York	Antibodies to the b12-transcobalamin receptor
US20130022551A1 (en)	2011-07-22	2013-01-24	Trustees Of Boston University	DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
US9120858B2 (en)	2011-07-22	2015-09-01	The Research Foundation Of State University Of New York	Antibodies to the B12-transcobalamin receptor
BR122022000334B1 (pt)	2011-08-01	2023-03-21	Genentech, Inc	Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek
PL2739649T3 (pl)	2011-08-05	2018-03-30	Bioasis Technologies Inc.	Fragmenty p97 o aktywności transferowej
WO2013025834A2 (en)	2011-08-15	2013-02-21	The University Of Chicago	Compositions and methods related to antibodies to staphylococcal protein a
KR20140068877A (ko)	2011-08-17	2014-06-09	제넨테크, 인크.	불응성 종양에서의 혈관신생의 억제
US20150017091A1 (en)	2011-08-18	2015-01-15	Cornell University	Detection and treatment of metastatic disease
JP6101205B2 (ja)	2011-08-23	2017-03-22	中外製薬株式会社	抗腫瘍活性を有する新規な抗ｄｄｒ１抗体
WO2013033069A1 (en)	2011-08-30	2013-03-07	Theraclone Sciences, Inc.	Human rhinovirus (hrv) antibodies
GB201212550D0 (en)	2012-07-13	2012-08-29	Novartis Ag	B cell assay
US10018630B2 (en)	2011-09-07	2018-07-10	Chugai Seiyaku Kabushiki Kaisha	Cancer stem cell isolation
SG11201400100SA (en)	2011-09-09	2014-06-27	Univ Osaka	Dengue-virus serotype neutralizing antibodies
UY34317A (es)	2011-09-12	2013-02-28	Genzyme Corp	Anticuerpo antireceptor de célula T (alfa)/ß
EP2755993B1 (de)	2011-09-16	2017-11-08	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Pseudomonas exotoxin a mit weniger immunogenen b-zellepitopen
US10024867B2 (en)	2011-09-30	2018-07-17	Chugai Seiyaku Kabushiki Kaisha	Ion concentration-dependent binding molecule library
US9575073B2 (en)	2011-10-10	2017-02-21	Rutgers, The State University Of New Jersey	Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
ES2682081T3 (es)	2011-10-11	2018-09-18	F. Hoffmann-La Roche Ag	Ensamblaje mejorado de anticuerpos biespecíficos
WO2013054320A1 (en)	2011-10-11	2013-04-18	Tel Hashomer Medical Research Infrastructure And Services Ltd.	Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
EP2581388A1 (de)	2011-10-14	2013-04-17	Centre National de la Recherche Scientifique (CNRS)	Antikörper gegen sPLA2-V und Gebrauch davon
EP2772268B8 (de)	2011-10-28	2020-01-08	Chugai Seiyaku Kabushiki Kaisha	Krebsstammzellenspezifisches molekül
JP6158090B2 (ja) *	2011-10-31	2017-07-05	ダニエル・ジェイ・カポン	非ペプチドヒンジ部含有フレキシブル抗体様分子
PL3257564T5 (pl)	2011-11-02	2024-10-07	F. Hoffmann-La Roche Ag	Chromatografia elucyjna z przeładowaniem
EP2776066B1 (de)	2011-11-07	2018-09-19	Universite Laval	Rank-/rankl-antagonisten zur verwendung zur behandlung neuromuskulärer erkrankungen, genetischer myopathien und/oder nicht genetischer myopathien
US20140370094A1 (en)	2011-11-08	2014-12-18	Tufts University	Silk-based scaffold platform for engineering tissue constructs
EP2776079B1 (de)	2011-11-09	2020-04-01	Trustees Of Tufts College	Injizierbare seidenfibroinschaumstoffe und ihre verwendungen
MX2014005702A (es)	2011-11-09	2015-02-17	Tufts College	Particulas de fibroina de seda inyectables y sus usos.
CN104185477B (zh)	2011-11-17	2017-05-24	辉瑞公司	细胞毒性肽及其抗体‑药物缀合物
KR20140095096A (ko)	2011-11-21	2014-07-31	제넨테크, 인크.	항-c-met 항체의 정제
SG11201402619VA (en)	2011-11-23	2014-10-30	Igenica Biotherapeutics Inc	Anti-cd98 antibodies and methods of use thereof
CA2856895C (en)	2011-11-28	2021-10-26	Merck Patent Gmbh	Anti-pd-l1 antibodies and uses thereof
WO2013082511A1 (en)	2011-12-02	2013-06-06	Genentech, Inc.	Methods for overcoming tumor resistance to vegf antagonists
EP2602265A1 (de)	2011-12-07	2013-06-12	Centre National de la Recherche Scientifique (CNRS)	Antikörper gegen Anti-sPLA2-X und Verwendungen damit
US10118958B2 (en)	2011-12-14	2018-11-06	AbbVie Deutschland GmbH & Co. KG	Composition and method for the diagnosis and treatment of iron-related disorders
WO2013090633A2 (en)	2011-12-14	2013-06-20	AbbVie Deutschland GmbH & Co. KG	Composition and method for the diagnosis and treatment of iron-related disorders
JP6320300B2 (ja)	2011-12-19	2018-05-09	ゾーマ（ユーエス）リミテッドライアビリティカンパニー	座瘡を治療するための方法
EP2794928B1 (de)	2011-12-22	2019-02-20	President and Fellows of Harvard College	Zusammensetzungen und verfahren zum nachweis von analyten
WO2013091903A1 (en)	2011-12-22	2013-06-27	Novo Nordisk A/S	Anti-crac channel antibodies
SI2794635T1 (sl)	2011-12-22	2018-12-31	F. Hoffmann-La Roche Ag	Ionskoizmenjevalna membranska kromatografija
WO2013096948A1 (en)	2011-12-23	2013-06-27	Lydon Nicholas B	Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en)	2011-12-23	2018-06-05	Nicholas B. Lydon	Immunoglobulins and variants directed against pathogenic microbes
KR101963230B1 (ko) *	2011-12-26	2019-03-29	삼성전자주식회사	복수개의 단일 항체를 포함하는 단백질 복합체
TWI593705B (zh)	2011-12-28	2017-08-01	Chugai Pharmaceutical Co Ltd	Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
WO2013102193A1 (en)	2011-12-29	2013-07-04	Trustees Of Tufts College	Functionalization of biomaterials to control regeneration and inflammation responses
UY34558A (es)	2011-12-30	2013-07-31	Abbvie Inc	Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
WO2013101771A2 (en)	2011-12-30	2013-07-04	Genentech, Inc.	Compositions and method for treating autoimmune diseases
US10774132B2 (en)	2012-01-09	2020-09-15	The Scripps Research Instittue	Ultralong complementarity determining regions and uses thereof
EP2802601B1 (de)	2012-01-09	2019-11-13	The Scripps Research Institute	Humanisierte antikörper mit ultralangem cdr3s
WO2013106572A1 (en)	2012-01-11	2013-07-18	Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University	Bispecific antibody fragments for neurological disease proteins and methods of use
IL316441A (en)	2012-01-27	2024-12-01	Abbvie Inc	Composition and method for diagnosing and treating diseases associated with axonal degeneration of nerve cells
US20130243750A1 (en)	2012-01-31	2013-09-19	Genentech, Inc.	Anti-ige antibodies and methods using same
AU2013200903B2 (en)	2012-02-08	2015-05-14	Mcure Biosciences Inc.	CDIM binding proteins and uses thereof
JP6486686B2 (ja)	2012-02-10	2019-03-20	ジェネンテック，インコーポレイテッド	単鎖抗体及び他のヘテロ多量体
JP6144286B2 (ja)	2012-02-29	2017-06-07	ギリアードバイオロジックス，インコーポレイテッド	マトリックスメタロプロテイナーゼ９に対する抗体
EP2820048B1 (de)	2012-02-29	2019-04-17	Gilead Biologics, Inc.	Antikörper gegen matrix-metalloproteinase-9
EP3388083A1 (de)	2012-03-09	2018-10-17	Lankenau Institute for Medical Research	Zusammensetzungen und verfahren zur behandlung von krebs
ES2693593T3 (es)	2012-03-15	2018-12-12	Omeros Corporation	Composición y método para la diversificación de secuencias diana
US9228006B2 (en)	2012-03-16	2016-01-05	University Health Network	Methods and compositions for modulating Toso activity
CA2867464A1 (en)	2012-03-20	2013-09-26	Trustees Of Tufts College	Silk reservoirs for drug delivery
EP2641916A1 (de)	2012-03-23	2013-09-25	Centre National de la Recherche Scientifique (C.N.R.S)	Neue Antikörper gegen Anti-sPLA2-IIA und Verwendungen damit
CA2865082A1 (en)	2012-03-27	2013-10-03	Genentech, Inc.	Diagnosis and treatments relating to her3 inhibitors
WO2013150518A1 (en)	2012-04-01	2013-10-10	Rappaport Family Institute For Research In The Medical Sciences	Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
WO2013151649A1 (en)	2012-04-04	2013-10-10	Sialix Inc	Glycan-interacting compounds
US9493744B2 (en)	2012-06-20	2016-11-15	Genentech, Inc.	Methods for viral inactivation and other adventitious agents
AU2013245785A1 (en)	2012-04-13	2014-10-23	Trustees Of Tufts College	Methods and compositions for preparing a silk microsphere
US20130281355A1 (en)	2012-04-24	2013-10-24	Genentech, Inc.	Cell culture compositions and methods for polypeptide production
US10653786B2 (en)	2012-04-25	2020-05-19	Trustees Of Tufts College	Silk microspheres and methods for surface lubrication
KR102413947B1 (ko)	2012-05-30	2022-06-27	추가이 세이야쿠 가부시키가이샤	표적 조직 특이적 항원 결합 분자
SG11201407859YA (en)	2012-05-31	2014-12-30	Genentech Inc	Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
MX2014014830A (es)	2012-06-15	2015-05-11	Genentech Inc	Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso.
CA2871882A1 (en)	2012-06-27	2014-01-03	F. Hoffmann-La Roche Ag	Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
CA2871880A1 (en)	2012-06-27	2014-01-03	F. Hoffmann-La Roche Ag	Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
EP3539563A1 (de)	2012-07-19	2019-09-18	Redwood Bioscience, Inc.	Für cd22 spezifischer antikörper und verfahren zur verwendung davon
EP2879709B1 (de)	2012-07-31	2020-01-08	The Brigham and Women's Hospital, Inc.	Modulation der immunreaktion
WO2014022515A1 (en)	2012-07-31	2014-02-06	Bioasis Technologies, Inc.	Dephosphorylated lysosomal storage disease proteins and methods of use thereof
FR2994390B1 (fr)	2012-08-10	2014-08-15	Adocia	Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
GB2507207A (en)	2012-08-16	2014-04-23	Ipierian Inc	Treatment of Tauopathies
CN105073132B (zh)	2012-08-23	2020-01-10	艾更斯司股份有限公司	结合158p1d7蛋白的抗体药物偶联物(adc)
WO2014036520A1 (en)	2012-08-30	2014-03-06	Merrimack Pharmaceuticals, Inc.	Combination therapies comprising anti-erbb3 agents
UA115789C2 (uk)	2012-09-05	2017-12-26	Трейкон Фармасутікалз, Інк.	Композиція антитіла до cd105 та її застосування
ES2643571T3 (es)	2012-09-27	2017-11-23	Chugai Seiyaku Kabushiki Kaisha	Gen de fusión FGFR3 y fármaco que se dirige al mismo
CA2886422C (en)	2012-10-03	2022-12-13	Jason Baardsnes	Methods of quantitating heavy and light chain polypeptide pairs
PL2903629T3 (pl)	2012-10-03	2019-12-31	Philogen S.P.A.	Koniugat przeciwciała do zastosowania w leczeniu nieswoistego zapalenia jelita
AR092908A1 (es)	2012-10-05	2015-05-06	Genentech Inc	Metodos para diagnosticar y tratar enfermedad intestinal inflamatoria
JP2015533832A (ja)	2012-10-09	2015-11-26	アイジェニカバイオセラピューティクスインコーポレイテッド	抗Ｃ１６ｏｒｆ５４抗体およびその使用方法
CN118955699A (zh)	2012-10-18	2024-11-15	洛克菲勒大学	广泛中和性抗hiv抗体
EP3722320A3 (de)	2012-10-25	2020-12-30	Bioverativ USA Inc.	Anti-komplement-c1s-antikörper und verwendungen davon
WO2014070939A1 (en)	2012-10-30	2014-05-08	Gilead Sciences, Inc.	Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)
KR101911438B1 (ko)	2012-10-31	2018-10-24	삼성전자주식회사	이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
AR093311A1 (es)	2012-11-01	2015-05-27	Abbvie Inc	Inmunoglobulinas de dominio variable dual contra el factor de crecimiento endotelial vascular (vegf) y el ligando involucrado en la señalizacion celula a celula a traves del receptor notch (dll4)
WO2014071206A1 (en)	2012-11-02	2014-05-08	True North Therapeutics, Inc.	Anti-complement c1s antibodies and uses thereof
BR112015010070B1 (pt)	2012-11-05	2022-06-21	Pfizer Inc	Compostos análogos de spliceostatin, composição e usos
MX2015005810A (es)	2012-11-07	2015-09-23	Pfizer	Anticuerpos anti-notch y conjugados de anticuerpo-farmaco.
WO2014074905A1 (en)	2012-11-08	2014-05-15	Eleven Biotherapeutics, Inc.	Il-6 antagonists and uses thereof
CN105051528A (zh)	2012-11-15	2015-11-11	弗·哈夫曼-拉罗切有限公司	离子强度介导的pH梯度离子交换色谱
US10550171B2 (en)	2012-11-21	2020-02-04	The Governors Of The University Of Alberta	Immunomodulatory peptides and methods of use thereof
CN105452295B (zh)	2012-12-10	2020-06-12	比奥根Ma公司	抗血液树突细胞抗原2抗体及其用途
GB201223172D0 (en)	2012-12-21	2013-02-06	Immunocore Ltd	Method
AR093984A1 (es)	2012-12-21	2015-07-01	Merck Sharp & Dohme	Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014107739A1 (en)	2013-01-07	2014-07-10	Eleven Biotherapeutics, Inc.	Antibodies against pcsk9
EP2767549A1 (de)	2013-02-19	2014-08-20	Adienne S.A.	Anti-CD26-Antikörper und Verwendungen davon
AR094873A1 (es)	2013-02-25	2015-09-02	Genentech Inc	Métodos y composiciones para detectar y tratar mutantes de akt resistentes a fármacos
US9834575B2 (en)	2013-02-26	2017-12-05	Triact Therapeutics, Inc.	Cancer therapy
UY35397A (es)	2013-03-12	2014-10-31	Amgen Inc	INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
SG11201507475UA (en)	2013-03-13	2015-10-29	Genentech Inc	Antibody formulations
NZ711373A (en)	2013-03-13	2020-07-31	Bioasis Technologies Inc	Fragments of p97 and uses thereof
US10081673B2 (en)	2013-03-14	2018-09-25	Ffe Therapeutics Llc	Compositions and methods for treating angiogenesis-related disorders
DK2968503T3 (en)	2013-03-15	2018-12-03	Intrinsic Lifesciences Llc	ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF
CA2906076A1 (en)	2013-03-15	2014-09-18	Abvitro, Inc.	Single cell bar-coding for antibody discovery
WO2014144280A2 (en)	2013-03-15	2014-09-18	Abbvie Inc.	DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
EP2970499B1 (de)	2013-03-15	2022-08-10	Novo Nordisk A/S	Antikörper für spezifische bindung zweier epitope auf dem gewebefaktor-pathway-inhibitor
WO2014143739A2 (en)	2013-03-15	2014-09-18	Biogen Idec Ma Inc.	Anti-alpha v beta 6 antibodies and uses thereof
US10035859B2 (en)	2013-03-15	2018-07-31	Biogen Ma Inc.	Anti-alpha V beta 6 antibodies and uses thereof
US20140363433A1 (en)	2013-03-15	2014-12-11	Omeros Corporation	Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
CN105392801A (zh)	2013-03-15	2016-03-09	比奥根Ma公司	使用抗αvβ5抗体治疗和预防急性肾损伤
US20140283157A1 (en)	2013-03-15	2014-09-18	Diadexus, Inc.	Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
US9469686B2 (en)	2013-03-15	2016-10-18	Abbott Laboratories	Anti-GP73 monoclonal antibodies and methods of obtaining the same
PT3611180T (pt)	2013-03-15	2022-03-15	Biomolecular Holdings Llc	Imunoglobulina híbrida que contém uma ligação não peptídica
US10233249B2 (en)	2013-03-19	2019-03-19	Beijing Shenogen Pharma Group Ltd.	Antibodies and methods for treating estrogen receptor-associated diseases
CN105188764B (zh)	2013-03-21	2020-03-20	詹尼斯费尔公司	Dna嵌入剂的细胞递送
EP3495814A3 (de)	2013-03-27	2019-07-17	F. Hoffmann-La Roche AG	Verwendung von biomarkern zur beurteilung der behandlung von magen-darm-entzündungserkrankungen mit beta7-integrin-antagonisten
WO2014169076A1 (en)	2013-04-09	2014-10-16	Annexon,,Inc.	Methods of treatment for neuromyelitis optica
DK2984108T3 (en)	2013-04-09	2017-09-18	Lykera Biomed S A	Anti-s100a7 antibodies for the treatment and diagnosis of cancer
SG10201800800YA (en)	2013-05-06	2018-03-28	Scholar Rock Inc	Compositions and methods for growth factor modulation
WO2014188423A1 (en)	2013-05-21	2014-11-27	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Treatment of mast cell related pathologies
EP3006042B1 (de)	2013-05-30	2024-05-08	National University Corporation Chiba University	Zusammensetzung zur behandlung von entzündungskrankheiten mit anti-myosin-regulatorischem leichtketten-polypeptidantikörper
WO2014197885A2 (en)	2013-06-07	2014-12-11	Duke University	Inhibitors of complement factor h
DK3007726T3 (da)	2013-06-10	2020-07-06	Ipierian Inc	Fremgangsmåder til behandling af en tauopati
WO2014200767A1 (en)	2013-06-12	2014-12-18	The General Hospital Corporation	Methods, kits, and systems for multiplexed detection of target molecules and uses thereof
WO2014205187A1 (en)	2013-06-20	2014-12-24	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor
CN105517571A (zh)	2013-06-24	2016-04-20	中外制药株式会社	含有人源化抗上皮调节蛋白抗体作为有效成分的腺癌以外的非小细胞肺癌的治疗药
WO2015001082A1 (en)	2013-07-05	2015-01-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
WO2015006507A1 (en)	2013-07-09	2015-01-15	Annexon, Inc.	Methods of treatment for alzheimer's disease and huntington's disease
BR112016000231A8 (pt)	2013-07-12	2019-12-31	Genentech Inc	métodos para identificações de condições de separação com cromatografia de troca de íons e para análises de composições de polipeptídeos
US10208125B2 (en)	2013-07-15	2019-02-19	University of Pittsburgh—of the Commonwealth System of Higher Education	Anti-mucin 1 binding agents and uses thereof
AU2014290069B2 (en)	2013-07-16	2019-01-03	Genentech, Inc.	Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
AU2014290361B2 (en)	2013-07-18	2019-04-18	Taurus Biosciences, Llc	Humanized antibodies with ultralong complementarity determining regions
US20160168231A1 (en)	2013-07-18	2016-06-16	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
EP3786187A1 (de)	2013-08-01	2021-03-03	Université catholique de Louvain	Antikörper, der einen komplex des humanen glycoproteins mit einem wiederholten überwiegenden (garp) und latenten tgf-beta-1 bindet
KR20160060634A (ko)	2013-08-01	2016-05-30	어젠시스 인코포레이티드	Ｃｄ37 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
RU2016107426A (ru)	2013-08-02	2017-09-07	Адуро Байотек Холдингс, Юроуп Б.В.	Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета
KR20160042438A (ko)	2013-08-12	2016-04-19	제넨테크, 인크.	보체-연관 상태의 치료를 위한 조성물 및 방법
AR097306A1 (es)	2013-08-20	2016-03-02	Merck Sharp & Dohme	Modulación de la inmunidad tumoral
US20160208016A1 (en)	2013-08-29	2016-07-21	University Of Copenhagen	Anti-ADAM12 antibodies for the treatment of cancer
AU2014317009A1 (en)	2013-09-05	2016-03-10	Aduro Biotech Holdings, Europe B.V.	CD70-binding peptides and method, process and use relating thereto
MX2016002798A (es)	2013-09-05	2016-07-21	Genentech Inc	Metodo para reutilizacion de cromatografia.
CN105917235A (zh)	2013-09-06	2016-08-31	赛拉诺斯股份有限公司	用于检测感染性疾病的系统和方法
NL2011406C2 (en)	2013-09-06	2015-03-10	Bionovion Holding B V	Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
WO2015035410A1 (en)	2013-09-09	2015-03-12	Triact Therapeutic, Inc.	Cancer therapy
CA3174012A1 (en)	2013-09-13	2015-03-19	Genentech, Inc.	Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
NZ756750A (en)	2013-09-13	2022-05-27	Genentech Inc	Methods and compositions comprising purified recombinant polypeptides
GB201317207D0 (en)	2013-09-27	2013-11-13	Univ Glasgow	Materials and methods for modulating disc1 turnover
ES2881306T3 (es)	2013-09-27	2021-11-29	Chugai Pharmaceutical Co Ltd	Método para la producción de heteromultímeros de polipéptidos
EP3940065A1 (de)	2013-09-30	2022-01-19	Chugai Seiyaku Kabushiki Kaisha	Verfahren zur herstellung eines antigenbindenden moleküls unter verwendung von modifizierten helferphagen
US9243294B2 (en)	2013-09-30	2016-01-26	Hadasit Medical Research Services And Development Ltd.	Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
AU2014329437B2 (en)	2013-10-06	2018-10-18	F. Hoffmann-La Roche Ag	Modified Pseudomonas exotoxin A
WO2015057939A1 (en)	2013-10-18	2015-04-23	Biogen Idec Ma Inc.	Anti-s1p4 antibodies and uses thereof
EP3733868A3 (de)	2013-10-28	2021-01-13	DOTS Technology Corp.	Allergennachweis
TW201605904A (zh)	2013-11-07	2016-02-16	諾佛儂迪克股份有限公司	治療凝血病變之新穎方法及抗體
EA201600354A1 (ru)	2013-11-11	2016-12-30	Чугаи Сеияку Кабушики Каиша	Антигенсвязывающая молекула, содержащая вариабельную область антитела
MX2016006167A (es)	2013-11-15	2016-08-08	Genentech Inc	Metodos para la inactivacion viral usando detergentes ecologico.
JP6555687B2 (ja)	2013-11-20	2019-08-07	国立大学法人北海道大学	免疫制御剤
EP3074035B1 (de)	2013-11-25	2020-05-13	FameWave Ltd.	Zusammensetzungen mit anti-ceacam-1- und anti-pd-antikörper zur krebsbehandlung
EP2876114A1 (de)	2013-11-25	2015-05-27	Consejo Superior De Investigaciones Científicas	Antikörper gegen CCR9 und Anwendungen davon
WO2015081073A2 (en)	2013-11-26	2015-06-04	The Brigham And Women's Hospital, Inc.	Compositions and methods for modulating an immune response
MX2016006356A (es)	2013-11-27	2016-10-28	Ipierian Inc	Metodos de tratamiento de una tauopatia.
AU2014360539A1 (en)	2013-12-03	2016-06-23	President And Fellows Of Harvard College	Methods and reagents for the assessment of gestational diabetes
CN105980557B (zh)	2013-12-04	2020-04-07	中外制药株式会社	抗原结合能力根据化合物的浓度而变化的抗原结合分子及其文库
JP2017505756A (ja)	2013-12-13	2017-02-23	ザジェネラルホスピタルコーポレイション	可溶性高分子量（ｈｍｗ）タウ種およびその用途
CN105899535A (zh)	2013-12-17	2016-08-24	豪夫迈·罗氏有限公司	用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
EP3083682B1 (de)	2013-12-20	2024-04-17	F. Hoffmann-La Roche AG	Dualspezifische antikörper
US10023636B2 (en)	2013-12-20	2018-07-17	Intervet Inc.	Caninized murine antibodies to human PD-1
EP3581179A1 (de)	2013-12-27	2019-12-18	Chugai Seiyaku Kabushiki Kaisha	Mutantes fgfr-gatekeeper-gen und dagegen gerichteter wirkstoff
CN106062005A (zh)	2013-12-30	2016-10-26	医药生命融合研究团	抗krs单克隆抗体及其用途
EP2896400A1 (de)	2014-01-17	2015-07-22	Université Catholique De Louvain	Verfahren zur Erhöhung der Bioverfügbarkeit von inhaliertem Verbindungen
WO2015110923A2 (en)	2014-01-21	2015-07-30	Acerta Pharma B.V.	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
SG11201606018UA (en)	2014-01-24	2016-08-30	Ngm Biopharmaceuticals Inc	Binding proteins and methods of use thereof
KR101871088B1 (ko)	2014-01-27	2018-06-25	화이자 인코포레이티드	이관능성 세포독성제
ES2764973T3 (es)	2014-02-03	2020-06-05	Bioasis Technologies Inc	Proteínas de fusión de P97
US10106623B2 (en)	2014-02-12	2018-10-23	Michael Uhlin	Bispecific antibodies for use in stem cell transplantation
WO2015126729A1 (en)	2014-02-19	2015-08-27	Bioasis Technologies, Inc.	P97-ids fusion proteins
TW201544511A (zh)	2014-02-27	2015-12-01	Gilead Sciences Inc	針對基質金屬蛋白酶９之抗體及其使用方法
US20150252434A1 (en)	2014-03-07	2015-09-10	University Health Network	Methods and compositions for detection of targets involved in cancer metastasis
EP3116486B1 (de)	2014-03-14	2019-12-04	Daniel J. Capon	Hybrides immunglobulin mit nichtpeptidylverbindung
WO2015140351A1 (en)	2014-03-21	2015-09-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for enhancing myelination
WO2015143343A2 (en)	2014-03-21	2015-09-24	The Brigham And Women's Hospital, Inc.	Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
US20170174764A1 (en)	2014-03-27	2017-06-22	Yeda Research And Development Co. Ltd.	T-cell receptor cdr3 peptides and antibodies
KR20220065091A (ko)	2014-03-27	2022-05-19	제넨테크, 인크.	염증성 장 질환의 진단 및 치료 방법
EP3572093A1 (de)	2014-03-31	2019-11-27	Debiopharm International SA	Fgfr-fusionen
PL3126391T3 (pl)	2014-03-31	2020-05-18	Universitetet I Tromsø - Norges Arktiske Universitet	Przeciwciała przeciwko HPA-1a
WO2015152908A1 (en)	2014-04-02	2015-10-08	U.S. Army Medical Research Institute Of Infectious Diseases	Rapid dual direct fluorescent antibody assay for the identification of bacillus anthracis
ES2830849T3 (es)	2014-04-25	2021-06-04	Brigham & Womens Hospital Inc	Ensayo y método para tratar sujetos con enfermedades inmunomediadas
JP6792454B2 (ja)	2014-04-25	2020-11-25	ザブリガムアンドウィメンズホスピタルインコーポレイテッドＴｈｅＢｒｉｇｈａｍａｎｄＷｏｍｅｎ’ｓＨｏｓｐｉｔａｌ，Ｉｎｃ．	アルファ−フェトプロテイン（ａｆｐ）を操作するための方法
US11427647B2 (en)	2014-04-27	2022-08-30	Famewave Ltd.	Polynucleotides encoding humanized antibodies against CEACAM1
MD20160130A2 (ro)	2014-04-27	2017-04-30	Ccam Biotherapeutics Ltd.	Anticorpi umanizaţi contra CEACAM1
US9388239B2 (en)	2014-05-01	2016-07-12	Consejo Nacional De Investigation Cientifica	Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
HRP20231139T1 (hr)	2014-05-06	2024-01-05	F. Hoffmann - La Roche Ag	Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
SG11201609959UA (en)	2014-05-30	2016-12-29	Henlius Biotech Co Ltd	Anti-epidermal growth factor receptor (egfr) antibodies
LT3151859T (lt)	2014-06-09	2021-03-25	Ultragenyx Pharmaceutical Inc.	Veiksminga ir efektyvi serumo fosfatų kontrolė optimaliam kaulų formavimosi užtikrinimui
MX2016016295A (es)	2014-06-11	2017-03-31	Gilead Sciences Inc	Metodos para tratar enfermedades cardiovasculares.
RS59353B1 (sr)	2014-06-12	2019-10-31	Ra Pharmaceuticals Inc	Modulacija aktivnosti komplementa
WO2016007919A2 (en)	2014-07-11	2016-01-14	Regents Of The University Of Minnesota	Antibody fragments for detecting cancer and methods of use
ES2742500T3 (es)	2014-07-15	2020-02-14	Federal Express Corp	Composiciones para tratamiento del cáncer usando antagonistas de unión al eje de pd-1 e inhibidores de MEK
MX2017001531A (es)	2014-08-08	2017-05-15	Alector Llc	Anticuerpos anti-trem2 y metodos de uso de los mismos.
TW201609099A (zh)	2014-08-11	2016-03-16	艾森塔製藥公司	使用布魯頓（Ｂｒｕｔｏｎ）氏酪胺酸激酶（ＢＴＫ）抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
EP3179992B1 (de)	2014-08-11	2022-05-11	Acerta Pharma B.V.	Therapeutische kombinationen eines btk-inhibitors, eines pd-1-inhibitors und/oder eines pd-l1-inhibitors
JO3663B1 (ar)	2014-08-19	2020-08-27	Merck Sharp & Dohme	الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
AP2017009765A0 (en)	2014-08-19	2017-02-28	Merck Sharp & Dohme	Anti-tigit antibodies
WO2016026143A1 (en)	2014-08-22	2016-02-25	Huiru Wang	Saccharide-based biomarkers and therapeutics
RU2704611C2 (ru)	2014-09-15	2019-10-30	Дженентек, Инк.	Составы на основе антител
AR101875A1 (es)	2014-09-15	2017-01-18	Amgen Inc	Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
EP3194593B1 (de)	2014-09-15	2019-02-06	AbVitro LLC	Nukleotidbibliotheksequenzierung mit hohem durchsatz
ES2804826T3 (es)	2014-09-16	2021-02-09	Synermore Biologics Co Ltd	Anticuerpo anti-EGFR y usos del mismo
EP3197915A4 (de)	2014-09-22	2018-12-19	Intrinsic Lifesciences LLC	Humanisierte anti-hepcidin-antikörper und verwendungen davon
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
TWI700300B (zh)	2014-09-26	2020-08-01	日商中外製藥股份有限公司	中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh)	2014-09-26	2020-08-11	日商中外製藥股份有限公司	測定ｆｖｉｉｉ的反應性之方法
GB201419108D0 (en)	2014-10-27	2014-12-10	Glythera Ltd	Materials and methods relating to linkers for use in antibody drug conjugates
CN107207587B (zh)	2014-11-05	2022-04-19	安尼艾克松股份有限公司	人源化抗-补体因子c1q抗体及其应用
MX2017003478A (es)	2014-11-05	2018-02-01	Genentech Inc	Anticuerpos anti-fgfr2/3 y metodos para su uso.
AU2015343494A1 (en)	2014-11-06	2017-04-27	Genentech, Inc.	Combination therapy comprising OX40 binding agonists and TIGIT inhibitors
WO2016073157A1 (en)	2014-11-06	2016-05-12	Genentech, Inc.	Anti-ang2 antibodies and methods of use thereof
EP3632931A1 (de)	2014-11-07	2020-04-08	Sesen Bio, Inc.	Verbesserte il-6-antikörper
WO2016073894A1 (en)	2014-11-07	2016-05-12	Eleven Biotherapeutics, Inc.	Therapeutic agents with increased ocular retention
US10093730B2 (en)	2014-11-10	2018-10-09	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
JP2018500882A (ja)	2014-11-10	2018-01-18	ジェネンテック，インコーポレイテッド	腎症の動物モデルおよびそれを治療するための薬剤
US10155820B2 (en)	2014-11-12	2018-12-18	Tracon Pharmaceuticals, Inc.	Anti-endoglin antibodies and uses thereof
US9926375B2 (en)	2014-11-12	2018-03-27	Tracon Pharmaceuticals, Inc.	Anti-endoglin antibodies and uses thereof
US9879087B2 (en)	2014-11-12	2018-01-30	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
EP4183806A3 (de)	2014-11-12	2023-08-02	Seagen Inc.	Glycaninteragierende verbindungen und verfahren zur verwendung
CN107429075B (zh)	2014-11-17	2022-11-01	卡内基梅隆大学	可激活的双组份光敏剂
ES2981450T3 (es)	2014-11-19	2024-10-08	P & M Venge Ab	Métodos de diagnóstico que emplean HNL
EP3221445B1 (de)	2014-11-20	2021-07-14	The Regents of The University of California	Zusammensetzungen und verfahren in zusammenhang mit hämatologischer erholung
WO2016086147A1 (en)	2014-11-26	2016-06-02	Millennium Pharmaceuticals, Inc.	Vedolizumab for the treatment of fistulizing crohn's disease
US10584366B2 (en)	2014-12-03	2020-03-10	IsoPlexis Corporation	Analysis and screening of cell secretion profiles
WO2016087416A1 (en)	2014-12-03	2016-06-09	F. Hoffmann-La Roche Ag	Multispecific antibodies
WO2016090300A1 (en)	2014-12-05	2016-06-09	Genentech, Inc.	Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
WO2016094881A2 (en)	2014-12-11	2016-06-16	Abbvie Inc.	Lrp-8 binding proteins
AU2015358868A1 (en)	2014-12-11	2017-06-01	Inbiomotion S.L.	Binding members for human C-Maf
WO2016097420A1 (en)	2014-12-19	2016-06-23	Universite De Nantes	Anti il-34 antibodies
CA2971734A1 (en)	2014-12-22	2016-06-30	Enumeral Biomedical Holdings, Inc.	Anti-pd-1 antibodies
WO2016102657A1 (en)	2014-12-23	2016-06-30	Novo Nordisk A/S	Alpha-cell re-generation combined with conversion to beta cells
NL2014108B1 (en)	2015-01-09	2016-09-30	Aduro Biotech Holdings Europe B V	Altered april binding antibodies.
SG10201906471PA (en)	2015-01-14	2019-09-27	Brigham & Womens Hospital Inc	Treatment of cancer with anti-lap monoclonal antibodies
WO2016123329A2 (en)	2015-01-28	2016-08-04	Genentech, Inc.	Gene expression markers and treatment of multiple sclerosis
HRP20211824T1 (hr)	2015-01-28	2022-03-04	Ra Pharmaceuticals, Inc.	Modulatori aktivnosti komplementa
CA3012602A1 (en)	2015-01-30	2016-08-04	President And Fellows Of Harvard College	Peritumoral and intratumoral materials for cancer therapy
EP3253796A1 (de)	2015-02-03	2017-12-13	Université Catholique de Louvain	Anti-garp-protein und verwendungen davon
MA41451A (fr)	2015-02-04	2017-12-12	Univ Washington	Constructions anti-tau
TW202248212A (zh)	2015-02-05	2022-12-16	日商中外製藥股份有限公司	包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
SI3253865T1 (sl)	2015-02-06	2022-10-28	National University Of Singapore	Postopki za izboljšanje učinkovitosti terapevtskih imunskih celic
WO2016128912A1 (en)	2015-02-12	2016-08-18	Acerta Pharma B.V.	Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
RU2714233C2 (ru)	2015-02-26	2020-02-13	Мерк Патент Гмбх	Ингибиторы pd-1 / pd-l1 для лечения рака
CA2972099A1 (en)	2015-02-26	2016-09-01	Genentech, Inc.	Integrin beta7 antagonists and methods of treating crohn's disease
EP3265491A1 (de)	2015-03-03	2018-01-10	Xoma (Us) Llc	Behandlung von postprandialer hyperinsulinämie und hyperglykämie nach bariatrischer chirurgie
MA41636A (fr)	2015-03-06	2018-01-09	Millennium Pharm Inc	Méthode de traitement de la cholangite sclérosante primitive
ES2761726T3 (es)	2015-03-06	2020-05-20	Hoffmann La Roche	DsbA y DsbC ultrapurificadas y procedimientos de preparación y uso de las mismas
US20180057588A1 (en)	2015-03-16	2018-03-01	Aarhus Universitet	Antibodies Towards an Extracellular Region of NBCn1
US10780179B2 (en)	2015-03-18	2020-09-22	Immunobiochem Corporation	Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
WO2016150444A1 (en)	2015-03-20	2016-09-29	Aarhus Universitet	Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
BR112017018706B1 (pt)	2015-03-20	2023-01-24	Pfizer Inc	Agentes citotóxicos bifuncionais contendo o farmacoforo cti, composição farmacêutica e uso dos mesmos
WO2016159213A1 (ja)	2015-04-01	2016-10-06	中外製薬株式会社	ポリペプチド異種多量体の製造方法
EP3277306B1 (de)	2015-04-01	2023-02-22	Hadasit Medical Research Services and Development Ltd.	Inhibitoren der neuroligin-4-neurexin-1-beta-protein-protein-wechselwirkung zur verwendung in der behandlung von lebererkrankungen
EP3277722B1 (de)	2015-04-02	2021-08-18	Intervet International B.V.	Antikörper gegen caninen interleukin-4 rezeptor alpha
US11279768B1 (en)	2015-04-03	2022-03-22	Precision Biologics, Inc.	Anti-cancer antibodies, combination therapies, and uses thereof
EP3770171A1 (de)	2015-04-03	2021-01-27	XOMA Technology Ltd.	Behandlung von krebs unter verwendung von inhibitoren von tgf-beta und pd-1
WO2016161390A1 (en)	2015-04-03	2016-10-06	Eureka Therapeutics, Inc.	Constructs targeting afp peptide/mhc complexes and uses thereof
ES2866202T3 (es)	2015-04-06	2021-10-19	Subdomain Llc	Polipéptidos que contienen dominios de unión de novo y usos de los mismos
FI3280440T3 (fi)	2015-04-06	2023-03-09	Bioverativ Usa Inc	Humanisoituja anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
CN107708733B (zh)	2015-04-07	2022-11-15	艾利妥	抗分拣蛋白抗体和其使用方法
AU2016246695A1 (en)	2015-04-07	2017-10-26	Genentech, Inc.	Antigen binding complex having agonistic activity and methods of use
EP3081575A1 (de)	2015-04-12	2016-10-19	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Anti-plasmodium-parasiten-antikörper
BR112017016952A2 (pt)	2015-04-17	2018-04-03	F. Hoffmann-La Roche Ag	terapia de combinação com fatores de coagulação e anticorpos multiespecíficos
EP3913052A1 (de)	2015-04-24	2021-11-24	F. Hoffmann-La Roche AG	Verfahren zur identifizierung von bakterien mit bindenden polypeptiden
WO2016183104A1 (en)	2015-05-11	2016-11-17	Genentech, Inc.	Compositions and methods of treating lupus nephritis
US10787517B2 (en)	2015-05-18	2020-09-29	Agensys, Inc.	Antibodies that bind to AXL proteins
EP3154439A1 (de)	2015-05-19	2017-04-19	Yaya Diagnostics GmbH	Mittel und verfahren zur anreicherung von nukleinsäuren
JP7028765B2 (ja)	2015-05-22	2022-03-02	トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー	ベンズアミドおよび活性化合物組成物および使用方法
WO2016189091A1 (en)	2015-05-26	2016-12-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas
WO2016189118A1 (en)	2015-05-28	2016-12-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
JP6810058B2 (ja)	2015-05-28	2021-01-06	ジェネンテック，インコーポレイテッド	抗ｃｄ３ホモ二量体を検出するための細胞に基づくアッセイ
PL3303619T3 (pl)	2015-05-29	2020-10-05	F. Hoffmann-La Roche Ag	Metylacja promotora PD-L1 w chorobach nowotworowych
BR112017025332A2 (pt)	2015-06-01	2018-07-31	Medigene Immunotherapies Gmbh	anticorpos específicos de receptor de célula t
EP3303392B1 (de)	2015-06-01	2020-08-05	Medigene Immunotherapies GmbH	Verfahren zur erzeugung von antikörpern gegen t-zellrezeptor
JP6568239B2 (ja)	2015-06-01	2019-08-28	メディジーンイミュノテラピーズゲーエムベーハー	Ｔ細胞受容体ライブラリ
US10696745B2 (en)	2015-06-11	2020-06-30	Wuxi Biologics (Shanghai) Co. Ltd.	Anti-PD-L1 antibodies
KR20180033502A (ko)	2015-06-12	2018-04-03	알렉터 엘엘씨	항-cd33 항체 및 그의 사용 방법
EP3307779A2 (de)	2015-06-12	2018-04-18	Alector LLC	Anti-cd33-antikörper und verfahren zur verwendung davon
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3310810A1 (de)	2015-06-16	2018-04-25	Merck Patent GmbH	Kombinationsbehandlungen mit pd-l1-antagonisten
EP3313885A1 (de)	2015-06-29	2018-05-02	H. Hoffnabb-La Roche Ag	Typ-ii-cd20-antikörper zur verwendung in der organtransplantation
US10287338B2 (en)	2015-07-10	2019-05-14	Miran NERSISSIAN	Factor VIII protein compositions and methods of treating of hemophilia A
KR101750411B1 (ko)	2015-07-10	2017-06-27	한국생명공학연구원	엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법
JP2018528763A (ja)	2015-07-31	2018-10-04	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	バイオフィルムの除去のためのペプチドおよび抗体
EP3331536A4 (de)	2015-08-03	2019-03-27	The Regents of The University of California	Zusammensetzungen und verfahren zur modulierung der abhd2-aktivität
RS63482B1 (sr)	2015-08-05	2022-09-30	Acticor Biotech	Nova anti-humana gpvi antitela i njihove upotrebe
WO2017020291A1 (en)	2015-08-06	2017-02-09	Wuxi Biologics (Shanghai) Co. Ltd.	Novel anti-pd-l1 antibodies
WO2017021023A1 (en)	2015-08-06	2017-02-09	Yaya Diagnostics Gmbh	Means and methods for the detection of targets
RU2020124273A (ru)	2015-08-11	2020-12-03	Уси Байолоджикс (Кайман) Инк.	Новые анти-pd-1 антитела
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
US20190008859A1 (en)	2015-08-21	2019-01-10	Acerta Pharma B.V.	Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
AU2016316768A1 (en)	2015-08-28	2018-03-29	Alector Llc	Anti-Siglec-7 antibodies and methods of use thereof
US10407484B2 (en)	2015-09-02	2019-09-10	The Regents Of The University Of Colorado, A Body Corporate	Compositions and methods for modulating T-cell mediated immune response
US10946095B2 (en)	2015-09-02	2021-03-16	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
JP7074341B2 (ja)	2015-09-02	2022-05-24	イムテップエス．アー．エス．	抗ｌａｇ－３抗体
MX2018003183A (es)	2015-09-15	2018-08-23	Amgen Inc	Proteinas de enlace de antigeno biespecifico y tetraespecifico tetravalentes y usos de las mismas.
WO2017046746A1 (en)	2015-09-15	2017-03-23	Acerta Pharma B.V.	Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
MA44909A (fr)	2015-09-15	2018-07-25	Acerta Pharma Bv	Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
US11078251B2 (en)	2015-09-18	2021-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	T cell receptors (TCR) and uses thereof for the diagnosis and treatment of diabetes
KR20230079500A (ko)	2015-09-18	2023-06-07	추가이 세이야쿠 가부시키가이샤	Il-8에 결합하는 항체 및 그의 사용
EP3352760A4 (de)	2015-09-21	2019-03-06	Aptevo Research and Development LLC	Cd3-bindende polypeptide
US10647752B2 (en)	2015-09-22	2020-05-12	Inserm (Institut National De La Santé Et De La Recherche Medicale)	Polypeptides capable of inhibiting the binding between leptin and Neuropilin-1
MY191756A (en)	2015-09-23	2022-07-14	Genentech Inc	Optimized variants of anti-vegf antibodies
CN108291257B (zh)	2015-09-24	2023-12-29	阿布维特罗有限责任公司	亲和-寡核苷酸缀合物及其用途
WO2017050955A1 (en)	2015-09-24	2017-03-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Agents capable of inhibiting the binding between leptin and vegf165
BR112018005931A2 (pt)	2015-09-24	2018-10-09	Abvitro Llc	composições de anticorpo para hiv e métodos de uso
MX2018003534A (es)	2015-09-25	2019-04-25	Abvitro Llc	Proceso de alto rendimiento para identificacion de blanco de receptor de celula t de secuencias de receptor de celula t apareadas de manera natural.
EP4360646A3 (de)	2015-09-25	2024-05-15	F. Hoffmann-La Roche AG	Anti-tigit-antikörper und verfahren zur verwendung
US10428145B2 (en)	2015-09-29	2019-10-01	Celgene Corporation	PD-1 binding proteins and methods of use thereof
CA2997444A1 (en)	2015-09-29	2017-04-06	Amgen Inc.	Asgr inhibitors for reducing cholesterol levels
WO2017055484A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for determining the metabolic status of lymphomas
EP3355902B1 (de)	2015-09-30	2022-04-13	Merck Patent GmbH	Kombination eines pd-1-achsen-bindungsantagonisten und eines alk-inhibitors zur behandlung von alk-negativem krebs
IL293708A (en)	2015-10-06	2022-08-01	Genentech Inc	Method for treating multiple sclerosis
AU2016334051B2 (en)	2015-10-06	2023-10-26	Alector Llc	Anti-TREM2 antibodies and methods of use thereof
US10556953B2 (en)	2015-10-12	2020-02-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
EP3362093A4 (de)	2015-10-13	2019-05-08	Technion Research & Development Foundation Limited	Heparanase-neutralisierende monoklonale antikörper
EP3365027B1 (de)	2015-10-14	2022-03-30	Research Institute at Nationwide Children's Hospital	Hu-spezifische antikörper und deren verwendeng zur hemmung von biofilm
WO2017067944A1 (en)	2015-10-19	2017-04-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of subjects suffering from triple negative breast cancer
JO3555B1 (ar)	2015-10-29	2020-07-05	Merck Sharp & Dohme	جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
JP7060502B2 (ja)	2015-10-29	2022-04-26	アレクトルエルエルシー	抗Ｓｉｇｌｅｃ－９抗体及びその使用方法
UA123773C2 (uk)	2015-10-30	2021-06-02	Дженентек, Інк.	ВИДІЛЕНЕ АНТИТІЛО ПРОТИ HtrA1 ТА ЙОГО ЗАСТОСУВАННЯ ПРИ ЛІКУВАННІ ПОВ'ЯЗАНОГО З HtrA1 ПОРУШЕННЯ АБО ХВОРОБИ ОКА
EP4410376A3 (de)	2015-11-03	2024-10-30	Regents of the University of Minnesota	Cd200-hemmer und verfahren zur verwendung davon
IL258768B2 (en)	2015-11-12	2023-11-01	Siamab Therapeutics Inc	Compounds interacting with glycans and methods of use
WO2017086419A1 (ja)	2015-11-18	2017-05-26	中外製薬株式会社	液性免疫応答の増強方法
WO2017086367A1 (ja)	2015-11-18	2017-05-26	中外製薬株式会社	免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
SI3383920T1 (sl)	2015-11-30	2024-06-28	The Regents Of The University Of California	Dostava tumorsko specifičnega koristnega tovora in imunska aktivacija z uporabo humanega protitelesa, ki cilja visoko specifičen površinski antigen tumorskih celic
WO2017106061A1 (en)	2015-12-14	2017-06-22	Macrogenics, Inc.	Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
WO2017106578A1 (en)	2015-12-15	2017-06-22	Amgen Inc.	Pacap antibodies and uses thereof
MY186414A (en)	2015-12-15	2021-07-22	Gilead Sciences Inc	Human immunodeficiency virus neutralizing antibodies
CA3008244A1 (en)	2015-12-16	2017-06-22	Merck Sharp & Dohme Corp.	Anti-lag3 antibodies and antigen-binding fragments
CN108697759B (zh)	2015-12-16	2022-08-02	Ra制药公司	补体活性的调节剂
WO2017106566A1 (en)	2015-12-17	2017-06-22	Gilead Sciences, Inc.	Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
EP3389693A4 (de)	2015-12-18	2019-08-21	Agilvax, Inc.	Zusammensetzungen und verfahren im zusammenhang mit xct-peptiden
CN108430511B (zh)	2015-12-21	2021-06-04	合肥立方制药股份有限公司	一种药物设计方法和获得的药物及其应用
JP6676759B2 (ja)	2015-12-23	2020-04-08	メディジーンイミュノテラピーズゲーエムベーハー	抗原特異的ｔｃｒの新規生成
WO2017110980A1 (ja)	2015-12-25	2017-06-29	中外製薬株式会社	増強された活性を有する抗体及びその改変方法
MX2018007781A (es)	2015-12-28	2018-09-05	Chugai Pharmaceutical Co Ltd	Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
ES2837155T3 (es)	2016-01-04	2021-06-29	Inst Nat Sante Rech Med	Uso de PD-1 y Tim-3 como medida de células CD8+ para predecir y tratar el carcinoma de células renales
US11306140B2 (en)	2016-01-07	2022-04-19	The Schepens Eye Research Institute, Inc.	Therapeutics for ocular immunoinflammatory diseases
RU2766000C2 (ru)	2016-01-08	2022-02-07	АльтруБио Инк.	Четырехвалентные антитела к psgl-1 и их применения
PL3402503T3 (pl)	2016-01-13	2021-04-19	Acerta Pharma B.V.	Kombinacje terapeutyczne antyfolianu oraz inhibitora btk
ES2847155T3 (es)	2016-01-21	2021-08-02	Novartis Ag	Moléculas multiespecíficas que fijan como objetivo CLL-1
AU2017209083A1 (en)	2016-01-22	2018-07-12	Adimab, Llc	Anti-coagulation factor XI antibodies
US11513127B2 (en)	2016-01-25	2022-11-29	Genentech, Inc.	Methods for assaying T-cell dependent bispecific antibodies
WO2017129558A1 (en)	2016-01-25	2017-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
US11028410B2 (en)	2016-01-27	2021-06-08	Just-Evotec Biologics, Inc.	Hybrid promoter and uses thereof
EP3407912B1 (de)	2016-01-28	2022-05-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren zur verbesserung der potenz immunologischer checkpoint-hemmer
EP4035681A1 (de)	2016-01-28	2022-08-03	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren und pharmazeutische zusammensetzung zur behandlung von krebs
WO2017129763A1 (en)	2016-01-28	2017-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
JP2019507126A (ja)	2016-02-01	2019-03-14	ファイザー・インク	ツブリシン類似体およびこれらの調製のための方法
WO2017139975A1 (en)	2016-02-19	2017-08-24	Huiru Wang	Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
EP3419599A4 (de)	2016-02-23	2019-09-11	Sesen Bio, Inc.	Il-6-antagonistformulierungen und verwendung davon
US11066456B2 (en)	2016-02-25	2021-07-20	Washington University	Compositions comprising TREM2 and methods of use thereof
EP4043492A1 (de)	2016-03-01	2022-08-17	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.	Gegen humanen poliovirus-rezeptor (pvr) spezifische antikörper
US11472877B2 (en)	2016-03-04	2022-10-18	Alector Llc	Anti-TREM1 antibodies and methods of use thereof
WO2017161169A1 (en)	2016-03-17	2017-09-21	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Anti-py1235-met immunological binding reagent
EP3433277A4 (de)	2016-03-23	2020-06-17	Mabspace Biosciences (Suzhou) Co., Ltd	Neuartige anti-pd-l1-antikörper
MA43835A (fr)	2016-03-25	2018-11-28	Seattle Genetics Inc	Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
HRP20231614T1 (hr)	2016-03-28	2024-03-15	Incyte Corporation	Spojevi pirolotriazina kao tam inhibitori
US20190112380A1 (en)	2016-03-29	2019-04-18	University Of Southern California	Chimeric antigen receptors targeting cancer
CA3018253A1 (en)	2016-03-31	2017-10-05	University Of Southern California	A highly sensitive and specific luciferase based reporter assay for antigen detection
US10883108B2 (en)	2016-03-31	2021-01-05	The Schepens Eye Research Institute, Inc.	Endomucin inhibitor as an anti-angiogenic agent
PE20190209A1 (es)	2016-04-04	2019-02-07	Bioverativ Usa Inc	Anticuerpos anti-factor bb del complemento y uso de estos
US20200330459A1 (en)	2016-04-06	2020-10-22	Inserm (Institut National De La Santé Et La Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases
EP3440113A1 (de)	2016-04-08	2019-02-13	Gilead Sciences, Inc.	Zusammensetzungen und verfahren zur behandlung von krebs, entzündungs- und autoimmunerkrankungen
US10954287B2 (en)	2016-04-15	2021-03-23	Ra Pharmaceuticals, Inc.	Ras binding peptides and methods of use
CA3019588A1 (en)	2016-04-20	2017-10-26	Merck Sharp & Dohme Corp.	Cmv neutralizing antigen binding proteins
EP3445779A1 (de)	2016-04-22	2019-02-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren und pharmazeutische zusammensetzung zur behandlung von entzündlichen hauterkrankungen im zusammenhang mit desmoglein-1-mangel
WO2017189483A1 (en)	2016-04-25	2017-11-02	The Johns Hopkins University	Znt8 assays for drug development and pharmaceutical compositions
US10875919B2 (en)	2016-04-26	2020-12-29	Alector Llc	Chimeric receptors and methods of use thereof
EP3452092B1 (de)	2016-05-06	2020-08-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Pharmazeutische zusammensetzungen zur behandlung von chemoresistenter akuter myeloischer leukämie (aml)
WO2017194554A1 (en)	2016-05-10	2017-11-16	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Combinations therapies for the treatment of cancer
EP3454884B1 (de)	2016-05-10	2023-07-12	Sorbonne Université	Wirkstoffe zur aktivierung von cd47 zur verwendung bei der behandlung von entzündungen
JP7359547B2 (ja)	2016-05-17	2023-10-11	ジェネンテック，インコーポレイテッド	免疫療法における診断及び使用のための間質遺伝子シグネチャー
US20190292259A1 (en)	2016-05-24	2019-09-26	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
MX2018014435A (es)	2016-05-26	2019-04-15	Merck Patent Gmbh	Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
WO2017202890A1 (en)	2016-05-27	2017-11-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for predicting and treating myeloma
BR112018075858A2 (pt)	2016-06-14	2019-04-02	Merck Sharp & Dohme Corp.	anticorpos anti-fator xi de coagulação
MX2018015173A (es)	2016-06-17	2019-07-04	Genentech Inc	Purificacion de anticuerpos multiespecificos.
DK3264087T3 (da)	2016-06-27	2020-07-20	Chimera Biotec Gmbh	Fremgangsmåde og indretning til kvantificering af målmolekyler
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
EP3487880A1 (de)	2016-07-25	2019-05-29	Biogen MA Inc.	Anti-hspa5(grp78)-antikörper und verwendungen davon
NL2017267B1 (en)	2016-07-29	2018-02-01	Aduro Biotech Holdings Europe B V	Anti-pd-1 antibodies
EP3490600A1 (de)	2016-08-01	2019-06-05	Xoma (Us) Llc	Parathormon-rezeptor 1 (pth1r)-antikörper und verwendungen davon
NL2017270B1 (en)	2016-08-02	2018-02-09	Aduro Biotech Holdings Europe B V	New anti-hCTLA-4 antibodies
CA3032559C (en)	2016-08-03	2022-04-19	Pfizer Inc.	Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
AU2017306709A1 (en)	2016-08-05	2019-03-14	Humabs, BioMed SA	Anti-o2 antibodies and uses thereof
JP2019530434A (ja)	2016-08-05	2019-10-24	ジェネンテック，インコーポレイテッド	アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
KR20190038914A (ko)	2016-08-15	2019-04-09	노파르티스 아게	오파투무맙을 사용한 다발성 경화증의 치료 요법 및 방법
CN109716127B (zh)	2016-08-15	2022-06-14	豪夫迈·罗氏有限公司	定量包含非离子表面活性剂和多肽的组合物中非离子表面活性剂的层析方法
WO2018041989A1 (en)	2016-09-02	2018-03-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing and treating refractory celiac disease type 2
KR102560808B1 (ko)	2016-09-06	2023-07-27	추가이 세이야쿠 가부시키가이샤	응고 제 ix 인자 및/또는 활성화 응고 제 ix 인자 및 응고 제 x 인자 및/또는 활성화 응고 제 x 인자를 인식하는 이중특이성 항체의 사용법
WO2018049083A1 (en)	2016-09-07	2018-03-15	The Regents Of The University Of California	Antibodies to oxidation-specific epitopes
EP3510398A1 (de)	2016-09-12	2019-07-17	Isoplexis Corporation	System und verfahren zur multiplex-analyse von zellularen und anderen immunotherapeutika
IL265362B2 (en)	2016-09-14	2024-05-01	Merck Patent Gmbh	Anti-c-met antibodies and such antibody drug conjugates
CA3035132A1 (en)	2016-09-15	2018-03-22	Novimmune Sa	Bispecific antibody display on phage surface
ES2977137T3 (es)	2016-09-16	2024-08-19	Shanghai Henlius Biotech Inc	Anticuerpos anti-PD-1
JP2019534859A (ja)	2016-09-19	2019-12-05	セルジーンコーポレイション	Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
SG11201901950TA (en)	2016-09-19	2019-04-29	Celgene Corp	Methods of treating immune disorders using pd-1 binding proteins
JP2020502991A (ja)	2016-09-20	2020-01-30	ウーシーバイオロジクスアイルランドリミテッド	新規抗ｐｃｓｋ９抗体
WO2018054959A1 (en)	2016-09-20	2018-03-29	Aarhus Universitet	Compounds for treatment of lipoprotein metabolism disorders
WO2018055031A1 (en)	2016-09-21	2018-03-29	Aarhus Universitet	Acid-base transport inhibitors
US11525008B2 (en)	2016-09-22	2022-12-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of lung cancer
AU2017332495A1 (en)	2016-09-24	2019-04-11	Abvitro Llc	Affinity-oligonucleotide conjugates and uses thereof
JOP20190055A1 (ar)	2016-09-26	2019-03-24	Merck Sharp & Dohme	أجسام مضادة ضد cd27
WO2018058111A1 (en)	2016-09-26	2018-03-29	The Brigham And Women's Hospital, Inc.	Regulators of b cell-mediated immunosuppression
EP3518969A2 (de)	2016-09-28	2019-08-07	Xoma (Us) Llc	Antikörper zur bindung von interleukin-2 und verwendungen davon
GB201616699D0 (en)	2016-09-30	2016-11-16	Mab Designs Ltd	Antibodies
JP2019535015A (ja)	2016-10-03	2019-12-05	アボット・ラボラトリーズＡｂｂｏｔｔＬａｂｏｒａｔｏｒｉｅｓ	患者サンプルにおけるｇｆａｐ状況を評価する改善された方法
WO2018067754A1 (en)	2016-10-04	2018-04-12	Fairbanks Pharmaceuticals, Inc.	Anti-fstl3 antibodies and uses thereof
MX2019003755A (es)	2016-10-06	2019-08-12	Pfizer	Regimen de dosificacion de avelumab para el tratamiento de cancer.
WO2018068201A1 (en)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
KR20190064636A (ko)	2016-10-19	2019-06-10	메디뮨 엘엘씨	항-o1 항체 및 이의 용도
JP2019535306A (ja)	2016-10-25	2019-12-12	インセルム（インスティチュートナショナルデラサンテエデラリシェルシェメディカル）	Ｃｄ１６０膜貫通型アイソフォームと結合するモノクローナル抗体
WO2018081531A2 (en)	2016-10-28	2018-05-03	Ariad Pharmaceuticals, Inc.	Methods for human t-cell activation
EP3532101B1 (de)	2016-10-28	2021-12-08	Astute Medical, Inc.	Verwendung von antikörpern gegen timp-2 zur verbesserung der nierenfunktion
TWI788307B (zh)	2016-10-31	2023-01-01	美商艾歐凡斯生物治療公司	用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11617815B2 (en)	2016-10-31	2023-04-04	Sofregen Medical, Inc.	Compositions comprising silk fibroin particles and uses thereof
WO2018089829A1 (en)	2016-11-10	2018-05-17	Fortis Therapeutics, Inc.	Cd46-specific effector cells and uses thereof
DK3538891T3 (da)	2016-11-11	2022-03-28	Isoplexis Corp	Sammensætninger og fremgangsmåder til samtidig genomisk, transkriptomisk og proteomisk analyse af enkeltceller
WO2018093797A1 (en)	2016-11-15	2018-05-24	The Schepens Eye Research Institute, Inc.	Compositions and methods for the treatment of aberrant angiogenesis
US11401330B2 (en)	2016-11-17	2022-08-02	Seagen Inc.	Glycan-interacting compounds and methods of use
CN109937034B (zh)	2016-11-21	2022-09-16	济世-伊沃泰克生物制品有限公司	阿柏西普制剂及其用途
CN110234319B (zh)	2016-11-23	2022-09-27	转化药物开发有限责任公司	苯甲酰胺和活性化合物的组合物及其使用方法
EP3548894B1 (de)	2016-12-02	2021-10-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren und zusammensetzungen zur diagnose eines nierenzellkarzinoms
US10759855B2 (en)	2016-12-02	2020-09-01	Rigel Pharmaceuticals, Inc.	Antigen binding molecules to TIGIT
WO2018106859A1 (en)	2016-12-07	2018-06-14	Ra Pharmaceuticals, Inc.	Modulators of complement activity
CA3045857A1 (en)	2016-12-22	2018-06-28	Universita Degli Studi Magna Graecia Catanzaro	A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
WO2018122249A1 (en)	2016-12-28	2018-07-05	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
WO2018122245A1 (en)	2016-12-28	2018-07-05	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
WO2018129029A1 (en)	2017-01-04	2018-07-12	Immunogen, Inc.	Met antibodies and immunoconjugates and uses thereof
US11564982B2 (en)	2017-01-04	2023-01-31	Research Institute At Nationwide Children's Hospital	DNABII vaccines and antibodies with enhanced activity
WO2018129336A1 (en)	2017-01-06	2018-07-12	Iovance Biotherapeutics, Inc.	Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
KR20190104048A (ko)	2017-01-06	2019-09-05	이오반스 바이오테라퓨틱스, 인크.	종양 괴사 인자 수용체 슈퍼패밀리 (tnfrsf) 효능제를 사용한 종양 침윤 림프구 (til)의 확장 및 til과 tnfrsf 효능제의 치료 조합물
EP3565549B1 (de)	2017-01-09	2022-03-09	Shuttle Pharmaceuticals, Inc.	Selektive histondeacetylaseinhibitoren zur behandlung von menschlichen erkrankungen
US11584733B2 (en)	2017-01-09	2023-02-21	Shuttle Pharmaceuticals, Inc.	Selective histone deacetylase inhibitors for the treatment of human disease
EP3568468A4 (de)	2017-01-12	2020-12-30	Eureka Therapeutics, Inc.	Gegen histon-h3-peptid/mhc-komplexe gerichtete konstrukte und verwendungen davon
BR112019015069A2 (pt)	2017-01-24	2020-03-03	Pfizer Inc.	Derivados de caliqueamicina e conjugados de anticorpo-fármaco dos mesmos
CA3051169A1 (en)	2017-02-03	2018-08-09	Acticor Biotech	Inhibition of platelet aggregation using anti-human gpvi antibodies
US11471538B2 (en)	2017-02-10	2022-10-18	INSERM (Institut National de la Santéet de la Recherche Medicale)	Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
AU2018217816A1 (en)	2017-02-10	2019-08-15	Genentech, Inc.	Anti-tryptase antibodies, compositions thereof, and uses thereof
WO2018152496A1 (en)	2017-02-17	2018-08-23	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Compositions and methods for the diagnosis and treatment of zika virus infection
KR102653141B1 (ko)	2017-03-03	2024-04-01	씨젠 인크.	글리칸-상호작용 화합물 및 사용 방법
KR20190128676A (ko)	2017-03-14	2019-11-18	바이오버라티브 유에스에이 인코포레이티드	보체-매개된 질환 및 장애의 치료 방법
JP7596069B2 (ja)	2017-03-15	2024-12-09	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法
IL269000B2 (en)	2017-03-15	2024-06-01	Cue Biopharma Inc	Methods for modulating an immune response
EP3596126A4 (de)	2017-03-15	2021-03-03	Tsinghua University	Neuartige anti-trkb-antikörper
AU2018240375C1 (en)	2017-03-22	2024-02-01	Ascendis Pharma A/S	Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
AR111249A1 (es)	2017-03-22	2019-06-19	Genentech Inc	Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
WO2018175942A1 (en)	2017-03-23	2018-09-27	Abbott Laboratories	Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
WO2018175924A1 (en)	2017-03-24	2018-09-27	The Broad Institute, Inc.	Methods and compositions for regulating innate lymphoid cell inflammatory responses
US20210186982A1 (en)	2017-03-24	2021-06-24	Universite Nice Sophia Antipolis	Methods and compositions for treating melanoma
CA3056134A1 (en)	2017-03-24	2018-09-27	Seattle Genetics, Inc.	Process for the preparation of glucuronide drug-linkers and intermediates thereof
WO2018178029A1 (en)	2017-03-27	2018-10-04	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
WO2018178030A1 (en)	2017-03-27	2018-10-04	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
US20210275543A1 (en)	2017-03-30	2021-09-09	Nserm (Institut National De La Santé Et De La Recherche Médicale)	Methods for the treatment of mitochondrial genetic diseases
RU2765997C2 (ru)	2017-03-30	2022-02-07	Мерк Патент Гмбх	Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования
US20190048055A1 (en)	2017-03-31	2019-02-14	Altor Bioscience Corporation	Alt-803 in combination with anti-cd38 antibody for cancer therapies
WO2018183921A1 (en)	2017-04-01	2018-10-04	The Broad Institute, Inc.	Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
IL315837A (en)	2017-04-13	2024-11-01	Sairopa B V	Anti-SIRP-alpha antibodies
CN110944665B (zh)	2017-04-14	2024-04-19	埃克塞里艾克西斯公司	用于预防或治疗肺癌的amhrii结合化合物
WO2018189379A1 (en)	2017-04-14	2018-10-18	Gamamabs Pharma	Amhrii-binding compounds for preventing or treating cancers
CN110546513A (zh)	2017-04-15	2019-12-06	雅培实验室	使用早期生物标记物帮助超急性诊断和确定人类受试者中的创伤性脑损伤的方法
SG11201909708VA (en)	2017-04-21	2019-11-28	Mellitus Llc	Methods and antibodies for diabetes-related applications
JOP20190248A1 (ar)	2017-04-21	2019-10-20	Amgen Inc	بروتينات ربط مولد ضد trem2 واستخداماته
EP4230649A3 (de)	2017-04-25	2023-10-25	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Antikörper und verfahren zur diagnose und behandlung von epstein barr-virusinfektion
SG11201909728XA (en)	2017-04-26	2019-11-28	Eureka Therapeutics Inc	Constructs specifically recognizing glypican 3 and uses thereof
EP3615572A1 (de)	2017-04-27	2020-03-04	Tesaro Inc.	Gegen lymphozytenaktivierungsgen 3 (lag-3) gerichtete antikörpermittel und verwendungen davon
AU2018256845B2 (en)	2017-04-28	2024-03-14	Abbott Laboratories	Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
US10865238B1 (en)	2017-05-05	2020-12-15	Duke University	Complement factor H antibodies
WO2018209115A1 (en)	2017-05-10	2018-11-15	Iovance Biotherapeutics, Inc.	Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
GB201707561D0 (en)	2017-05-11	2017-06-28	Argenx Bvba	GARP-TGF-beta antibodies
EP3625258A1 (de)	2017-05-16	2020-03-25	Alector LLC	Anti-siglec-5-antikörper und verfahren zur verwendung davon
BR112019024701A2 (pt)	2017-05-25	2020-06-09	Abbott Lab	métodos para auxiliar na determinação se um exame de imagem deve ser realizado em um indivíduo humano que sofreu ou pode ter sofrido uma lesão na cabeça com o uso de biomarcadores precoces
ES2926722T3 (es)	2017-05-26	2022-10-27	Abvitro Llc	Secuenciación de alto rendimiento de biblioteca de polinucleótidos y análisis de transcriptoma
CN110720041B (zh)	2017-05-30	2024-04-26	雅培实验室	用心肌肌钙蛋白i和早期生物标记物帮助诊断和评价人受试者中轻度创伤性脑损伤的方法
WO2018232195A1 (en)	2017-06-14	2018-12-20	The Broad Institute, Inc.	Compositions and methods targeting complement component 3 for inhibiting tumor growth
US11325957B2 (en)	2017-06-19	2022-05-10	Cell Design Labs, Inc.	Methods and compositions for reducing the immunogenicity of chimeric notch receptors
EP3641802A1 (de)	2017-06-22	2020-04-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren und pharmazeutische zusammensetzungen zur behandlung von fibrose mit mitteln zur hemmung der aktivierung von mukosa-assoziierten invarianten t-zellen (mait)
JP2020525019A (ja)	2017-06-27	2020-08-27	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	白血病におけるｃｔｌａ４アンタゴニストに対する耐性を同定および治療するための組成物および方法
WO2019002548A1 (en)	2017-06-29	2019-01-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
EP3649474A1 (de)	2017-07-03	2020-05-13	Abbott Laboratories	Verbesserte verfahren zur messung von ubiquitin-carboxy-terminalen hydrolase-l1-konzentrationen in blut
JP7270596B2 (ja)	2017-07-06	2023-05-10	メモリアルスローンケタリングキャンサーセンター	抗ｄｏｔａ／抗腫瘍抗原二重特異性抗体による事前標的化放射免疫治療のためのｄｏｔａ－ハプテン組成物
US11892457B2 (en)	2017-07-12	2024-02-06	The Johns Hopkins University	Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
US11827669B2 (en)	2017-07-19	2023-11-28	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
WO2019018729A1 (en)	2017-07-20	2019-01-24	Dana-Farber Cancer Institute, Inc.	COMPOSITIONS AND METHODS FOR IDENTIFICATION AND TREATMENT OF NEUROENDOCRINE METASTATIC TUMORS OF INTESTINAL HAIL
WO2019016310A1 (en)	2017-07-20	2019-01-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	METHODS AND COMPOSITIONS FOR TREATING CANCERS
WO2019020593A1 (en)	2017-07-25	2019-01-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS
JP7368856B2 (ja)	2017-07-25	2023-10-25	トゥルーバインディング，インコーポレイテッド	Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
WO2019023525A1 (en)	2017-07-28	2019-01-31	Dana-Farber Cancer Institute, Inc.	ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTION MODULATORS
WO2019020807A1 (en)	2017-07-28	2019-01-31	Gene Signal International Sa	CD9P-1 TARGETING ANTIBODIES AND USES THEREOF
MY205541A (en)	2017-08-03	2024-10-25	Alector Llc	Anti-cd33 antibodies and methods of use thereof
PT3601358T (pt)	2017-08-03	2023-08-30	Alector Llc	Anticorpos anti-trem2 e métodos de uso dos mesmos
US11085929B2 (en)	2017-08-31	2021-08-10	Arizona Board Of Regents On Behalf Of Arizona State University	Nanoshell-structured material as co-matrix for peptide characterization in mass spectrometry
JP7281774B2 (ja)	2017-09-19	2023-05-26	ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア	抗ｈｌａ－ａ２抗体及びその使用方法
EP3684471A1 (de)	2017-09-20	2020-07-29	Institut National de la Sante et de la Recherche Medicale (INSERM)	Verfahren und pharmazeutische zusammensetzungen zur modulation von autophagie
AU2018338423A1 (en)	2017-09-20	2020-04-09	Sangamo Therapeutics France	Novel anti-HLA-A2 antibodies and uses thereof
EP3988552A1 (de)	2017-09-27	2022-04-27	Incyte Corporation	Salze von pyrrolotriazinderivaten als tam-inhibitoren
EP3688007B1 (de)	2017-09-27	2024-07-31	The University of York	Biokonjugation von polypeptiden
JP6496095B1 (ja)	2017-09-29	2019-04-03	中外製薬株式会社	血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）補因子機能代替活性を有する多重特異性抗原結合分子および当該分子を有効成分として含有する薬学的製剤
EP3689903A4 (de)	2017-09-30	2022-01-12	Hefei Lifeon Pharmaceutical Co. Ltd.	Bindung von protein an fibronectin-b-domäne
US12043870B2 (en)	2017-10-02	2024-07-23	The Broad Institute, Inc.	Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
JP2020536871A (ja)	2017-10-06	2020-12-17	キャンプ４セラピューティクスコーポレイション	尿素サイクル異常症、特にｏｔｃ欠損症を治療するための方法及び組成物
US11230601B2 (en)	2017-10-10	2022-01-25	Tilos Therapeutics, Inc.	Methods of using anti-lap antibodies
CA3185107A1 (en)	2017-10-12	2019-04-18	Immunowake Inc.	Vegfr-antibody light chain fusion protein
WO2019079362A1 (en)	2017-10-16	2019-04-25	Massachusetts Institute Of Technology	HOST-PATHOGENIC INTERACTION OF MYCOBACTERIUM TUBERCULOSIS
WO2019084460A1 (en)	2017-10-26	2019-05-02	The Regents Of The University Of California	INHIBITION OF OXIDATION-SPECIFIC EPITOPES TO TREAT ISCHEMIC REPERFUSION INJURY
GB201717966D0 (en)	2017-10-31	2017-12-13	Xenikos Bv	Immunotoxins, formulations thereof and their use in medicine
CA3082365A1 (en)	2017-11-09	2019-05-16	Pinteon Therapeutics Inc.	Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
JP7416700B2 (ja)	2017-11-14	2024-01-17	ザスキーペンズアイリサーチインスティチュートインコーポレイテッド	増殖性硝子体網膜症および上皮間葉転換と関連付けられる状態の治療のためのｒｕｎｘ１阻害の方法
EP3710067A4 (de)	2017-11-14	2021-10-27	Arcellx, Inc.	D-domäne enthaltende polypeptide und deren verwendung
TWI816715B (zh)	2017-11-17	2023-10-01	美商默沙東有限責任公司	對免疫球蛋白樣轉錄本3(ilt3)具特異性之抗體及其用途
JP7183268B2 (ja)	2017-11-20	2022-12-05	ジャスト－エヴォテックバイオロジックス、インコーポレイテッド	等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
EP3714041A1 (de)	2017-11-22	2020-09-30	Iovance Biotherapeutics, Inc.	Expansion von peripheren blutlymphozyten (pbls) aus peripherem blut
WO2019101995A1 (en)	2017-11-27	2019-05-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for cardiac regeneration
WO2019102456A1 (en)	2017-11-27	2019-05-31	University Of Rijeka Faculty Of Medicine	Immunotoxins for treating cancer
WO2019113506A1 (en)	2017-12-07	2019-06-13	The Broad Institute, Inc.	Methods and compositions for multiplexing single cell and single nuclei sequencing
CA3067057A1 (en)	2017-12-09	2019-06-13	Abbott Laboratories	Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
BR112020010085A2 (pt)	2017-12-09	2020-10-13	Abbott Laboratories	métodos para auxiliar no diagnóstico e avaliar uma lesão cerebral traumática em um indivíduo humano usando uma combinação de gfap e uch-l1
AU2018385409A1 (en)	2017-12-12	2020-07-02	Macrogenics Inc.	Bispecific CD 16-binding molecules and their use in the treatment of disease
EP3498293A1 (de)	2017-12-15	2019-06-19	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Behandlung monogener erkrankungen mit einem anti-cd45rc-antikörper
CA3085765A1 (en)	2017-12-15	2019-06-20	Iovance Biotherapeutics, Inc.	Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
EA202091521A1 (ru)	2017-12-19	2020-10-22	Дзе Рокфеллер Юниверсити	ВАРИАНТЫ ДОМЕНА Fc IgG ЧЕЛОВЕКА С УЛУЧШЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
CA3082280A1 (en)	2017-12-28	2019-07-04	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against tigit
CA3078849A1 (en)	2017-12-28	2019-07-04	Nanjing Legend Biotech Co., Ltd.	Antibodies and variants thereof against pd-l1
BR112020010430A2 (pt)	2017-12-29	2020-11-24	Abbott Laboratories	biomarcadores e métodos inovadores para diagnosticar e avaliar lesão cerebral traumática
CN108218990B (zh)	2017-12-29	2021-03-02	南京优迈生物科技有限公司	分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
EP3735590A1 (de)	2018-01-04	2020-11-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren und zusammensetzungen zur behandlung von resistentem melanom
WO2019139987A1 (en)	2018-01-09	2019-07-18	Elstar Therapeutics, Inc.	Calreticulin binding constructs and engineered t cells for the treatment of diseases
SG11202004233UA (en)	2018-01-15	2020-06-29	Nanjing Legend Biotech Co Ltd	Single-domain antibodies and variants thereof against pd-1
JP2021510594A (ja)	2018-01-25	2021-04-30	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	臓器の虚血再灌流傷害を予防する方法における使用のためのｉｌ−３３のアンタゴニスト
WO2019148412A1 (en)	2018-02-01	2019-08-08	Merck Sharp & Dohme Corp.	Anti-pd-1/lag3 bispecific antibodies
KR20220098056A (ko)	2018-02-09	2022-07-08	제넨테크, 인크.	비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
EP3752600A1 (de)	2018-02-13	2020-12-23	Iovance Biotherapeutics, Inc.	Expansion von tumorinfiltrierenden lymphozyten (tils) mit adenosin-a2a-rezeptor-antagonisten und therapeutische kombinationen von tils und adenosin-a2a-rezeptor-antagonisten
BR112020016485A2 (pt)	2018-02-15	2020-12-15	Macrogenics, Inc.	Molécula de ligação, composição farmacêutica e método para o tratamento de uma doença
US20210061917A1 (en)	2018-02-16	2021-03-04	Inserm (Institut National De La Santé Et De La Recherche Medicale)	Methods and compositions for treating vitiligo
US20200384030A1 (en)	2018-02-21	2020-12-10	Cell Design Labs, Inc.	Chimeric transmembrane receptors and uses thereof
KR20200135313A (ko)	2018-02-26	2020-12-02	제넨테크, 인크.	항-tigit 및 항-pd-l1 길항제 항체에 의한 치료를 위한 투약
AU2019227607C1 (en)	2018-02-27	2023-07-20	Incyte Corporation	Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
NL2020520B1 (en)	2018-03-02	2019-09-12	Labo Bio Medical Invest B V	Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
WO2019178362A1 (en)	2018-03-14	2019-09-19	Elstar Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
WO2019179420A1 (en)	2018-03-20	2019-09-26	Wuxi Biologics (Shanghai) Co., Ltd.	Novel anti-tim-3 antibodies
SG11202006674QA (en)	2018-03-30	2020-08-28	Nanjing Legend Biotech Co Ltd	Single-domain antibodies against lag-3 and uses thereof
WO2019193375A1 (en)	2018-04-04	2019-10-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of fzd7 inhibitors for the treatment of retinal neovascularization
WO2019195181A1 (en)	2018-04-05	2019-10-10	Gilead Sciences, Inc.	Antibodies and fragments thereof that bind hepatitis b virus protein x
US10633458B2 (en)	2018-04-10	2020-04-28	Y-Biologics Inc.	Cell engaging binding molecules
CN118615457A (zh)	2018-04-13	2024-09-10	基因泰克公司	稳定的抗cd79b免疫缀合物制剂
CA3096500A1 (en)	2018-04-13	2019-10-17	Sangamo Therapeutics France	Chimeric antigen receptor specific for interleukin-23 receptor
WO2019207030A1 (en)	2018-04-26	2019-10-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
US11957695B2 (en)	2018-04-26	2024-04-16	The Broad Institute, Inc.	Methods and compositions targeting glucocorticoid signaling for modulating immune responses
EP3788071A1 (de)	2018-05-02	2021-03-10	The United States Of America, As Represented By The Secretary, Department of Health and Human Services	Antikörper und verfahren zur diagnose, prävention und behandlung von epstein-barr-virusinfektion
EP3787683A1 (de)	2018-05-04	2021-03-10	Merck Patent GmbH	Kombinierte inhibierung von pd-1/pd-l1, tgfss und dna-pk zur behandlung von krebs
WO2019213619A1 (en)	2018-05-04	2019-11-07	Abbott Laboratories	Hbv diagnostic, prognostic, and therapeutic methods and products
WO2019213660A2 (en)	2018-05-04	2019-11-07	The Broad Institute, Inc.	Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
CA3097679A1 (en)	2018-05-09	2019-11-14	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Antibodies specific to human nectin4
JP7391046B2 (ja)	2018-05-18	2023-12-04	インサイト・コーポレイション	Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
PL3797121T3 (pl)	2018-05-23	2024-09-23	Pfizer Inc.	Przeciwciała swoiste dla CD3 i ich zastosowania
TWI803637B (zh)	2018-05-23	2023-06-01	美商輝瑞大藥廠	特異性針對gucy2c之抗體及其用途
SG11202010996QA (en)	2018-05-23	2020-12-30	Nat Univ Singapore	Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
GB201808927D0 (en)	2018-05-31	2018-07-18	Institute Of Cancer Res Royal Cancer Hospital	Materials and methods for monitoring the development of resistance of cancers to treatment
EP3802604A1 (de)	2018-05-31	2021-04-14	Glyconex Inc.	An biantennäre lewis-b und lewis-y antigene bindende, therapeutische antikörper
WO2019232542A2 (en)	2018-06-01	2019-12-05	Massachusetts Institute Of Technology	Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
WO2019227490A1 (en)	2018-06-01	2019-12-05	Tayu Huaxia Biotech Medical Group Co., Ltd.	Compositions and methods for imaging
UY38251A (es)	2018-06-01	2019-12-31	Novartis Ag	Moléculas de unión contra bcma y usos de las mismas
MX2020012613A (es)	2018-06-01	2021-04-13	Tayu Huaxia Biotech Medical Group Co Ltd	Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones.
CA3100626A1 (en)	2018-06-08	2019-12-12	Alector Llc	Anti-siglec-7 antibodies and methods of use thereof
TWI848953B (zh)	2018-06-09	2024-07-21	德商百靈佳殷格翰國際股份有限公司	針對癌症治療之多特異性結合蛋白
EP3806888B1 (de)	2018-06-12	2024-01-31	Obsidian Therapeutics, Inc.	Von pde5 abgeleitete regulatorische konstrukte und verfahren zur verwendung in der immuntherapie
US12036240B2 (en)	2018-06-14	2024-07-16	The Broad Institute, Inc.	Compositions and methods targeting complement component 3 for inhibiting tumor growth
EP3806904A4 (de)	2018-06-18	2022-04-27	Eureka Therapeutics, Inc.	Auf prostataspezifisches membranantigen (psma) abzielende konstrukte und verwendungen davon
WO2019246110A1 (en)	2018-06-20	2019-12-26	Incyte Corporation	Anti-pd-1 antibodies and uses thereof
PE20211805A1 (es)	2018-06-29	2021-09-14	Incyte Corp	Formulaciones de un inhibidor de axl/mer
CA3102859A1 (en)	2018-07-03	2020-01-09	Gilead Sciences, Inc.	Antibodies that target hiv gp120 and methods of use
SG11202013216RA (en)	2018-07-05	2021-01-28	Incyte Corp	Fused pyrazine derivatives as a2a / a2b inhibitors
WO2020014306A1 (en)	2018-07-10	2020-01-16	Immunogen, Inc.	Met antibodies and immunoconjugates and uses thereof
ES2940311T3 (es)	2018-07-13	2023-05-05	Alector Llc	Anticuerpos anti-sortilina y métodos de uso de los mismos
WO2020021061A1 (en)	2018-07-26	2020-01-30	Pieris Pharmaceuticals Gmbh	Humanized anti-pd-1 antibodies and uses thereof
JP7535495B2 (ja)	2018-07-27	2024-08-16	アレクトルエルエルシー	抗Ｓｉｇｌｅｃ－５抗体及びその使用方法
CN112789292A (zh)	2018-07-31	2021-05-11	皮里斯制药有限公司	对cd137和pd-l1特异性的新型融合蛋白
KR20210046006A (ko)	2018-08-10	2021-04-27	상가모 테라퓨틱스 프랑스	Tnfr2 도메인을 포함하는 신규한 car 작제물
CN113166241B (zh)	2018-08-16	2025-02-25	约翰霍普金斯大学	人类znt8抗体
JP7459058B2 (ja)	2018-08-27	2024-04-01	ピエリスファーマシューティカルズゲーエムベーハー	Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法
TW202016307A (zh)	2018-08-31	2020-05-01	美商阿列克特有限責任公司	抗cd33 抗體及其使用方法
TW202031273A (zh)	2018-08-31	2020-09-01	美商艾歐凡斯生物治療公司	抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
CN112585169A (zh)	2018-09-04	2021-03-30	南京优迈生物科技有限公司	融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用
EP3849545A1 (de)	2018-09-10	2021-07-21	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren zur behandlung von neurofibromatose
TWI841595B (zh)	2018-09-10	2024-05-11	大陸商南京傳奇生物科技有限公司	針對ｃｄ３３之單域抗體及其構築體
JP7618950B2 (ja)	2018-09-19	2025-01-22	インサーム（インスティテュートナショナルデラサンテエデラルシェルシェメディカル）	免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
IL281423B2 (en)	2018-09-20	2024-08-01	Iovance Biotherapeutics Inc	Expansion of tils from cryopreserved tumor samples
EP3626265A1 (de)	2018-09-21	2020-03-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-human-cd45rc-antikörper und verwendungen davon
WO2020064702A1 (en)	2018-09-25	2020-04-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
EP3856787A4 (de)	2018-09-27	2022-06-29	Celgene Corporation	SIRPalpha-BINDENDE PROTEINE UND VERFAHREN ZUR VERWENDUNG DAVON
WO2020065594A1 (en)	2018-09-28	2020-04-02	Kyowa Kirin Co., Ltd.	Il-36 antibodies and uses thereof
WO2020070062A1 (en)	2018-10-01	2020-04-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
US20210340278A1 (en)	2018-10-04	2021-11-04	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of mucosal inflammatory diseases
JP7541513B2 (ja)	2018-10-05	2024-08-28	リサーチインスティチュートアットネイションワイドチルドレンズホスピタル	細菌バイオフィルムの酵素的破壊のための組成物および方法
JP2022512648A (ja)	2018-10-09	2022-02-07	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	心筋線維化の処置のためのαＶ－インテグリン（ＣＤ５１）阻害剤の使用
CN113164780A (zh)	2018-10-10	2021-07-23	泰洛斯治疗公司	抗lap抗体变体及其用途
US20220411783A1 (en)	2018-10-12	2022-12-29	The Broad Institute, Inc.	Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
US20210379057A1 (en)	2018-10-16	2021-12-09	Massachusetts Institute Of Technology	Nutlin-3a for use in treating a mycobacterium tuberculosis infection
US20210386788A1 (en)	2018-10-24	2021-12-16	Obsidian Therapeutics, Inc.	Er tunable protein regulation
EP3873488B1 (de)	2018-10-31	2025-03-19	The University of Sydney	Pharmazeutische zusammensetzungen zur verwendung bei der behandlung einer hbv- oder hdv-infektion
AU2019370485A1 (en)	2018-11-02	2021-05-13	Annexon, Inc.	Compositions and methods for treating brain injury
JP2022506508A (ja)	2018-11-05	2022-01-17	アイオバンスバイオセラピューティクス，インコーポレイテッド	Ａｋｔ経路阻害剤を利用したｔｉｌの拡大培養
JP2022512899A (ja)	2018-11-05	2022-02-07	アイオバンスバイオセラピューティクス，インコーポレイテッド	抗ｐｄ－１抗体に対して不応性のｎｓｃｌｃ患者の治療
GB201818618D0 (en)	2018-11-15	2019-01-02	Amlo Biosciences Ltd	Monoclonal antibodies against ambra-1
GB201818622D0 (en)	2018-11-15	2019-01-02	Amlo Biosciences Ltd	Monoclonal antibodies against loricrin
WO2020104479A1 (en)	2018-11-20	2020-05-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
WO2020115261A1 (en)	2018-12-07	2020-06-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
TW202031684A (zh)	2018-12-20	2020-09-01	日商協和麒麟股份有限公司	Fn14抗體及其用途
WO2020127885A1 (en)	2018-12-21	2020-06-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Compositions for treating cancers and resistant cancers
US20220073626A1 (en)	2019-01-03	2022-03-10	Institut National De La Santé Et De La Recheche Médicale (Inserm)	Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
US11739156B2 (en)	2019-01-06	2023-08-29	The Broad Institute, Inc. Massachusetts Institute of Technology	Methods and compositions for overcoming immunosuppression
CA3125762A1 (en)	2019-01-10	2020-07-16	Iovance Biotherapeutics, Inc.	System and methods for monitoring adoptive cell therapy clonality and persistence
AU2020207664A1 (en)	2019-01-13	2021-07-22	University Of Rijeka Faculty Of Medicine	Antibodies specific to human Nectin-2
US11680105B2 (en)	2019-01-17	2023-06-20	Regents Of The University Of Minnesota	Antibody fragments for detecting cancer and methods of use
CA3126727A1 (en)	2019-01-28	2020-08-06	Maple Biotech Llc	Psmp antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
KR20210124308A (ko)	2019-01-30	2021-10-14	트루바인딩 아이엔씨.	항-gal3 항체 및 이의 용도
EP3921031A1 (de)	2019-02-04	2021-12-15	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren und zusammensetzungen zur modulation der blut-gehirn-schranke
WO2020168059A1 (en)	2019-02-15	2020-08-20	Integral Molecular, Inc.	Claudin 6 antibodies and uses thereof
CN113661175A (zh)	2019-02-15	2021-11-16	整体分子公司	包含共同轻链的抗体及其用途
BR112021014582A2 (pt)	2019-02-15	2021-10-05	Just-Evotec Biologics, Inc.	Sistemas, instalações e processos de biomanufatura automatizados
EP3928794A4 (de)	2019-02-18	2022-11-30	NB Health Laboratory Co. Ltd.	Verfahren zur auswahl von zellen, verfahren zur herstellung von nukleinsäuren, verfahren zur herstellung von rekombinanten zellen, verfahren zur herstellung einer zielsubstanz, verfahren zur herstellung einer pharmazeutischen zusammensetzung und reagens
SG11202106353VA (en)	2019-02-26	2021-07-29	Pieris Pharmaceuticals Gmbh	Novel fusion proteins specific for cd137 and gpc3
EP3931220A1 (de)	2019-02-27	2022-01-05	F. Hoffmann-La Roche AG	Dosierung zur behandlung mit anti-tigit und anti-cd20 oder anti-cd38-antikörpern
SG11202109331QA (en)	2019-03-01	2021-09-29	Iovance Biotherapeutics Inc	Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP3930744A1 (de)	2019-03-01	2022-01-05	Allogene Therapeutics, Inc.	Gegen dll3 gerichtete chimäre antigenrezeptoren und bindende wirkstoffe
EP3935391B1 (de)	2019-03-05	2024-04-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Biomarker im nierenzellkarzinom
KR20210152472A (ko)	2019-03-11	2021-12-15	메모리얼 슬로안 케터링 캔서 센터	Cd22 항체 및 이를 사용하는 방법
US20220154282A1 (en)	2019-03-12	2022-05-19	The Broad Institute, Inc.	Detection means, compositions and methods for modulating synovial sarcoma cells
US20220143148A1 (en)	2019-03-14	2022-05-12	The Broad Institute, Inc.	Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells
WO2020191069A1 (en)	2019-03-18	2020-09-24	The Broad Institute, Inc.	Modulation of type 2 immunity by targeting clec-2 signaling
EP3942023A1 (de)	2019-03-18	2022-01-26	The Broad Institute, Inc.	Zusammensetzungen und verfahren zur modulation metabolischer regulatoren der t-zell-pathogenität
US20220153875A1 (en)	2019-03-19	2022-05-19	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
US20220154153A1 (en)	2019-03-22	2022-05-19	Université de Paris	New inhibitors of lrrk2/pp1 interaction
WO2020194317A1 (en)	2019-03-28	2020-10-01	Yeda Research And Development Co. Ltd.	Method of treating lipid-related disorders
EP3946330A1 (de)	2019-03-29	2022-02-09	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren zur behandlung von keloid, hypertrophischen narben und/oder hyperpigmentierungserkrankungen
EP3946417A1 (de)	2019-03-29	2022-02-09	Pieris Pharmaceuticals GmbH	Inhalierte verabreichung von lipocalin-muteinen
CN113660953A (zh)	2019-04-01	2021-11-16	豪夫迈·罗氏有限公司	用于稳定含蛋白质制剂的组合物和方法
BR112021019701A2 (pt)	2019-04-02	2021-12-14	Kenjockety Biotechnology Inc	Anticorpos multiespecíficos para antígeno de câncer de bomba de efluxo e composições, reagentes, kits e métodos relacionados aos mesmos
WO2020201362A2 (en)	2019-04-02	2020-10-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting and preventing cancer in patients having premalignant lesions
JP2022527345A (ja)	2019-04-03	2022-06-01	オレガ・バイオテック	Ｐｄ１阻害剤及びｉｌ－１７ｂ阻害剤に基づく複合療法
JP7575401B2 (ja)	2019-04-03	2024-10-29	ジェンザイム・コーポレーション	断片化が低減した抗アルファベータｔｃｒ結合ポリペプチド
MA55613A (fr)	2019-04-08	2022-02-16	Biogen Ma Inc	Anticorps anti-intégrine et leurs utilisations
CA3136453A1 (en)	2019-04-18	2020-10-22	Qlsf Biotherapeutics Inc.	Humanized anti-pd-l1 antibodies
WO2020214963A1 (en)	2019-04-18	2020-10-22	Genentech, Inc.	Antibody potency assay
EP3963109A1 (de)	2019-04-30	2022-03-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren und zusammensetzungen zur behandlung von melanom
GB201906302D0 (en)	2019-05-03	2019-06-19	Amlo Biosciences Ltd	Methods of determining the margin of a tumour
GB201906297D0 (en)	2019-05-03	2019-06-19	Amlo Biosciences Ltd	Biomarkers for disease progression in squamous cell carcinoma
EP3962924A1 (de)	2019-05-03	2022-03-09	Genentech, Inc.	Verfahren zur verminderung der enzymatischen hydrolyseaktivitätsrate in einer aus einer reinigungsplattform erhaltenen zusammensetzung
EP3966227A1 (de)	2019-05-07	2022-03-16	Voyager Therapeutics, Inc.	Zusammensetzungen und verfahren zur vektorisierten vermehrung von proteinzerstörung, -expression und/oder -regulierung
JP7604396B2 (ja)	2019-05-10	2024-12-23	武田薬品工業株式会社	抗体薬物複合体
WO2020234399A1 (en)	2019-05-20	2020-11-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Novel anti-cd25 antibodies
AU2020279974B2 (en)	2019-05-21	2024-12-19	Novartis Ag	CD19 binding molecules and uses thereof
CN114173810B (zh)	2019-05-21	2024-09-06	诺华股份有限公司	针对bcma的三特异性结合分子及其用途
EP3972993A1 (de)	2019-05-21	2022-03-30	Novartis AG	Variante cd58-domänen und deren verwendungen
TW202231277A (zh)	2019-05-21	2022-08-16	美商基利科學股份有限公司	鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
EP3976043A1 (de)	2019-05-24	2022-04-06	Pfizer Inc.	Kombinationstherapien mit cdk-hemmern
CN113874036A (zh)	2019-05-24	2021-12-31	辉瑞公司	使用cdk抑制剂的联合治疗
GB2598520B (en)	2019-05-28	2024-07-24	Univ Shanghai Technology	Composition and methods to treat ectodermal dysplasia 2, Clouston type
KR20220016139A (ko)	2019-05-30	2022-02-08	암젠 인크	항체 이량체화를 유도하기 위한 경첩 영역 조작
US20220243178A1 (en)	2019-05-31	2022-08-04	The Broad Institute, Inc.	Methods for treating metabolic disorders by targeting adcy5
US20220235142A1 (en)	2019-06-04	2022-07-28	Shanghai GenBase Biotechnology Co., Ltd.	Anti-ceacam5 monoclonal antibody, preparation method thereof and use thereof
AR119264A1 (es)	2019-06-05	2021-12-09	Genentech Inc	Método para reutilización de cromatografía
CN114008713A (zh)	2019-06-07	2022-02-01	中外制药株式会社	信息处理系统、信息处理方法、程序、以及制备抗原结合分子或蛋白质的方法
AU2020304671A1 (en)	2019-06-28	2022-01-20	Amgen Inc.	Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
CA3145385A1 (en)	2019-07-08	2021-01-14	Steven D. Goodman	Antibody compositions for disrupting biofilms
EP3999538A1 (de)	2019-07-15	2022-05-25	Intervet International B.V.	Caninisierte antikörper gegen canines ctla-4
US20220251234A1 (en)	2019-07-16	2022-08-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies having specificity for cd38 and uses thereof
CN112300279A (zh)	2019-07-26	2021-02-02	上海复宏汉霖生物技术股份有限公司	针对抗cd73抗体和变体的方法和组合物
MX2022001133A (es)	2019-08-01	2022-04-25	Incyte Corp	Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).
CN114401743A (zh)	2019-08-02	2022-04-26	法国国家健康和医学研究院	中和颗粒酶b用于向经历过心肌梗塞的受试者提供心脏保护
GB201911210D0 (en)	2019-08-06	2019-09-18	Amlo Biosciences Ltd	Clinical management of oropharyngeal squamous cell carcinoma
WO2021030303A1 (en)	2019-08-12	2021-02-18	Voyager Therapeutics, Inc.	High-sensitivity immunoassay for the detection of frataxin in biofluids
WO2021030627A1 (en)	2019-08-13	2021-02-18	The General Hospital Corporation	Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US20220348937A1 (en)	2019-09-06	2022-11-03	Obsidian Therapeutics, Inc.	Compositions and methods for dhfr tunable protein regulation
WO2021048292A1 (en)	2019-09-11	2021-03-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
EP4438057A3 (de)	2019-09-12	2025-01-01	F. Hoffmann-La Roche AG	Zusammensetzungen und verfahren zur behandlung von lupus nephritis
CA3147179A1 (en)	2019-09-20	2021-03-25	Joseph Haw-Ling Lin	Dosing for anti-tryptase antibodies
CA3155930A1 (en)	2019-09-27	2021-04-01	Starkage Therapeutics	Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
KR20220070237A (ko)	2019-09-27	2022-05-30	제넨테크, 인크.	항-tigit 및 항-pd-l1 길항제 항체를 이용한 치료를 위한 투약
US10975169B1 (en)	2019-09-27	2021-04-13	Memorial Sloan Kettering Cancer Center	Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
WO2021063968A1 (en)	2019-09-30	2021-04-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method and composition for diagnosing chronic obstructive pulmonary disease
US11981922B2 (en)	2019-10-03	2024-05-14	Dana-Farber Cancer Institute, Inc.	Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US12195725B2 (en)	2019-10-03	2025-01-14	Dana-Farber Cancer Institute, Inc.	Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
WO2021064180A1 (en)	2019-10-03	2021-04-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for modulating macrophages polarization
AU2020357550A1 (en)	2019-10-04	2022-05-05	Tae Life Sciences, Llc	Antibody compositions comprising Fc mutations and site-specific conjugation properties
GB201914399D0 (en)	2019-10-04	2019-11-20	Univ Newcastle	Biomarkers for assessing explant organ viability
EP4037710A1 (de)	2019-10-04	2022-08-10	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren und pharmazeutische zusammensetzung zur behandlung von eierstockkrebs, brustkrebs oder bauchspeicheldrüsenkrebs
US11793787B2 (en)	2019-10-07	2023-10-24	The Broad Institute, Inc.	Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
WO2021076798A1 (en)	2019-10-15	2021-04-22	Sofregen Medical, Inc.	Delivery devices for delivering and methods of delivering compositions
EP3808766A1 (de)	2019-10-15	2021-04-21	Sangamo Therapeutics France	Interleukin-23-rezeptor-spezifischer chimärer antigen-rezeptor
EP3812008A1 (de)	2019-10-23	2021-04-28	Gamamabs Pharma	Amh-kompetitiver antagonistischer antikörper
WO2021089588A1 (en)	2019-11-04	2021-05-14	Pieris Pharmaceuticals Gmbh	Her2/4-1bb bispecific fusion proteins for the treatment of cancer
AU2020378335A1 (en)	2019-11-05	2022-04-07	Merck Patent Gmbh	Anti-TIGIT antibodies and uses thereof
IL292458A (en)	2019-11-06	2022-06-01	Genentech Inc	Diagnostic and treatment methods for the treatment of hematological cancer
EP4055060A1 (de)	2019-11-08	2022-09-14	Amgen Inc.	Technische ladungspaarmutationen zum paaren von hetero-igg-molekülen
WO2021099600A1 (en)	2019-11-22	2021-05-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
WO2021113655A1 (en)	2019-12-05	2021-06-10	Alector Llc	Methods of use of anti-trem2 antibodies
GB201918103D0 (en)	2019-12-10	2020-01-22	Oblique Therapeutics Ab	Epitopes and antibodies
US20230227559A1 (en)	2019-12-10	2023-07-20	Institut Pasteur	New antibody blocking human fcgriiia and fcgriiib
CN115066437A (zh)	2019-12-12	2022-09-16	艾利妥	使用抗cd33抗体的方法
KR20230015874A (ko)	2019-12-17	2023-01-31	치누크 세라퓨틱스, 인크.	아트라센탄에 의해 iga 신장병증을 치료하는 방법
CN115397853A (zh)	2019-12-17	2022-11-25	辉瑞大药厂	对cd47、pd-l1具特异性的抗体及其用途
US11865168B2 (en)	2019-12-30	2024-01-09	Massachusetts Institute Of Technology	Compositions and methods for treating bacterial infections
CN115605509A (zh)	2019-12-30	2023-01-13	思进股份有限公司（Us）	用非岩藻糖基化抗cd70抗体治疗癌症的方法
MX2022007575A (es)	2020-01-03	2022-09-23	Incyte Corp	Anticuerpos anti cumulo de diferenciacion 73 (cd73) y usos de estos.
CA3166549A1 (en)	2020-01-03	2021-07-08	Incyte Corporation	Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
EP4084870A1 (de)	2020-01-03	2022-11-09	Incyte Corporation	Cd73-inhibitor und a2a/a2b-adenosinrezeptor-inhibitorkombinationstherapie
WO2021144426A1 (en)	2020-01-17	2021-07-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
US12165747B2 (en)	2020-01-23	2024-12-10	The Broad Institute, Inc.	Molecular spatial mapping of metastatic tumor microenvironment
WO2021194481A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CN115315256A (zh)	2020-01-27	2022-11-08	基因泰克公司	用抗tigit拮抗剂抗体治疗癌症的方法
WO2022050954A1 (en)	2020-09-04	2022-03-10	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CA3164608A1 (en)	2020-01-29	2021-08-05	Kenjockety Biotechnology, Inc.	Anti-mdr1 antibodies and uses thereof
WO2021165484A1 (en)	2020-02-21	2021-08-26	Université de Liège	Depletion of ext1 expression and/or activity improves cellular production of biological entities
CA3167851A1 (en)	2020-02-24	2021-09-02	Francesca CIGNARELLA	Methods of use of anti-trem2 antibodies
CN115443153A (zh)	2020-02-24	2022-12-06	欧比力克治疗公司	Kras表位以及抗体
WO2021174091A1 (en)	2020-02-28	2021-09-02	Tallac Therapeutics, Inc.	Transglutaminase-mediated conjugation
JP2023514957A (ja)	2020-02-28	2023-04-12	オレガ・バイオテック	Ｃｔｌａ４阻害剤及びｉｌ－１７ｂ阻害剤に基づく複合療法
AU2021230385A1 (en)	2020-03-06	2022-09-22	Incyte Corporation	Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
CN115605507A (zh)	2020-03-13	2023-01-13	基因泰克公司（Us）	抗白介素-33抗体及其用途
US11365239B2 (en)	2020-03-20	2022-06-21	Tsb Therapeutics (Beijing) Co., Ltd.	Anti-SARS-COV-2 antibodies and uses thereof
BR112022018795A2 (pt)	2020-03-20	2023-01-10	Inst Nat Sante Rech Med	Receptor de antígeno quimérico específico para cd45rc humano e usos dos mesmos
CN116249549A (zh)	2020-03-27	2023-06-09	诺华股份有限公司	用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
CN113461817A (zh)	2020-03-31	2021-10-01	苏州泽璟生物制药股份有限公司	一种抗人cd47抗体及其抗原结合片段、制备方法和应用
CN115667308A (zh)	2020-04-03	2023-01-31	艾利妥	抗trem2抗体的使用方法
WO2021198511A1 (en)	2020-04-03	2021-10-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treatment of sars-cov-2 infection
CA3179348A1 (en)	2020-04-06	2021-10-14	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
WO2021204878A1 (en)	2020-04-08	2021-10-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of cdon inhibitors for the treatment of endothelial dysfunction
EP4132971A1 (de)	2020-04-09	2023-02-15	Merck Sharp & Dohme LLC	Affinitätsgereifte anti-lap-antikörper und verwendungen davon
WO2021211331A1 (en)	2020-04-13	2021-10-21	Abbott Point Of Care Inc.	METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
IL297200A (en)	2020-04-15	2022-12-01	Voyager Therapeutics Inc	tau binding compounds
JP2023106635A (ja)	2020-04-17	2023-08-02	中外製薬株式会社	二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
JP2023525664A (ja)	2020-04-21	2023-06-19	ユニヴェルシテカソリークデルーヴァン	がんの処置のためのアルファ－２アドレナリン作動性受容体アゴニスト
JP2023522109A (ja)	2020-04-21	2023-05-26	ウニベルシテカソリークデルーベン	脾臓障害の防止及び／又は処置のためのアルファ－２アドレナリン受容体アゴニスト
WO2021214258A1 (en)	2020-04-22	2021-10-28	Fabmid	Methods for circularizing linear double stranded nucleic acids
KR20230004520A (ko)	2020-04-27	2023-01-06	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	지단백(ａ)에 대한 이소형-비의존성 항체
US20230183354A1 (en)	2020-04-30	2023-06-15	Sairopa B.V.	Anti-cd103 antibodies
WO2021224401A1 (en)	2020-05-07	2021-11-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for determining a reference range of β-galactose exposure platelet
GB202007312D0 (en)	2020-05-18	2020-07-01	Synthetic Vac Ltd	Mimotope peptides of the spike protein from the sars-cov-2 virus
GB202007404D0 (en)	2020-05-19	2020-07-01	Nasser Syed Muhammad Tahir	Treatment for viral respiratory infections
US20230220057A1 (en)	2020-05-27	2023-07-13	Staidson (Beijing) Biopharmaceuticals Co., Ltd.	Antibodies specifically recognizing nerve growth factor and uses thereof
CA3176246A1 (en)	2020-06-02	2021-12-09	Arcus Biosciences, Inc.	Antibodies to tigit
US20230212305A1 (en)	2020-06-04	2023-07-06	Kenjockety Biotechnology, Inc.	Anti-abcg2 antibodies and uses thereof
WO2021247423A1 (en)	2020-06-04	2021-12-09	Kenjockety Biotechnology, Inc.	Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
JP2023527578A (ja)	2020-06-05	2023-06-29	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	眼疾患を処置するための方法及び医薬組成物
US20230227568A1 (en)	2020-06-05	2023-07-20	Pieris Pharmaceuticals Gmbh	Multimeric immunomodulator targeting 4-1bb
GB202008651D0 (en)	2020-06-09	2020-07-22	Univ Newcastle	Method of identifying complement modulators
CN115916348A (zh)	2020-06-18	2023-04-04	基因泰克公司	使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
WO2022008597A1 (en)	2020-07-08	2022-01-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of infectious diseases
WO2022007955A1 (zh)	2020-07-09	2022-01-13	北京凯因科技股份有限公司	结合乙型肝炎病毒表面抗原的抗体及其应用
JP2023534214A (ja)	2020-07-16	2023-08-08	ノバルティスアーゲー	抗ベータセルリン抗体、その断片、及び多重特異性結合分子
WO2022023379A1 (en)	2020-07-28	2022-02-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for preventing and treating a cancer
TW202212354A (zh)	2020-08-03	2022-04-01	美商健生生物科技公司	用於病毒治療劑中之多向生物運輸的材料及方法
US20230323299A1 (en)	2020-08-03	2023-10-12	Inserm (Institut National De La Santé Et De La Recherch Médicale)	Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
CN116568824A (zh)	2020-08-03	2023-08-08	基因泰克公司	淋巴瘤的诊断和治疗方法
EP4193149A1 (de)	2020-08-04	2023-06-14	Abbott Laboratories	Verbesserte verfahren und kits zum nachweis von sars-cov-2-protein in einer probe
BR112023002346A2 (pt)	2020-08-07	2023-05-02	Fortis Therapeutics Inc	Imunoconjugados direcionados a cd46 e métodos de uso dos mesmos
CA3191710A1 (en)	2020-08-20	2022-02-24	Amgen Inc.	Antigen binding proteins with non-canonical disulfide in fab region
WO2022044010A1 (en)	2020-08-26	2022-03-03	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
IL301003A (en)	2020-09-01	2023-04-01	Merck Patent Gmbh	Compounds based on B7-H6, their preparation and pharmaceutical preparations containing them
CN116490522A (zh)	2020-09-02	2023-07-25	肯乔克蒂生物技术股份有限公司	抗abcc1抗体及其应用
EP3970752A1 (de)	2020-09-17	2022-03-23	Merck Patent GmbH	Moleküle mit löslichkeitsmarkierung und zugehörige verfahren
JP2023541482A (ja)	2020-09-18	2023-10-02	ピエリスファーマシューティカルズゲーエムベーハー	バイオマーカー法および使用法
KR20230073196A (ko)	2020-09-21	2023-05-25	제넨테크, 인크.	다중특이성 항체의 정제
WO2022064049A1 (en)	2020-09-28	2022-03-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for diagnosing brucella infection
WO2022076606A1 (en)	2020-10-06	2022-04-14	Iovance Biotherapeutics, Inc.	Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023546359A (ja)	2020-10-06	2023-11-02	アイオバンスバイオセラピューティクス，インコーポレイテッド	腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
JP2023544769A (ja)	2020-10-07	2023-10-25	アムジエン・インコーポレーテツド	多重特異性抗体の構築のためのビルディングブロックの合理的選択
EP3981789A1 (de)	2020-10-12	2022-04-13	Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives	Anti-lilrb-antikörper und verwendungen davon
US20230382978A1 (en)	2020-10-15	2023-11-30	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
EP4228670A1 (de)	2020-10-15	2023-08-23	Institut National de la Santé et de la Recherche Médicale (INSERM)	Tg2-inhibitoren zur verbesserung der mukoziliären clearance bei atemwegserkrankungen
EP4228697A4 (de)	2020-10-16	2025-01-01	Invisishield Tech Ltd	Zusammensetzungen zur prävention oder behandlung von viralen und anderen mikrobiellen infektionen
WO2022084300A1 (en)	2020-10-20	2022-04-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosis and monitoring form of coronavirus infection
WO2022087274A1 (en)	2020-10-21	2022-04-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies that neutralize type-i interferon (ifn) activity
WO2022084531A1 (en)	2020-10-23	2022-04-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating glioma
AR123947A1 (es)	2020-10-30	2023-01-25	Genentech Inc	Plataformas de purificación para obtener composiciones farmacéuticas que tienen una tasa de actividad enzimática hidrolítica reducida
EP4241086A1 (de)	2020-11-03	2023-09-13	Isoplexis Corporation	Verfahren und vorrichtungen zur multiplexierten proteomischen und genetischen analyse und herstellung von cdna auf einer vorrichtung
WO2022096547A1 (en)	2020-11-05	2022-05-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of il-6 inhibitors for the treatment of acute chest syndrome in patients suffering from sickle cell disease
IL302412A (en)	2020-11-06	2023-06-01	Novartis Ag	Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
AU2021373366A1 (en)	2020-11-06	2023-06-01	Novartis Ag	Cd19 binding molecules and uses thereof
TW202233251A (zh)	2020-11-09	2022-09-01	日商武田藥品工業股份有限公司	抗體藥物綴合物
EP4244246A1 (de)	2020-11-10	2023-09-20	Amgen Inc.	Neue linker von multispezifischen antigenbindenden domänen
CA3195799A1 (en)	2020-11-11	2022-05-19	Stephen R. Martin	Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
US20240010747A1 (en)	2020-11-13	2024-01-11	Kenjockety Biotechnology, Inc.	Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
US20230416830A1 (en)	2020-11-16	2023-12-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for predicting and treating uveal melanoma
CN116917318A (zh)	2020-11-20	2023-10-20	法国国家健康和医学研究院	抗cd25抗体
WO2022106663A1 (en)	2020-11-20	2022-05-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-cd25 antibodies
CA3198161A1 (en)	2020-12-01	2022-06-09	Beth MCQUISTON	Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en)	2021-11-30	2023-06-08	Abbott Laboratories	Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
GB202019522D0 (en)	2020-12-10	2021-01-27	Oblique Therapeutics Ab	Epitopes and antibodies
TW202241468A (zh)	2020-12-11	2022-11-01	美商艾歐凡斯生物治療公司	用腫瘤浸潤性淋巴球療法與ｂｒａｆ抑制劑及／或ｍｅｋ抑制劑組合治療癌症患者
WO2022132923A1 (en)	2020-12-16	2022-06-23	Voyager Therapeutics, Inc.	Tau binding compounds
WO2022130206A1 (en)	2020-12-16	2022-06-23	Pfizer Inc.	TGFβr1 INHIBITOR COMBINATION THERAPIES
US20240123067A1 (en)	2020-12-17	2024-04-18	Iovance Biotherapeutics, Inc.	Treatment of cancers with tumor infiltrating lymphocyte therapies
JP2023554395A (ja)	2020-12-17	2023-12-27	アイオバンスバイオセラピューティクス，インコーポレイテッド	Ｃｔｌａ－４及びｐｄ－１阻害剤と併用した腫瘍浸潤リンパ球療法による治療
WO2022140797A1 (en)	2020-12-23	2022-06-30	Immunowake Inc.	Immunocytokines and uses thereof
AU2021411952A1 (en)	2020-12-29	2023-08-10	Incyte Corporation	Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
EP4271998A1 (de)	2020-12-30	2023-11-08	Abbott Laboratories	Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
EP4271482A2 (de)	2020-12-31	2023-11-08	Alamar Biosciences, Inc.	Bindemoleküle mit hoher affinität und/oder spezifität sowie verfahren zur herstellung und verwendung davon
CA3203382A1 (en)	2020-12-31	2022-07-07	Adrian Emanual Wells	Devices and processes for automated production of tumor infiltrating lymphocytes
WO2022165260A1 (en)	2021-01-29	2022-08-04	Iovance Biotherapeutics, Inc.	Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
EP4303233A1 (de)	2021-02-01	2024-01-10	St Phi Therapeutics Co., Ltd.	Gezieltes proteinabbausystem und verwendung davon
CN116829591A (zh)	2021-02-11	2023-09-29	奈克汀治疗有限公司	针对cd112r的抗体及其用途
WO2022178253A1 (en)	2021-02-19	2022-08-25	IsoPlexis Corporation	Methods and devices for spatially resolved analysis of proteomic and genetic information
CA3209052A1 (en)	2021-02-19	2022-08-25	Rafael Cristian CASELLAS	Single domain antibodies that neutralize sars-cov-2
US20240141026A1 (en)	2021-03-04	2024-05-02	Centre National De La Recherche Scientifique	Use of a periostin antibody for treating inflammation, fibrosis and lung diseases
EP4301138A2 (de)	2021-03-05	2024-01-10	Iovance Biotherapeutics, Inc.	Tumorspeicherungs- und zellkulturzusammensetzungen
KR20230148226A (ko)	2021-03-10	2023-10-24	이뮤노웨이크 인크.	면역조절 분자 및 이의 용도
CA3213599A1 (en)	2021-03-15	2022-09-22	Genentech, Inc.	Compositions and methods of treating lupus nephritis
EP4308118A1 (de)	2021-03-17	2024-01-24	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren und zusammensetzungen zur melanombehandlung
JP2024510505A (ja)	2021-03-19	2024-03-07	アイオバンスバイオセラピューティクス，インコーポレイテッド	Ｃｄ３９／ｃｄ６９選択に関連した腫瘍浸潤リンパ球（ｔｉｌ）拡張及びｔｉｌにおける遺伝子ノックアウトのための方法
US20240175873A1 (en)	2021-03-23	2024-05-30	Institut National de la Santé et de la Recherche Médicale	Methods for the diagnosis and treatment of t cell-lymphomas
CA3211591A1 (en)	2021-03-23	2022-09-29	Markus Zettl	Her2/4-1bb bispecific fusion proteins for the treatment of cancer
EP4313122A1 (de)	2021-03-23	2024-02-07	Iovance Biotherapeutics, Inc.	Cish-geneditierung von tumorinfiltrierenden lymphozyten und verwendungen davon in der immuntherapie
WO2022200478A1 (en)	2021-03-24	2022-09-29	Pieris Pharmaceuticals Gmbh	Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor
KR20240032711A (ko)	2021-03-25	2024-03-12	이오반스 바이오테라퓨틱스, 인크.	T-세포 공배양 효능 검정 및 세포 치료제와 함께 사용하기 위한 방법 및 조성물
US20240228562A1 (en)	2021-04-08	2024-07-11	Pieris Pharmaceuticals Gmbh	Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
WO2022214664A1 (en)	2021-04-09	2022-10-13	Philogen S.P.A.	Improved interferon-gamma mutant
WO2022214681A1 (en)	2021-04-09	2022-10-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of anaplastic large cell lymphoma
WO2022219152A1 (en)	2021-04-16	2022-10-20	Oblique Therapeutics Ab	Kras antibodies
US20240368605A1 (en)	2021-04-19	2024-11-07	Institut National de la Santé et de la Recherche Médicale	Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2
IL307800A (en)	2021-04-19	2023-12-01	Iovance Biotherapeutics Inc	Chimeric costimulatory receptors, chemokine receptors and their use in cellular immunotherapy
EP4326761A1 (de)	2021-04-20	2024-02-28	Amgen Inc.	Ausgeglichene ladungsverteilung bei der elektrostatischen lenkung von kettenpaarung in einer multispezifischen und monovalenten igg-molekülanordnung
EP4326779A1 (de)	2021-04-23	2024-02-28	Philogen S.p.A.	Antikörper gegen fibroblastenaktivierungsprotein
WO2022223791A1 (en)	2021-04-23	2022-10-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating cell senescence accumulation related disease
US20240269180A1 (en)	2021-05-17	2024-08-15	Iovance Biotherapeutics, Inc.	Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
CA3216320A1 (en)	2021-05-18	2022-11-24	Abbott Laboratories	Methods of evaluating brain injury in a pediatric subject
WO2022243341A1 (en)	2021-05-18	2022-11-24	Pieris Pharmaceuticals Gmbh	Lipocalin muteins with binding affinity for ox40
EP4342913A4 (de)	2021-05-19	2024-11-20	Shanghai Escugen Biotechnology Co., Ltd.	Chimäres antigenrezeptormolekül zur spezifischen erkennung von baff-r und anwendung eines chimären antigenrezeptormoleküls
JP2024518844A (ja)	2021-05-20	2024-05-07	ダイアンサスセラピューティクスオプコ，インコーポレイテッド	Ｃ１ｓに結合する抗体およびその使用
CA3220629A1 (en)	2021-05-28	2022-12-01	Tobin J. CAMMETT	Methods for detecting cm-tma biomarkers
WO2022266034A1 (en)	2021-06-14	2022-12-22	Abbott Laboratories	Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
WO2022261846A1 (zh)	2021-06-16	2022-12-22	上海鑫湾生物科技有限公司	靶向axl蛋白的抗体及其抗原结合片段、其制备方法和应用
AU2022299282A1 (en)	2021-06-22	2024-02-01	Merck Patent Gmbh	Vhh-based nkp30 binders
AU2022304582A1 (en)	2021-06-29	2024-02-01	Seagen Inc.	Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
IL309780A (en)	2021-07-02	2024-02-01	Merck Patent Gmbh	Antibodies and antiprotec complexes
US20240309095A1 (en)	2021-07-07	2024-09-19	Incyte Corporation	Anti-b7-h4 antibodies and uses thereof
TW202317633A (zh)	2021-07-08	2023-05-01	美商舒泰神（加州）生物科技有限公司	特異性識別ｔｎｆｒ２的抗體及其用途
EP4370550A1 (de)	2021-07-12	2024-05-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verwendung von il-36 inhibitoren zur behandlung des netherton syndroms
JP2024526764A (ja)	2021-07-13	2024-07-19	トゥルーバインディング，インコーポレイテッド	タンパク質凝集を防止する方法
JP2024525769A (ja)	2021-07-14	2024-07-12	舒泰神（北京）生物製薬股フン有限公司	Ｃｄ４０を特異的に認識する抗体およびその使用
WO2023287707A1 (en)	2021-07-15	2023-01-19	Just-Evotec Biologics, Inc.	Bidirectional tangential flow filtration (tff) perfusion system
EP4373270A2 (de)	2021-07-22	2024-05-29	Iovance Biotherapeutics, Inc.	Verfahren zur kryokonservierung von festen tumorfragmenten
EP4377446A1 (de)	2021-07-28	2024-06-05	Iovance Biotherapeutics, Inc.	Behandlung von krebspatienten mit tumorinfiltrierenden lymphozytentherapien in kombination mit kras-hemmern
CN117813320A (zh)	2021-07-30	2024-04-02	Inserm(法国国家健康医学研究院)	嵌合蛋白和免疫治疗方法
CN117897409A (zh)	2021-08-13	2024-04-16	基因泰克公司	抗类胰蛋白酶抗体的给药
WO2023017149A1 (en)	2021-08-13	2023-02-16	Oblique Therapeutics Ab	Thioredoxin 1 antibodies
CA3229139A1 (en)	2021-08-20	2023-02-23	Pavel Strop	Nectin-4 antibodies and conjugates
EP4392783A1 (de)	2021-08-27	2024-07-03	Abbott Laboratories	Verfahren zum nachweis von immunoglobulin g, subklassen 4 (igg4) in einer biologischen probe
WO2023034809A1 (en)	2021-08-30	2023-03-09	Lassen Therapeutics 1, Inc.	Anti-il-11rα antibodies
CN118715440A (zh)	2021-08-31	2024-09-27	雅培实验室	诊断脑损伤的方法和系统
AU2022339759A1 (en)	2021-08-31	2024-03-07	Abbott Laboratories	Methods and systems of diagnosing brain injury
US20240424097A1 (en)	2021-09-09	2024-12-26	Iovance Biotherapeutics, Inc.	Processes for generating til products using pd-1 talen knockdown
EP4401842A1 (de)	2021-09-16	2024-07-24	Aboleris Pharma	Anti-human-cd45rc-bindungsdomänen und verwendungen davon
EP4404969A1 (de)	2021-09-24	2024-07-31	Iovance Biotherapeutics, Inc.	Expansionsverfahren und mittel für tumorinfiltrierende lymphozyten
WO2023056268A1 (en)	2021-09-30	2023-04-06	Abbott Laboratories	Methods and systems of diagnosing brain injury
CA3234995A1 (en)	2021-10-14	2023-04-20	Latticon (Suzhou) Biopharmaceuticals Co., Ltd.	Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
EP4416186A1 (de)	2021-10-14	2024-08-21	Teneobio, Inc.	Mesothelinbindende proteine und verwendungen davon
WO2023067348A1 (en)	2021-10-21	2023-04-27	Biosirius Ltd	Treatment for virally-induced pneumonia
WO2023072958A1 (en)	2021-10-25	2023-05-04	Fabmid	Methods for circularizing linear double stranded nucleic acids and the products thereof
AR127482A1 (es)	2021-10-27	2024-01-31	Iovance Biotherapeutics Inc	Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
EP4427044A1 (de)	2021-11-03	2024-09-11	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren und zusammensetzungen zur behandlung von dreifach negativem brustkrebs (tnbc)
WO2023081898A1 (en)	2021-11-08	2023-05-11	Alector Llc	Soluble cd33 as a biomarker for anti-cd33 efficacy
US20230279120A1 (en)	2021-11-09	2023-09-07	Truebinding, Inc.	Methods of treating or inhibiting cardiovascular diseases
WO2023086807A1 (en)	2021-11-10	2023-05-19	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
EP4430167A1 (de)	2021-11-10	2024-09-18	Iovance Biotherapeutics, Inc.	Verfahren zur expansionsbehandlung mit cd8-tumorinfiltrierenden lymphozyten
WO2023089079A1 (en)	2021-11-19	2023-05-25	Pieris Pharmaceuticals Gmbh	Novel fusion protein specific for ox40 and pd-l1
EP4433084A1 (de)	2021-11-19	2024-09-25	Lykera Biomed, S.A.	Behandlung und diagnose von erkrankungen im zusammenhang mit pathogener fibrose
WO2023103788A1 (zh)	2021-12-06	2023-06-15	北京三诺佳邑生物技术有限责任公司	特异性结合肺炎克雷伯菌o2抗原和o1抗原的双特异性抗体以及组合物
PE20241998A1 (es)	2021-12-08	2024-09-27	Incyte Corp	Anticuerpos anti-calreticulina (calr) mutante y usos de estos
WO2023105528A1 (en)	2021-12-12	2023-06-15	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Antibodies specific to ceacam1
AU2022413942A1 (en)	2021-12-13	2024-05-30	William Robert Arathoon Living Trust Dated August 29, 2016	Anti-abcb1 antibodies
WO2023110937A1 (en)	2021-12-14	2023-06-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
AU2022409802A1 (en)	2021-12-15	2024-06-06	Interius Biotherapeutics, Inc.	Pseudotyped viral particles, compositions comprising the same, and uses thereof
WO2023114978A1 (en)	2021-12-17	2023-06-22	Abbott Laboratories	Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
EP4452257A1 (de)	2021-12-21	2024-10-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren und zusammensetzungen zur melanombehandlung
WO2023118497A1 (en)	2021-12-22	2023-06-29	Pieris Pharmaceuticals Gmbh	Novel il-18 variants
EP4453034A1 (de)	2021-12-23	2024-10-30	The Broad Institute Inc.	Parallele antikörper-engineering-zusammensetzungen und verfahren
WO2023144235A1 (en)	2022-01-27	2023-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
EP4469066A1 (de)	2022-01-28	2024-12-04	Iovance Biotherapeutics, Inc.	Zur expression von nutzlasten manipulierte tumorinfiltrierende lymphozyten
WO2023147488A1 (en)	2022-01-28	2023-08-03	Iovance Biotherapeutics, Inc.	Cytokine associated tumor infiltrating lymphocytes compositions and methods
EP4472740A1 (de)	2022-01-31	2024-12-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cd38 als biomarker und biotarget bei t-zell-lymphomen
JP2025507303A (ja)	2022-02-04	2025-03-18	アボット・ラボラトリーズ	試料におけるユビキチンカルボキシ末端ヒドロラーゼｌ１及び／又はグリア原線維性酸性タンパク質の存在を検出する又はその量を測定するためのラテラルフロー方法、アッセイ及びデバイス
WO2023148707A1 (en)	2022-02-07	2023-08-10	Yeda Research And Development Co. Ltd.	Humanized anti quiescin suefhydrye oxidase 1 (qsox1) antibodies and uses thereof
WO2023159220A1 (en)	2022-02-18	2023-08-24	Kenjockety Biotechnology, Inc.	Anti-cd47 antibodies
EP4482863A1 (de)	2022-02-21	2025-01-01	Acticor Biotech	Behandlung von herz-kreislauf-erkrankungen mit anti-humanen gpvi-antikörpern
MX2024010324A (es)	2022-02-23	2024-08-30	Alector Llc	Metodos de uso de anticuerpos anti-trem2.
GB202202569D0 (en)	2022-02-24	2022-04-13	Amlo Biosciences Ltd	Biomarkers for disease progression and/or recurrence in squamous cell carcinoma
EP4490188A1 (de)	2022-03-09	2025-01-15	Alderaan Biotechnology	Antikörper gegen die transmembrane isoform cd160
WO2023180523A1 (en)	2022-03-24	2023-09-28	Pieris Pharmaceuticals Gmbh	Process for purifying fusion proteins
EP4504148A1 (de)	2022-04-01	2025-02-12	Genentech, Inc.	Hydroxypropylmethylcellulosederivate zur stabilisierung von polypeptiden
WO2023196877A1 (en)	2022-04-06	2023-10-12	Iovance Biotherapeutics, Inc.	Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4257609A1 (de)	2022-04-08	2023-10-11	iOmx Therapeutics AG	Kombinationstherapien basierend auf pd-1-inhibitoren und sik3-inhibitoren
WO2023198648A1 (en)	2022-04-11	2023-10-19	Institut National de la Santé et de la Recherche Médicale	Methods for the diagnosis and treatment of t-cell malignancies
EP4507704A1 (de)	2022-04-15	2025-02-19	Iovance Biotherapeutics, Inc.	Til-expansionsverfahren unter verwendung spezifischer zytokinkombinationen und/oder einer akti-behandlung
WO2023198874A1 (en)	2022-04-15	2023-10-19	Institut National de la Santé et de la Recherche Médicale	Methods for the diagnosis and treatment of t cell-lymphomas
AU2023264591A1 (en)	2022-05-02	2024-11-07	Arcus Biosciences, Inc.	Anti-tigit antibodies and uses of the same
CN119487065A (zh)	2022-05-09	2025-02-18	舒泰神（北京）生物制药股份有限公司	特异性识别gdf15的抗体及其应用
EP4522202A1 (de)	2022-05-10	2025-03-19	Iovance Biotherapeutics, Inc.	Behandlung von krebspatienten mit tumorinfiltrierenden lymphozytentherapien in kombination mit einem il-15r-agonisten
TWI866210B (zh)	2022-05-17	2024-12-11	大陸商蘇州創勝醫藥集團有限公司	雙功能蛋白質及其製劑和用途
WO2023222886A1 (en)	2022-05-20	2023-11-23	Depth Charge Ltd	Antibody-cytokine fusion proteins
TW202412744A (zh)	2022-06-07	2024-04-01	瑞士商意梭凱普公司	包括應用在食道黏膜之藥劑的藥物遞送系統及其應用
KR20250022049A (ko)	2022-06-07	2025-02-14	제넨테크, 인크.	항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
WO2023237661A1 (en)	2022-06-09	2023-12-14	Institut National de la Santé et de la Recherche Médicale	Use of endothelin receptor type b agonists for the treatment of aortic valve stenosis
WO2023245105A1 (en)	2022-06-17	2023-12-21	Genentech, Inc.	Use of kosmotropes to enhance yield of an affinity chromatography purification step
WO2023250388A1 (en)	2022-06-22	2023-12-28	Voyager Therapeutics, Inc.	Tau binding compounds
AU2023298134A1 (en)	2022-06-29	2024-11-28	Abbott Laboratories	Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024003380A1 (en)	2022-06-30	2024-01-04	Icm (Institut Du Cerveau Et De La Moelle Épinière)	Vascular endothelial growth factor receptor-1 (vegfr-1) inhibitors for promoting myelination and neuroprotection
WO2024003310A1 (en)	2022-06-30	2024-01-04	Institut National de la Santé et de la Recherche Médicale	Methods for the diagnosis and treatment of acute lymphoblastic leukemia
WO2024011114A1 (en)	2022-07-06	2024-01-11	Iovance Biotherapeutics, Inc.	Devices and processes for automated production of tumor infiltrating lymphocytes
WO2024008799A1 (en)	2022-07-06	2024-01-11	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of proliferative glomerulonephritis
WO2024013234A1 (en)	2022-07-13	2024-01-18	Institut National de la Santé et de la Recherche Médicale	Methods for diagnosis, prognosis, stratification and treating of myocarditis
AU2023307223A1 (en)	2022-07-14	2025-02-20	The Broad Institute, Inc.	Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor
TW202417503A (zh)	2022-07-19	2024-05-01	美商舒泰神（加州）生物科技有限公司	特異性識別ｂ和ｔ淋巴細胞衰減器（ｂｔｌａ）的抗體及其應用
WO2024018046A1 (en)	2022-07-22	2024-01-25	Institut National de la Santé et de la Recherche Médicale	Garp as a biomarker and biotarget in t-cell malignancies
IL317811A (en)	2022-07-25	2025-02-01	Interius Biotherapeutics Inc	Mutated polypeptides, compositions containing them and uses thereof
EP4311557A1 (de)	2022-07-26	2024-01-31	Oncomatryx Biopharma, S.L.	Auf fap abzielende antikörper-arzneimittelkonjugate
AU2023312905A1 (en)	2022-07-27	2025-01-16	Teneobio, Inc.	Mesothelin binding proteins and uses thereof
WO2024023283A1 (en)	2022-07-29	2024-02-01	Institut National de la Santé et de la Recherche Médicale	Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
WO2024030758A1 (en)	2022-08-01	2024-02-08	Iovance Biotherapeutics, Inc.	Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024028433A1 (en)	2022-08-04	2024-02-08	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of lymphoproliferative disorders
WO2024033400A1 (en)	2022-08-10	2024-02-15	Institut National de la Santé et de la Recherche Médicale	Sk2 inhibitor for the treatment of pancreatic cancer
WO2024033399A1 (en)	2022-08-10	2024-02-15	Institut National de la Santé et de la Recherche Médicale	Sigmar1 ligand for the treatment of pancreatic cancer
WO2024038165A1 (en)	2022-08-18	2024-02-22	Immunocore Ltd	T cell receptor fusion proteins specific for mage a4
WO2024228717A2 (en)	2022-09-07	2024-11-07	Quantitative Biosciences, Inc.	Fentanyl-specific single variable-domain antibodies and use in a continuous agglutination assay
WO2024059708A1 (en)	2022-09-15	2024-03-21	Abbott Laboratories	Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
AU2023342086A1 (en)	2022-09-15	2025-03-13	Voyager Therapeutics, Inc.	Tau binding compounds
AU2023343487A1 (en)	2022-09-15	2025-03-20	Abbott Laboratories	Hbv diagnostic, prognostic, and therapeutic methods and products
TW202426501A (zh)	2022-09-21	2024-07-01	美商思進公司	結合cd228之抗體
AU2023347921A1 (en)	2022-09-21	2025-03-20	Pieris Pharmaceuticals Gmbh	Novel fusion protein specific for cd137 and cd228
WO2024077256A1 (en)	2022-10-07	2024-04-11	The General Hospital Corporation	Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024079192A1 (en)	2022-10-12	2024-04-18	Institut National de la Santé et de la Recherche Médicale	Cd81 as a biomarker and biotarget in t-cell malignancies
WO2024084034A1 (en)	2022-10-21	2024-04-25	Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical compositions for the treatment of osteoarthritis
WO2024088921A1 (en)	2022-10-24	2024-05-02	F. Hoffmann-La Roche Ag	Predicting response to il-6 antagonists
WO2024092240A1 (en)	2022-10-28	2024-05-02	Chinook Therapeutics, Inc.	Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
WO2024097328A1 (en)	2022-11-03	2024-05-10	Incyte Corporation	Combination therapies comprising an anti-gitr antibody for treating cancers
WO2024098024A1 (en)	2022-11-04	2024-05-10	Iovance Biotherapeutics, Inc.	Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024098027A1 (en)	2022-11-04	2024-05-10	Iovance Biotherapeutics, Inc.	Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
WO2024102734A1 (en)	2022-11-08	2024-05-16	Genentech, Inc.	Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024100663A1 (en)	2022-11-10	2024-05-16	Famewave Ltd.	Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities
WO2024108178A1 (en)	2022-11-18	2024-05-23	Genentech, Inc.	Signal amplification and multiplexing using mass tags for ia-lc-ms/ms based assays
WO2024112711A2 (en)	2022-11-21	2024-05-30	Iovance Biotherapeutics, Inc.	Methods for assessing proliferation potency of gene-edited t cells
WO2024112734A1 (en)	2022-11-21	2024-05-30	Dianthus Therapeutics Opco, Inc.	Antibodies that bind to c1s and uses thereof
WO2024112571A2 (en)	2022-11-21	2024-05-30	Iovance Biotherapeutics, Inc.	Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
TW202440623A (zh)	2022-11-28	2024-10-16	美商艾洛基因醫療公司	靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
WO2024115935A1 (en)	2022-11-29	2024-06-06	Inserm	Methods for the treatment of b-cell lymphoma using cd39 inhibitors
US12049502B2 (en)	2022-11-30	2024-07-30	Integral Molecular, Inc.	Antibodies directed to claudin 6, including bispecific formats thereof
EP4382120A1 (de)	2022-12-05	2024-06-12	Institut Regional du Cancer de Montpellier	Monoklonale anti-slc1a4-antikörper und verwendungen davon
WO2024133573A1 (en)	2022-12-20	2024-06-27	Nextera As	Antigen binding proteins
GB202219294D0 (en)	2022-12-20	2023-02-01	Nextera As	Antigen binding proteins
WO2024133723A1 (en)	2022-12-22	2024-06-27	Institut National de la Santé et de la Recherche Médicale	Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
WO2024141496A1 (en)	2022-12-27	2024-07-04	Merck Patent Gmbh	Vhh anti-protac antibodies and complexes
WO2024151885A1 (en)	2023-01-13	2024-07-18	Iovance Biotherapeutics, Inc.	Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2024165403A1 (en)	2023-02-06	2024-08-15	Philogen S.P.A.	Anti-cea antibodies
WO2024165500A1 (en)	2023-02-06	2024-08-15	Merck Patent Gmbh	Vhh-based nkp46 binders
WO2024178056A1 (en)	2023-02-21	2024-08-29	Teneobio, Inc.	C-kit binding proteins, chimeric antigen receptors, and uses thereof
WO2024175760A1 (en)	2023-02-24	2024-08-29	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of endometriosis
WO2024184812A1 (en)	2023-03-06	2024-09-12	Beigene Switzerland Gmbh	Anti-cldn6 antibodies and methods of use
WO2024184811A1 (en)	2023-03-06	2024-09-12	Beigene Switzerland Gmbh	Anti-cd3 multispecific antibodies and methods of use
TW202436353A (zh)	2023-03-06	2024-09-16	瑞士商百濟神州瑞士有限責任公司	抗ｃｌｄｎ６與抗ｃｄ３多重特異性抗體以及使用方法
GB202303531D0 (en)	2023-03-10	2023-04-26	Fusion Antibodies Plc	Antibodies and uses thereof
WO2024192141A1 (en)	2023-03-13	2024-09-19	Dana-Farber Cancer Institute, Inc.	Treatment of cancers having a drug-resistant mesenchymal cell state
GB202303784D0 (en)	2023-03-15	2023-04-26	Institute Of Cancer Res Royal Cancer Hospital	Cancer treatment
WO2024211475A1 (en)	2023-04-04	2024-10-10	Abbott Laboratories	Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
WO2024209089A1 (en)	2023-04-07	2024-10-10	Commissariat A L'energie Atomique Et Aux Energies Alternatives	Use of antibody against the endothelin receptor b for diagnostic and therapeutic applications
WO2024226971A1 (en)	2023-04-28	2024-10-31	Abbott Point Of Care Inc.	Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
WO2024245951A1 (en)	2023-05-26	2024-12-05	Institut National de la Santé et de la Recherche Médicale	Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
WO2024246224A1 (en)	2023-05-30	2024-12-05	Philikos B.V.	Methods and means for the treatment of chronic inflammatory and autoimmune disease
WO2024254455A1 (en)	2023-06-08	2024-12-12	Genentech, Inc.	Macrophage signatures for diagnostic and therapeutic methods for lymphoma
WO2024251983A1 (en)	2023-06-09	2024-12-12	Merck Patent Gmbh	Il-18 mimetics
WO2024258743A1 (en)	2023-06-13	2024-12-19	Adcentrx Therapeutics, Inc.	Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
WO2024256583A1 (en)	2023-06-14	2024-12-19	Immutrin Ltd	Anti-fibril antibodies
WO2024256635A1 (en)	2023-06-15	2024-12-19	Institut National de la Santé et de la Recherche Médicale	Dpm1 inhibitor for treating cancer
WO2024261302A1 (en)	2023-06-22	2024-12-26	Institut National de la Santé et de la Recherche Médicale	Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025014773A1 (en)	2023-07-07	2025-01-16	Viridian Therapeutics, Inc.	Methods of treating chronic thyroid eye disease
WO2025015318A2 (en)	2023-07-13	2025-01-16	Iovance Biotherapeutics, Inc.	Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025019790A1 (en)	2023-07-19	2025-01-23	Iovance Biotherapeutics, Inc.	Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
WO2025021928A1 (en)	2023-07-25	2025-01-30	Merck Patent Gmbh	Iduronidase-cleavable compounds
WO2025034806A1 (en)	2023-08-08	2025-02-13	Wisconsin Alumni Research Foundation	Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025040797A1 (en)	2023-08-23	2025-02-27	Depth Charge Ltd	Interleukin-2 variant proteins that facilitate covalent chemical conjugation and uses thereof
WO2025045251A2 (en)	2023-09-03	2025-03-06	Kira Pharmaceuticals (Us) Llc	Multispecific constructs comprising anti-factor d moiety
WO2025054500A2 (en)	2023-09-08	2025-03-13	Mlab Biosciences, Inc.	Bifunctional proteins and uses thereof
WO2025054398A1 (en)	2023-09-08	2025-03-13	Genentech, Inc.	High viscosity ultrafiltration/diafiltration and single-pass tangential flow filtration processes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4946778A (en) *	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
AU612370B2 (en) *	1987-05-21	1991-07-11	Micromet Ag	Targeted multifunctional proteins
GB9012995D0 (en) *	1990-06-11	1990-08-01	Celltech Ltd	Multivalent antigen-binding proteins

1992
- 1992-11-20 AT AT01109203T patent/ATE297465T1/de not_active IP Right Cessation
- 1992-11-20 AT AT93900545T patent/ATE207080T1/de not_active IP Right Cessation
- 1992-11-20 DE DE69232137T patent/DE69232137T2/de not_active Expired - Fee Related
- 1992-11-20 ES ES93900545T patent/ES2165851T3/es not_active Expired - Lifetime
- 1992-11-20 CA CA002122732A patent/CA2122732C/en not_active Expired - Lifetime
- 1992-11-20 EP EP01109203A patent/EP1136556B1/de not_active Expired - Lifetime
- 1992-11-20 WO PCT/US1992/009965 patent/WO1993011161A1/en not_active Application Discontinuation
- 1992-11-20 JP JP5510157A patent/JPH07501451A/ja active Pending
- 1992-11-20 DE DE69233528T patent/DE69233528T2/de not_active Expired - Lifetime
- 1992-11-20 ES ES01109203T patent/ES2241710T3/es not_active Expired - Lifetime
- 1992-11-20 DK DK93900545T patent/DK0617706T3/da active
- 1992-11-20 DK DK01109203T patent/DK1136556T3/da active
- 1992-11-20 EP EP93900545A patent/EP0617706B1/de not_active Revoked
- 1992-11-20 AU AU31789/93A patent/AU3178993A/en not_active Abandoned
2005
- 2005-09-29 US US11/239,510 patent/US20060063715A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP0617706A1 (de)	1994-10-05
ATE207080T1 (de)	2001-11-15
JPH07501451A (ja)	1995-02-16
DE69232137D1 (de)	2001-11-22
DE69233528D1 (de)	2005-07-14
ES2241710T3 (es)	2005-11-01
DK0617706T3 (da)	2001-11-12
EP1136556A1 (de)	2001-09-26
ES2165851T3 (es)	2002-04-01
DE69233528T2 (de)	2006-03-16
DK1136556T3 (da)	2005-10-03
CA2122732A1 (en)	1993-06-10
EP0617706A4 (en)	1995-09-27
EP1136556B1 (de)	2005-06-08
DE69232137T2 (de)	2002-05-29
AU3178993A (en)	1993-06-28
WO1993011161A1 (en)	1993-06-10
EP0617706B1 (de)	2001-10-17
US20060063715A1 (en)	2006-03-23
CA2122732C (en)	2008-04-08

Publication	Publication Date	Title
ATE297465T1 (de)	2005-06-15	Verfahren zur herstellung von multivalenten antigenbindenden proteinen
DE3382190D1 (de)	1991-04-11	Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
ATE145007T1 (de)	1996-11-15	Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieres
EP0677100A4 (de)	1997-04-23	Verfahren zur herstellung von neuroblasten.
DE3586263D1 (de)	1992-08-06	Verfahren zur herstellung von abbildungen.
ES2181674T3 (es)	2003-03-01	Dominios de union en las proteinas notch y delta.
DE3481279D1 (de)	1990-03-15	Verfahren zur herstellung von oel-in-wasser-emulsionen.
DE3881799D1 (de)	1993-07-22	Verfahren zur herstellung von cmos-bauelementen.
DE69000338D1 (de)	1992-11-05	Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern.
DE3761762D1 (de)	1990-04-05	Verfahren zur herstellung von fluoraliphatischen aetherhaltigen carbonylfluoridzusammensetzungen.
DE59104082D1 (de)	1995-02-09	Verfahren zur herstellung von öl-in-wasser-cremes.
DE3765983D1 (de)	1990-12-13	Verfahren zur herstellung von caprolactam.
DE59203503D1 (de)	1995-10-05	Verfahren zur herstellung von öl-in-wasser-emulsionen.
DE3483974D1 (de)	1991-02-28	Verfahren zur herstellung von bildern.
DE3485054D1 (de)	1991-10-17	Candida albicans zytoplasmaantigen, monoklonale antikoerper dagegen und verfahren zur herstellung.
DE3750775D1 (de)	1995-01-05	Verfahren zur Herstellung von Halbtonbildern.
DE3381934D1 (de)	1990-11-15	Verfahren zur herstellung von shampoos.
DE3863913D1 (de)	1991-08-29	Verfahren zur herstellung von gegenstaenden aus siliciumnitrid.
ATE190974T1 (de)	2000-04-15	Verfahren zur herstellung von n,n'- disubstituierten cyclischen harnstoffen
DE69325452D1 (de)	1999-07-29	Verfahren zur herstellung von (s)-3-amino-1-substituiert-pirrolidine
DE59100547D1 (de)	1993-12-09	Verfahren zur Herstellung von linearen Polyamiden.
DE3871486D1 (de)	1992-07-02	Verfahren zur herstellung von gegenstaenden aus siliciumnitrid.
DE69126592D1 (de)	1997-07-24	Nicht-lineare Peptide, die hydropatisch komplementär zu bekannten Aminosäuresequenzen sind, Verfahren zur Herstellung und Verwendung davon
DE3768784D1 (de)	1991-04-25	Verfahren zur herstellung von caprolactam.
DD128356A5 (de)	1977-11-16	Verfahren und vorrichtung zur herstellung von laenglichen gebilden,z.b.faeden,welche von kunststoff ummantelte seelen aufweisen

Legal Events

Date	Code	Title	Description
2006-02-15	UEP	Publication of translation of european patent specification	Ref document number: 1136556 Country of ref document: EP
2011-08-15	REN	Ceased due to non-payment of the annual fee

Date

Code

Title

Description

2006-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1136556

Country of ref document: EP

2011-08-15

REN

Ceased due to non-payment of the annual fee